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Abstract 
 
The Ewing’s sarcoma family of tumours (ESFT) comprises paediatric cancers of bone 
and soft tissue which presumably originate from mesenchymal progenitor cells 
(MPC). One hallmark of ESFT is the presence of a chromosomal translocation. In 
90% of the cases chromosome 11 fuses with chromosome 22. This translocation 
generates the EWS/FLI-1 fusion which acts as an aberrant transcription factor de-
regulating many genes involved in tumour development. Surgery and/or 
radiotherapy combined with chemotherapy are the usual forms of treatment for 
ESFT. But since there is only little progress in the field of chemotherapy the need 
for an animal model for pre-clinical drug testing is evident.  
Thus, the main focus of this thesis was to establish a mouse model that develops 
sarcomas resembling the phenotype of ESFT. We used a conditional EWS/FLI-1 
mouse model, which upon Cre activity (controlled by a tissue specific promotor) 
expressed EWS/FLI-1 in the targeted cells. Since ESFT arises in bone and 
surrounding soft tissue we decided to direct expression of EWS/FLI-1 to the 
mesenchymal lineage by using different Cre lines. Only when using the Prx1Cre, 
double transgenic mice tolerated EWS/FLI-1 expression. We observed 
developmental abnormalities with severe skeletal deformations. Bone formation 
was impaired due to the absence of mature chondrocytes and osteoblasts and 
hence a lack of calcified bone. The lack of mature bone cells in EWS/FLI-1 
expressing Prx1Cre mice supports in vitro data showing that EWS/FLI-1 impedes 
differentiation of murine mesenchymal progenitor cells. Currently, the project is 
extended to analysis of an inducible Prx1Cre system which circumvents the early 
lethality of Prx1Cre EF mice. This should provide the basis for tumour formation in 
these mice and hence the development of an appropriate mouse model for pre-
clinical research.  
 
In the second project of my PhD thesis, the role of the Janus Kinase/Signal 
Transducer and Activator of Transcription (JAK/STAT) signalling pathway in ESFT 
was investigated. This pathway is known to regulate many functions of a tumour 
cell such as proliferation, differentiation, survival or tumour surveillance. Although 
components of this signalling pathway are often de-regulated in human cancers the 
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role of this network was not investigated so far in detail in ESFT. Thus, we had a 
careful look on this pathway in ESFT. 
We analyzed three different ESFT cell lines for activation of the JAK/STAT pathway 
and observed activated STAT1 and STAT3 only upon subcutaneous injection into 
immunocompromised mice, but not in plain monolayer culture. Glycoprotein 
(gp)130 cytokines were shown to induce activation of STAT1 and STAT3 whereas 
Interferon (IFN)-γ only led to STAT1 activation. A profound reduction in cell 
number was observed when cells were stimulated with IFN-γ but proliferation in 
response to gp130-cytokines was not changed dramatically. Stimulation with gp130 
cytokines resulted in up-regulation of STAT1 target genes but STAT3 induced genes 
did not change their expression significantly.  
In summary, components of the JAK/STAT signalling pathway were observed to be 
active in ESFT cell line xenografts and upon cytokine stimulation. But further 
analysis is needed to understand the biological function of STAT activation in ESFT 
and so this project is still ongoing at the Ludwig Boltzmann Institute for Cancer 
Research. 
Zusammenfassung 
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Zusammenfassung 
 
Die Ewing Sarkom Familie der Tumoren (ESFT) beinhaltet Knochen- und 
Weichteiltumore, die vermutlich von mesenchymalen Progenitorzellen abstammen. 
Ein Kennzeichen der ESFT ist die Entstehung einer chromosomalen Translokation. In 
90% der Fälle fusioniert das Chromosom 11 mit dem Chromosom 22. Dadurch 
entsteht das Fusionsprotein EWS/FLI-1, welches als fehlgeleiteter 
Transkriptionsfaktor agiert und viele Gene beeinflusst, die zur Tumorentstehung 
beitragen. Chirurgische Maßnahmen und/oder Strahlentherapie in Kombination mit 
Chemotherapie sind die üblichen Formen der Behandlung für ESFT. Da es aber in 
den letzten Jahrzehnten im Bereich der Chemotherapie nur kleine Fortschritte gab, 
ist die Notwendigkeit eines Tiermodells für pre-klinische Studien offenkundig.  
Deshalb lag das Hauptaugenmerk dieser Doktorarbeit auf der Entwicklung eines 
solchen Mausmodells, welches Sarkome entwickelt, die den gleichen Phänotyp wie 
ESFT zeigen. Wir nutzten ein konditionales EWS/FLI-1 Modell, in welchem durch 
Steuerung der Aktivität des Cre Enzym das Fusionsprotein in einer bestimmten 
Zielzelle expremiert wird. Da ESFT in Knochen- und umgebenden Weichteilgewebe 
entsteht, haben wir uns entschieden die EWS/FLI-1 Expression auf die 
mesenchymale Abstammungslinie zu begrenzen, welches wir durch das Einsetzen 
verschiedener Cre Linien erreicht haben. Nur wenn wir die Prx1Cre benutzten, 
expremierten doppelt transgene Mäuse EWS/FLI-1. Diese Mäuse wiesen 
Abnormalitäten der Skelettentwicklung auf, am auffälligsten waren die verkürzten 
Extremitäten. Der Defekt in der Knochenentwicklung war bedingt durch ein Fehlen 
reifer Chondrozyten und Osteoblasten und damit der Abwesenheit von 
kalzifiziertem Knochen. Die fehlenden reifen Knochenzellen in EWS/FLI-1 
expremierenden Prx1Cre Mäusen unterstützen in vitro Daten, die zeigen, dass 
EWS/FLI-1 die Differenzierung mesenchymaler Progenitorzellen von Mäusen 
verhindern kann. Momentan wird das Projekt um die Analyse eines induzierbaren 
Prx1Cre Systems, das die frühe Sterblichkeit umgeht, erweitert. Dies sollte die 
Grundlage für die Entstehung von Tumoren bieten und folglich die Entwicklung 
eines adäquaten Mausmodells für die pre-klinische Forschung. 
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In dem zweiten Projekt meiner Dissertation wurde die Rolle des Janus 
Kinase/Signal Transducer und Aktivator der Transkription (JAK/STAT) Signalwegs in 
ESFT untersucht. Dieser Signalweg ist bekannt viele Funktionen einer Tumorzelle zu 
regulieren wie Zellteilung, Differenzierung, Überleben oder Tumorüberwachung. 
Obwohl Komponenten dieses Signalweges häufig in humanen Tumoren fehlgeleitet 
sind, ist die Rolle dieses Netzwerkes in ESFT noch nicht detailliert erforscht 
worden. Daher untersuchten wir diesen Signalweg in ESFT. 
Wir analysierten drei verschiedene ESFT Zelllinien auf die Aktivierung des 
JAK/STAT Signalweges. Wir konnten aktiviertes STAT1 und STAT3 nachweisen, aber 
nur wenn die ESFT Zellen subkutan in immunkomprimierte Mäuse injiziert wurden, 
nicht aber wenn die Zellen in einer Zellkulturschale kultiviert wurden. Glykoprotein 
(gp)130 Zytokine induzierten die Aktivierung von STAT1 und STAT3, wohingegen 
Interferon (IFN)-γ nur STAT1 stimulierte. Eine profunde Wachstumsretardation 
wurde in Zellen beobachtet, die mit IFN-γ inkubiert wurden. Proliferation als 
Antwort auf gp130 Zytokinstimulation wurde nicht dramatisch verändert. 
Stimulation mit gp130 Zytokinen resultierte in einer vermehrten Expression von 
STAT1 Zielgenen, aber STAT3 induzierte Gene änderten ihre Expressionslevel nicht 
signifikant. 
Zusammenfassend kann man sagen, dass Komponenten des JAK/STAT Signalweges 
aktiv waren in ESFT Xenotransplantaten und durch Zytokinstimulierung. Aber 
weitere Analysen sind nötig um die biologische Funktion der STAT Aktivierung in 
ESFT zu verstehen und deshalb wird dieses Projekt am Ludwig Boltzmann Institut 
für Krebsforschung noch weiter verfolgt. 
1. Introduction 
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1. Introduction 
 
 
 
 
1.1. Ewing’s sarcoma family of tumours-ESFT 
 
 
1.1.1. ESFT - the disease 
Cancer comprises malignant neoplasms in which cells acquire many genetic or 
epigenetic changes which render them immortal with increased proliferation and 
survival. Depending on the tissue of origin, there are three major sub-classes: 
epithelial cells form carcinomas, sarcomas are derived from cells of the 
mesenchymal tissue and leukaemia or lymphomas are malignancies arising from 
haematopoietic cells. Carcinomas account for most of the adult cancer cases 
whereas sarcomas are generally rare. (Alberts et al. 1994) 
Sarcomas represent less than 5% of adult neoplasms but approximately 15% of 
paediatric malignancies. This class of tumours includes amongst others synovial 
sarcoma, chondrosarcoma, osteosarcoma, rhabdomyosarcoma and Ewing’s 
sarcoma. (Mackall et al. 2002) 
Ewing’s sarcoma was first described by James Ewing in 1921 as a diffuse 
endothelioma of the bone. Since then, Askin tumour, primitive neuroectodermal 
tumour (PNET) and Ewing’s sarcoma were united under the term Ewing’s sarcoma 
family of tumours (ESFT), differing primarily by the degree of tumour cell 
differentiation. (Khoury 2005) They share a common histogenesis, tumour genetics 
and based on histo-pathology staining pattern belong to the small blue round cell 
tumours. (Triche 1987) 
 
1.1.1.1. Epidemiology 
ESFT is the second most common bone disease in children and young adolescents 
after osteosarcoma and comprises 3% of paediatric cancers. It is a rare disease with 
an incidence of 0,6/million worldwide and peaks in puberty. Boys are slightly more 
1. Introduction 
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affected than girls (1,3:1) and the disease is more commonly occurring in the 
Caucasian than the Asian population. Surprisingly, ESFT is underrepresented in 
African-Americans and Africans. (Burchill 2003; Ludwig 2008) 
 
1.1.1.2. Diagnosis 
ESFT is diagnosed with techniques employing histological, immunhistochemical, 
cytogenetic and molecular methods.  
CD99, a 32 kD transmembrane protein, is highly expressed in ESFT and strong 
diffuse immunostaining confers a useful marker. Expression of CD99 is not only 
restricted to ESFT, T- and B-lymphocytes but also neuroblastoma and 
rhabdomyosarcoma can have a positive CD99 staining. Therefore, an additional 
panel of markers is employed to discriminate ESFT from other diseases. 
Immunostainings specific for muscle (MyoD, myogenin), lymphoid (CD45, TdT) or 
neuronal tissue (synaptophysin) can help to obtain proper diagnosis. (Khoury 2005, 
Ludwig 2008) 
 
Chromosomal translocations are a hallmark of ESFT. The most prominent one 
connects chromosome 11 to chromosome 22, resulting in the EWS/FLI-1 fusion 
protein. The second most common translocation, which is found in 10% of ESFT 
cases, leads to a fusion of EWS to ERG. Other translocations fuse EWS to different 
members of the ETS transcription factor family (Table 1). In a rare subtype of ESFT 
the EWS related TLS/FUS is fused to ERG. (Kovar 2005) Until recently, only ETS 
family members were found to fuse to members of the EWS family in ESFT. Other 
combinations were associated with different tumour types and ESFT like neoplasms 
but an in-frame fusion between EWS and NFATc2 present in four ESFT cases was 
recently identified. (Szuhai et al. 2009) 
Several types of in-frame EWS/FLI-1 chimeric transcripts are possible, but all 
harbour exon 7 from EWS and exon 9 from FLI-1 (Figure 1). Reverse transcriptase 
polymerase chain reaction (RT-PCR) with primers specific for these exons can 
detect all forms of EWS/FLI-1. Another method to identify the translocation is 
fluorescence in situ hybdridisation (FISH) whereby one labelled probe marks the 
EWS part and the other binds to FLI-1. An adaption of this method utilises two 
probes flanking the EWS breakpoint region on chromosome 22 thereby detecting 
translocations regardless of the fusion partner. (Khoury 2005) 
1. Introduction 
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EWS family 
member 
transcription factor 
(type) translocation tumour type 
EWS FLI-1 (ETS) 11;22 ESFT (85%) 
EWS ERG (ETS) 21;22 ESFT (10%) 
EWS ETV1 (ETS) 7;22 ESFT (<1%) 
EWS E1AF (ETS) 17;22 ESFT (<1%) 
EWS FEV (ETS) 2;22 ESFT (<1%) 
TLS/FUS ERG (ETS) 11;22 ESFT (<1%) 
EWS NFATc2 20;22 ESFT (<1%) 
EWS POU5F1 6;22 ESFT like 
EWS SP3 (zinc finger) 2;22 ESFT like 
EWS PATZ1 (zinc finger) 1;22 ESFT like 
EWS ATF1 (leucine zipper) 12;22 
melanoma of soft parts, 
clear cell sarcoma 
EWS WT1 (zinc finger) 11;22 
desmoplastic small round 
cell tumour 
EWS CHOP (leucine zipper) 12;22 myxoid liposarcoma 
TLS/FUS CHOP (leucine zipper) 12;22 myxoid liposarcoma 
TLS/FUS ERG (ETS) 11;22 acute myeloid leukaemia 
 
Table 1: Different fusion types between TET proteins (EWS, TLS/FUS) and members of the ETS 
transcription factor family (FLI-1, ERG, ETV1, E1AF, FEV) or other fusion partners are present in 
a variety of tumours. Seven of these fusion types are found in ESFT. adapted from Kovar 2005 and 
Ordonez et al. 2009 
 
 
1.1.1.3. Survival rates and therapy 
Fourty years ago the 5-year survival rate for patients with a localised disease was 
only 10%. But progress in local therapy as well as systemic chemotherapy raised the 
survival rates to more than two-thirds. However, the prognosis for the 25% of 
patients with metastatic ESFT was and still remains poor. (Ludwig 2008) 
 
Management of ESFT consists of systemic chemotherapy and local control. Usually, 
three phases are employed: neoadjuvant multiagent chemotherapy (vincristine, 
doxorubicin, cyclophosphamide, ifosfamide, etoposide) to induce rapid 
cytoreduction; local therapy consisting of surgery and/or radiation therapy and 
consolidation therapy with chemotherapeutic regimens. (Ludwig 2008) 
1. Introduction 
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Even the latest generation of cytotoxic chemotherapy is not capable of improving 
the survival of patients with metastatic disease. Therefore, the need for targeted 
therapy is evident for these patients.  
The most suitable target in ESFT would be the translocation product itself. Several 
studies with antagonists or antisense RNA show that EWS/FLI-1 is indispensable for 
the growth of ESFT cells. (Kovar et al. 1996; Ouchida et al. 1995; Toretsky et al. 
1997) Nevertheless, application in the clinics is much more complicated due to 
difficulties in delivering nucleic acids. Inclusion of small interfering RNA (siRNA) 
into nanocapsules could be a solution. It was demonstrated that such nanocapsules 
are capable of inhibiting tumour growth in a xenograft model with EWS/FLI-1 
expressing NIH3T3 cells. (Toub et al. 2006) Additionally, inhibition of tumour 
growth by EWS/FLI-1 specific siRNA is also confirmed in xenograft models with ESFT 
cells. (Hu-Lieskovan et al. 2005a; Takigami et al. 2011) Further studies will show if 
this novel therapy is practicable in the clinics.  
CD99 might be another useful candidate for targeted therapy because of the high 
expression in ESFT. Inhibition of CD99 in vitro results in growth suppression and a 
reduced migratory ability. (Kreppel et al. 2006) Moreover, an in vivo study with an 
antibody binding to and silencing CD99 demonstrates that tumour growth is 
suppressed in an ESFT cell xenograft model. (Scotlandi et al. 2000) However, there 
is no direct homologue of CD99 in mice (Kreppel et al. 2006) so that the toxicity of 
this treatment cannot be assessed in mouse models for pre-clinical studies.  
The regulatory network responsible for ESFT transformation, growth and metastasis 
becomes more and more defined whereby novel targets for therapy are emerging. 
Recently, it was shown that CD99 modulates ESFT tumour differentiation, 
presumably by regulation of the mitogen activated protein kinase (MAPK) pathway 
and blockade of this CD99 downstream pathway could be exploited for novel 
therapeutic approaches. (Rocchi et al. 2010) Moreover, phosphatidylinositol 3-
kinase (PI3K)/AKT was identified as a core cancer pathway essential for ESFT 
growth. (Lawlor et al. 2002) Further signalling pathways activated in ESFT are Wnt 
(Wingless, int-1), Hedgehog and mTOR (mammalian target of rapamycin). (Uren et 
al. 2004; Zwerner et al. 2008; Zenali et al. 2009) These may serve to discover new 
therapeutic strategies. Recently, it was demonstrated that blocking the Hedgehog 
pathway with a drug called arsenic trioxide, directly inhibiting GLI1, suppresses 
growth of ESFT cells and reduces tumour growth in an ESFT xenograft model. 
1. Introduction 
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(Beauchamp et al. 2011) Moreover, ALK was recently identified as a EWS/FLI-1 
target in reprogrammed paediatric human mesenchymal stem cells (hMSC) and is 
also expressed in ESFT cell lines. This receptor tyrosine kinase may serve as a 
candidate for the novel selective small molecule kinase inhibitors. (Riggi et al. 
2010)  
The most promising strategy for therapy is targeting the insulin-like growth factor-1 
receptor (IGF-1R). The existence of an autocrine circuit mediated by IGF-1R and 
the importance for ESFT survival and pathogenesis was previously shown. (Scotlandi 
et al. 1996; Scotlandi et al. 1998) Pre-clinical testing of human monoclonal 
antibodies against IGF-1R demonstrated broad anti-tumour activity and phase 1 
clinical trials seem promising. (Kolb et al. 2008; Olmos et al. 2010) Currently, there 
are at least eight IGF-1R blocking antibodies from different pharmaceutical 
companies that have activity in ESFT, but only some and not all patients are 
responding. (Subbiah and Anderson 2011) Just these patients suffered from 
refractory advanced sarcomas that were resistant to all standard chemotherapies 
but now they have a chance of being cured. (Ludwig 2008) Other means to block 
IGF signalling are the use of small molecule inhibitors or recombinant proteins that 
systemically sequester IGF-1. (Hughes 2009)  
A new approach using small molecule inhibitors that disrupt the interaction of 
EWS/FLI-1 with its binding partners may also be applicable for ESFT therapy in the 
future. A compound found in a surface plasmon resonance screening was 
demonstrated to block interaction of EWS/FLI-1 with RNA helicase A. Since this co-
operation is essential for EWS/FLI-1 activity, the small compound is able to reduce 
growth of ESFT xenografts. (Erkizan et al. 2009) 
The therapeutic intervention targeting not the tumour itself but rather the tumour 
vasculature is not new but seems to be of use for ESFT as well. Antibodies directed 
against vascular endothelial growth factor receptor-2 (VEGFR-2) were shown to 
suppress tumour growth, to reduce tumour vessel formation and to inhibit 
migration of bone marrow cells into the tumour in ESFT xenograft models. (Zhou et 
al. 2007) 
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1.1.2. EWS/FLI-1 
As mentioned above the 11;22 translocation is the most abundant one, resulting in 
the fusion of EWS to FLI-1. Different types of in-frame transcripts are also possible 
within this group (Figure 1). Exon 7 of EWS and FLI-1 exon 9 are present in all of 
the different transcripts. The most common form (type 1) contains exon 1 – 7 of 
EWS and exon 6 - 9 of FLI-1 whereas the type 2 fusion links exon 1 – 7 of EWS and 
exon 5 - 9 of FLI-1. (Khoury 2005) 
 
 
Figure 1: Schematic representation of the most common EWS/FLI-1 fusion products. All 
translocations include exon 1 to 7 from EWS and exon 9 from FLI-1. Two cases have in addition exon 
8 to 10 from EWS. The contribution of FLI-1 exons is more versatile and the fusion protein can 
include exon 4 to 9, 5 to 9, 6 to 9, 7 to 9, 8 to 9 or exon 9 only, which is present in all fusion 
proteins. The number depicted in bold is the most prevalent translocation, termed type 1 fusion, 
which includes exon 1 to 7 from EWS and exon 6 to 9 from FLI-1. adapted from Khoury 2005 
 
For a long time it was believed that patients with a localised disease harbouring a 
type 1 fusion have a better clinical outcome. The type 1 fusion protein is less 
potent in transcriptional activation than the type 2 fusion proteins (Lin et al. 
1999), which would explain the difference in prognostic advantage. However, two 
recent studies published back to back disprove the assumption that there is a 
prognostic benefit for patients with a type 1 fusion. (Le Deley et al. 2010; van 
Doorninck et al. 2010) 
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EWS (Ewing’s sarcoma) is encoded on chromosome 22q12 and constitutes the 5’ 
part of the EWS/FLI-1 fusion. Together with TLS/FUS and TAFII68, EWS forms the 
TET family of proteins. Members of this family are characterised by a glutamine 
rich N-terminus and a putative RNA binding domain at the carboxy terminus (Figure 
2). (Arvand and Denny 2001) TET family members are ubiquitously expressed and 
primarily found in the nucleus. (Andersson et al. 2008) More and more insight in 
the physiological functions of TET family members is gathered. There is evidence 
that EWS interacts with the basal transcription factor TFIID and RNA polymerase II 
suggesting a role in RNA transcription and processing. (Bertolotti et al. 1998) 
Moreover, interactions of EWS with various splicing factors are proven, indicating 
an involvement in RNA splicing. (Knoop et al. 2000; Chansky et al. 2001) By using 
EWS-deficient mice, two groups recently proposed even more novel functions of 
EWS. They conclude that EWS might have roles in B-cell development, meiosis, 
DNA-repair/recombination and cellular senescence of haematopoietic stem cells. 
(Li et al. 2007; Cho et al. 2011) 
FLI-1 was first identified as a preferential retroviral integration site for the Friend 
murine leukaemia virus in erythroleukaemias. The ETS family of transcription 
factors consists of approximately 30 genes, one of them being FLI-1. (Arvand and 
Denny 2001) Members of this family are characterised by the evolutionary 
conserved ETS domain which binds to the 5’-GGAA/T-3’ motif. This winged helix-
turn-helix DNA binding domain can be located at variable sites in different family 
members. In FLI-1, the carboxy-terminal part contains the DNA binding domain and 
the transcriptional activation domain is located near the amino terminus (Figure 2). 
(Oikawa and Yamada 2003) In adult tissues FLI-1 is expressed mainly in 
haematopoietic tissues and plays a regulatory role in erythroid and lymphoid cell 
function. (Truong and Ben-David 2000) Knock-out studies indicate that FLI-1 
deficiency leads to a defect in haematopoiesis (granulocyte, erythrocyte and NK-
cell lineages are affected) and embryonic lethality. (Spyropoulos et al. 2000; 
Masuya et al. 2005) 
In ESFT the carboxy-terminal part of EWS, containing the RNA binding domain, is 
replaced by the carboxy terminus of FLI-1, harbouring the DNA binding domain. The 
residual glutamine rich repeats of the EWS amino terminus then function as a 
transcriptional activator in the EWS/FLI-1 fusion protein (Figure 2).  
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EWS (RNA binding protein) FLI-1 (ETS transcription factor)
NH2- -COOHTADNH2- RNA bindingQ-rich repeats DBD-COOH
EWS/FLI-1 aberrant transcription factor
-COOHNH2- Q-rich repeats DBD
 
Figure 2: Structure of EWS, FLI-1 and the resulting chimeric transcription factor. EWS contains 
glutamine-rich repeats in the amino-terminal part and a presumptive RNA binding domain at its 
carboxy terminus. The TAD of the transcription factor FLI-1 is located near the amino terminus and 
the carboxyl end of the protein harbours the DBD. In ESFT the 11;22 translocation generates a new 
protein which consists of the amino-terminal part of EWS with its glutamine-rich repeats and the 
DBD containing carboxy terminus of FLI-1. TAD = transactivation domain, DBD = DNA binding domain  
 
 
1.1.2.1. EWS/FLI-1 – the aberrant transcription factor  
Since the first experiments almost 20 years ago it became apparent that EWS/FLI-1 
is a potent chimeric transcription factor.  
Binding to DNA and nuclear localisation are prerequisites for a functional 
transcription factor. Like germline EWS and FLI-1, the fusion protein is located in 
the nucleus. The carboxy-terminal part of EWS/FLI-1 contains the ETS domain of 
FLI-1, conferring DNA binding to the ETS consensus sequence. Early analysis of the 
DNA binding specificity showed that EWS/FLI-1 retains the ability of FLI-1 to 
specifically bind to this core element. Deletion of the ETS domain abrogates DNA 
binding, revealing the importance of this part for the chimeric transcription factor. 
(May et al. 1993b)  
 
 
1.1.2.2. EWS/FLI-1 target genes 
In EWS/FLI-1 the ETS transcriptional domain of FLI-1 is replaced by the amino-
terminal part of EWS thereby generating a chimeric transcription factor with novel 
biochemical and genetic specificity. In a model reporter assay the transcriptional 
activity of EWS/FLI-1 was proven (May et al. 1993b) and since then comparative 
and functional strategies were used to identify target genes. It was surprising that 
several gene expression profiling studies uncovered an almost equal number of 
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genes down-regulated as up-regulated by EWS/FLI-1 (Siligan et al. 2005) but 
experiments in the beginning focused more on the activated targets. 
One of the first target genes discovered is stromelysin 1. It is a member of the 
metalloproteinase family that digests extracellular matrix proteins which is linked 
to tumour invasion and metastasis. (Braun et al. 1995) Up-regulation of manic 
fringe, a gene coding for gylcosyltransferase important in somatic development, 
was found in NIH3T3 cells ectopically expressing EWS/FLI-1. (May et al. 1997) The 
well-known proto-oncogene c-myc is highly expressed in ESFT cells and up-
regulated upon inducible expression of EWS/FLI-1 in neuroblastoma cells. 
(Dauphinot et al. 2001) The promoter activity of a putative tumour suppressor gene 
(transforming growth factor beta receptor II (TGFβ-RII)) was shown to be directly 
suppressed by EWS/FLI-1. (Hahm et al. 1999) This list of early studies to identify 
EWS/FLI-1 target genes is not complete and only a few are named since there is 
one evident limitation to these findings: all of the above mentioned targets were 
discovered in heterologous cell systems ectopically expressing EWS/FLI-1 and not in 
the original background of ESFT cells. 
A better way to determine target genes would be the down-regulation of EWS/FLI-1 
in ESFT cell lines and comparative gene expression profiling. The IGF binding 
protein 3 (IGFBP3), a major regulator of IGF-1 signalling, was found with this 
approach. (Prieur et al. 2004) Another target discovered with this strategy is 
NKX2.2, a homeobox containing protein with roles in neuronal development. (Smith 
et al. 2006) Immunoprecipitation of chromatin from ESFT cells that is bound by 
EWS/FLI-1 is a more direct way of identifying EWS/FLI-1 target genes in the 
authentic cellular background. With this approach 99 putative target genes were 
identified, one of them being MK-STYX, implicated in the regulation of MAPK 
pathway. (Siligan et al. 2005) A further target to be directly regulated by EWS/FLI-
1 is Id2, a helix-loop-helix protein involved in proliferation processes. (Fukuma et 
al. 2003) Caveolin-1 (CAV1), participating in tumour development and metastasis of 
a variety of cancers, is another direct target of EWS/FLI-1 that is over-expressed in 
ESFT cell lines and tumours. (Tirado et al. 2006) The orphan nuclear receptor DAX1 
was previously not involved in cancer but it is directly regulated by EWS/FLI-1 and 
is highly expressed in ESFT tumours. (Garcia-Aragoncillo et al. 2008) The Wnt and 
the Hedgehog pathway were already mentioned to play a role in ESFT. GLI1 is a 
downstream effector transmitting the Hedgehog signal to the nucleus and was 
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shown to be directly regulated by EWS/FLI-1. (Beauchamp et al. 2009) Moreover, 
the Wnt signalling pathway is controlled in ESFT by regulation of the Wnt inhibitor 
DICKKOPF-1 (DKK-1) and binding of EWS/FLI-1 to the transcription factor lymphoid 
enhancer factor 1 (Lef1). (Navarro et al. 2010) Among genes down-regulated by 
EWS/FLI-1 are cell cycle regulators like p21 and p57. (Matsumoto et al. 2001; 
Dauphinot et al. 2001) 
The hypothesis of ESFT arising from a mesenchymal progenitor cell is more and 
more substantiated by recent publications (for more detail see 1.1.3.). This offers 
the opportunity to study EWS/FLI-1 target genes that are required for ESFT 
initiation in the presumptive cell of origin. Induction of EZH2, a member of the 
polycomb group proteins, is up-regulated in EWS/FLI-1 expressing human MSCs and 
is also highly expressed in ESFT patient samples. (Riggi et al. 2008) IGF-1 is induced 
by EWS/FLI-1 in mouse as well as in human MSCs, depending on the DNA binding 
integrity of EWS/FLI-1, and may serve as a survival signal in the beginning of 
tumour development. (Riggi et al. 2005; Riggi et al. 2008) ALK, a receptor tyrosine 
kinase implicated in transformation and tumourigenesis, is expressed in ESFT cell 
lines and is also up-regulated in reprogrammed paediatric hMSC expressing 
EWS/FLI-1. Another kinase that shows enhanced expression upon EWS/FLI-1 
induction in reprogrammed paediatric hMSC is NTRK1. Its over-expression was 
shown to activate PI3K/AKT and MAPK signalling pathways. The embryonic stem 
cell genes OCT4 and SOX2 are responsible for maintaining an undifferentiated 
state. Induction of these genes by EWS/FLI-1 creates an environment allowing 
paediatric hMSC to form of a cell population with cancer stem cell characteristics. 
Both genes are indirectly regulated by EWS/FLI-1 via reversal of miRNA145 
repression and SOX2 is probably additionally regulated in a direct way. (Riggi et al. 
2010) 
For some of the mentioned target genes it was shown that down-regulation of 
EWS/FLI-1 activated genes (NKX2.2, CAV1, DAX1, GLI1, EZH2) and restoration of 
normal levels of EWS/FLI-1 repressed genes (TGF-βRII) results in diminished 
tumourigenic potential of ESFT cells. (Smith et al. 2006; Tirado et al. 2006; Garcia-
Aragoncillo et al. 2008; Riggi et al. 2008; Hahm et al. 1999) But until now, no 
single target gene was found that fully recapitulates the phenotype of a EWS/FLI-1 
transformed cell. (Arvand and Denny 2001) 
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Altogether, one can say that EWS/FLI-1 participates in ESFT pathogenesis by 
controlling the major characteristics of tumourigenesis: activation of genes 
involved in cell proliferation and survival (c-myc, NKX2.2, GLI1, DAX1…) and 
repression of genes regulating growth inhibition and apoptosis (p21, p57, TGF-
βRII...). More recently, EWS/FLI-1 is also implicated in up-regulation of genes 
involved in cell differentiation (SOX2, EZH2) and vascularisation (VEGF). (Riggi et 
al. 2010; Richter et al. 2009; Nagano et al. 2010) 
It is important to mention that EWS/FLI-1 influences the cells behaviour not only by 
target gene regulation but also through regulation of RNA-maturation and protein-
protein interactions. However, the two latter processes are not studied well 
enough in ESFT. (Lin et al. 2011) 
 
 
1.1.2.3. Biological functions of EWS/FLI-1 
Since it was not clear for a long time from which cell of origin ESFT arises, most of 
the experiments were carried out in heterologous cell systems. Through the use of 
a variety of different cells, it became early apparent that the biological function of 
EWS/FLI-1 is dependent on the cellular context.  
As already mentioned, the fusion protein is absolutely essential for ESFT cells to 
survive. Down-regulation of EWS/FLI-1 by means of antisense oligonucleotides or 
siRNA results in growth inhibition and a reduction of tumourigenicity in vitro as 
well as in vivo. (Toretsky et al. 1997; Takigami et al. 2011) Therefore, it became 
clear that EWS/FLI-1 as an aberrant transcription factor drives proliferation and is 
responsible for the transformed phenotype of ESFT cells.  
Introduction of EWS/FLI-1 into NIH3T3 cells uncovered that the fusion protein is a 
potent transforming agent whereas FLI-1 alone is not. The transforming ability is 
strictly dependent on the presence of both the EWS domain and the carboxy-
terminal DNA binding domain. (May et al. 1993a) The fusion protein is a more 
potent transcriptional activator than the amino-terminal region of FLI-1 alone. This 
might explain the discrepancy that FLI-1 is non-transforming whereas EWS/FLI-1 
efficiently transforms NIH3T3 cells. (May et al. 1993b) 
The cellular background of NIH3T3 cells seems to be permissive for stable EWS/FLI-
1 expression whereas the cellular context of primary mouse embryonic fibroblasts 
(MEFs) is not. Expression of EWS/FLI-1 in MEFs induces apoptosis and growth arrest. 
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(Deneen and Denny 2001) Experiments with primary human fibroblasts demonstrate 
the same growth inhibitory effect of EWS/FLI-1 in this cell system. (Lessnick et al. 
2002) 
Since more and more evidence uncovers a multi-potent mesenchymal progenitor as 
the ESFT cell of origin (see 1.1.3.), recent experiments make use of this cell type. 
Two reports published in the same year uncovered the tumourigenic potential of 
EWS/FLI-1 in such primary bone derived murine cells. (Castillero-Trejo et al. 2005; 
Riggi et al. 2005) In a subsequent publication, human MSCs were shown to tolerate 
EWS/FLI-1 expression without growth inhibition. (Riggi et al. 2008) The gene 
expression profile of hMSCs expressing EWS/FLI-1 is similar to that of ESFT but in 
paediatric hMSCs EWS/FLI-1 induces a molecular profile that more accurately 
recapitulates that of ESFT. (Riggi et al. 2010) Moreover, EWS/FLI-1 was shown to 
induce genetic reprogramming of paediatric hMSCs by modulating miRNA145 and 
SOX2 expression. (Riggi et al. 2010) 
There is also evidence that EWS/FLI-1 can block differentiation. A murine cell line 
with mesenchymal characteristics is blocked in differentiation after EWS/FLI-1 
induction and murine marrow stromal cells deficient in p19ARF lose their 
differentiation plasticity upon EWS/FLI-1 expression. (Eliazer et al. 2003; Li et al. 
2010; Torchia et al. 2003) In contrast, human EWS/FLI-1 expressing MSCs retain 
their differentiation potential. (Riggi et al. 2008) Despite the discrepancy between 
the species, ESFT cells itself are not able to differentiate into mesenchymal 
lineages but suppression of the fusion product recovers their differentiation 
potential. (Tirode et al. 2007) 
Another feature of EWS/FLI-1 is the induction of trans-differentiation with 
concomitant up-regulation of ESFT markers like c-myc and CD99. (Rorie et al. 2004; 
Hu-Lieskovan et al. 2005b) 
Altogether, these studies demonstrate that EWS/FLI-1 contributes to the ESFT 
morphology by attenuating the differentiation programme of its precursor cell 
leading to a less differentiated and more proliferative state. This assumption is also 
underscored by functional annotation of EWS/FLI-1 regulated genes showing that 
EWS/FLI-1 activated genes mainly regulate proliferation whereas repressed genes 
are involved in differentiation processes. (Kauer et al. 2009) 
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1.1.2.4. Cooperating mutations 
The p53 tumour suppressor gene is one of the most frequently altered genes in 
human malignancies. However, in childhood cancers like ESFT p53 mutations seem 
to play only a minor role. Different reports on the p53 status of ESFT patients 
demonstrate that mutations occur, but to a limited extent (5 to 14%). (de Alava et 
al. 2000; Komuro et al. 1993; Kovar et al. 1993; Park et al. 2001) In contrast, the 
frequency of p53 mutations in ESFT cell lines is dramatically increased, indicating a 
growth advantage in vitro. (Hamelin et al. 1994; Komuro et al. 1993; Kovar et al. 
1993) Moreover, patients with a p53 mutation have a reduced overall survival. 
Therefore, p53 alterations appear to define only a small subset of ESFT patients 
with a markedly poor outcome. (de Alava et al. 2000) 
Besides mutations in the p53 pathway, alterations of RB (retinoblastoma) pathway 
components play also a role in malignant transformation. p16INK4A is a member of 
the RB cell cycle regulatory pathway and is encoded by the INK4A/ARF locus, from 
which also p14ARF (in mouse: p19ARF) is expressed. This locus is often deleted in a 
variety of different cancers. The prevalence of INK4A/ARF alterations in ESFT 
varies from 13 to 30%. (Huang et al. 2005; Kovar et al. 1997; Lopez-Guerrero et al. 
2001) As seen with p53 alterations, loss of the INK4A/ARF locus is enriched in cell 
lines as a consequence of a selection process in vitro. (Kovar et al. 1997) Prognosis 
for patients with alterations in the INK4A/ARF locus is worse than for patients 
without this aberration. (Lopez-Guerrero et al. 2001) Loss of the INK4A/ARF locus 
is therefore the second most common molecular alteration observed in ESFT so far. 
Moreover, experiments with MEFs and primary human fibroblasts confirm the 
importance of INK4A/ARF in the transformation process of ESFT. EWS/FLI-1 leads to 
a reduced proliferation in MEFs but arrest effects are attenuated when EWS/FLI-1 
is expressed in INK4A/ARF deficient cells. These cells are able to form tumours in 
immunocompromised mice but p53 deficient EWS/FLI-1 expressing MEFs cannot. In 
primary human fibroblasts EWS/FLI-1 is only tolerated when the p16INK4A-Rb 
pathway is disrupted, whereas alterations in the p53 pathway alone do not have a 
similar effect. Hence, loss of the INK4A/ARF locus creates an environment 
permissive for EWS/FLI-1 expression, at least in immortal fibroblasts. (Deneen and 
Denny 2001) 
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1.1.3. Cell of origin 
Since the discovery of ESFT, the question of the cellular origin was eminent. James 
Ewing himself described the disease as a diffuse endothelioma of the bone with 
unknown origin. (Ewing 1972) Later on, a neural crest origin was discussed, as ESFT 
cells have the potential to differentiate into the neuronal lineage. (Cavazzana et 
al. 1987) Additionally, neuronal markers like neuron-specific enolase, Leu-7 and 
the Y1 receptor for neuropeptide Y were found on the ESFT cell surface. 
(Kawaguchi et al. 1987; van Valen et al. 1992) But later analysis revealed that 
EWS/FLI-1 itself induces a certain degree of neuronal features (Hu-Lieskovan et al. 
2005b; Riggi et al. 2008; Teitell et al. 1999) which led to a re-thinking in the quest 
for the ESFT cell of origin. 
The current hypothesis assumes that ESFT originates from a primitive multi-potent 
cell that can give rise to bone and soft tissue. MSCs would perfectly fit these 
requirements. Usually they are prepared from bone marrow, plated on plastic and 
the adherent cells are the presumptive MSCs. When cultured under appropriate 
conditions, these cells can differentiate along the osteogenic, adipogenic or 
chondrogenic lineage. It is noteworthy that these preparations are heterogeneous, 
composed of not one single cell type but rather a mixture of cells. (Lin et al. 2011) 
Authors give these cells different names: from mesenchymal stem cells, marrow 
stromal cells, primary bone derived cells to mesenchymal progenitor cells. 
Hereafter, the term mesenchymal progenitor cell (MPC) will be used to refer to this 
kind of cell mixture. 
Recent publications highlight the similarity of gene expression profiles of human 
MPCs and EWS/FLI-1 silenced ESFT cells. (Tirode et al. 2007; Kauer et al. 2009) 
Moreover, silencing of EWS/FLI-1 in ESFT cell lines recovers part of their 
differentiation potential and ESFT cells are then able to differentiate along the 
osteoblastic and adipogenic lineage, whereas wild type ESFT cells cannot. (Tirode 
et al. 2007) This is only partly true because within the ESFT cells a CD133-positive 
population exists that retains its differentiation plasticity. This CD133-positive 
population displays cancer stem cell (CSC) characteristics (= ESFT CSC) and is 
thought to arise from MPCs. (Suva et al. 2009) ESFT CSCs have the capacity to self-
renew, express genes involved in stem cell maintenance and nuclear 
reprogramming and have the potential to initiate and sustain tumour growth, 
thereby fulfilling the criteria of a CSC. (Suva et al. 2009) 
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Experiments with human MPCs identified their permissiveness for EWS/FLI-1 
expression and that MPCs expressing EWS/FLI-1 induce a gene expression profile 
reminiscent of that of ESFT. As opposed to mouse MPCs, human MPCs keep their 
differentiation potential after EWS/FLI-1 induction. (Riggi et al. 2008) Two years 
later the same group discovered that human paediatric MPCs expressing EWS/FLI-1 
resemble the gene expression profile of ESFT more closely than their adult 
counterpart. (Riggi et al. 2010) This was not surprising, since ESFT arises at a young 
age and only rarely in adults, from which usually the bone marrow is obtained to 
isolate MPCs. The highest similarity with ESFT gene expression profiles observed so 
far can be achieved with reprogrammed EWS/FLI-1 expressing paediatric MPCs, 
which then resemble some features of ESFT CSC. (Riggi et al. 2010) 
In summary, these results suggest that ESFT cells might arise from MPCs which are 
transformed by EWS/FLI-1 (CD133-positive, ESFT CSC characteristics) and retain 
their differentiation plasticity. (Riggi et al. 2010) ESFT CSCs can also generate a 
CD133-negative population which represents 92 - 96% of ESFT cells. (Suva et al. 
2009) These cells, which build up the tumour bulk, lost their differentiation ability 
and cannot give rise to cells of the mesenchymal lineages. (Tirode et al. 2007) 
 
 
1.1.4. Mouse models 
In recent years, some good candidates for targeted therapy were discovered (see 
1.1.1.3.) but their way into the clinics is demanding and cost intense. Another 
dilemma is that an appropriate mouse model for pre-clinical drug testing is lacking. 
So far, functionality of target modulation is tested in xenograft models where cell 
lines that have been cultivated over a long time, which may select for acquired 
mutations of tumour suppressor genes, form tumours in orthotopic sites, but this 
does not adequately recapitulate the biology of ESFT.  
Concerning translocation-associated sarcomas in general, there are currently three 
animal models that mimic the human disease. Conditional expression of TLS/FUS-
CHOP results in myxoid liposarcoma, alveolar rhabdomyosarcoma is formed in mice 
harbouring the Pax3-Fkhr fusion and synovial sarcoma is initiated by SYT-SSX2 in 
this mouse model. (Haldar et al. 2007; Keller et al. 2004; Perez-Losada et al. 2000) 
The first report about a mouse that expresses a fusion protein present in ESFT was 
published in 2005. This group uses a new conditional gene fusion model (invertor 
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knock-in) that mimics a chromosomal translocation. An ERG cassette, flanked by 
loxP sites, is knocked into the endogenous EWS locus in inverted orientation. Upon 
Cre activity, the cassette is flipped and the EWS/ERG chimeric protein is expressed 
(Figure 5A). The benefit of this strategy is that the fusion protein is under control 
of the endogenous EWS promoter, like in the human disease. The authors assess the 
tumour initiating potential of EWS/ERG in committed lymphoid cells. Therefore, 
they use the Rag1Cre to conditionally express EWS/ERG in B- and T-cells. 
Expression of the fusion protein is tolerated in this cellular background and clonal 
T-cell neoplasia arises in the invertor knock-in mice. Thus, EWS/ERG is able to 
initiate tumours in the lymphoid system. (Codrington et al. 2005) 
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Figure 3: Conditional mouse models for expression of fusion proteins present in ESFT. A The 
invertor knock-in strategy: an ERG cassette is introduced into the endogenous EWS locus in inverted 
orientation. Only upon Cre activity the ERG cassette is flipped and EWS/ERG can be expressed. B A 
floxed STOP-cassette in front of EWS/FLI-1 prevents transcription. Only upon Cre activity and 
concomitant excision of the STOP-cassette EWS/FLI-1 is expressed. This construct is knocked-in into 
the ubiquitously expressed Rosa26 locus. C This EWS/FLI-1 transgenic construct was designed with a 
β–actin promotor and a floxed GFP-cassette in front of EWS/FLI-1. Expression of GFP prevents 
transcription of the subsequent fusion gene. Only upon Cre activity and concomitant excision of the 
GFP-cassette EWS/FLI-1 is expressed. 
 
Two years later another strategy for the generation of a conditional EWS/FLI-1 
mouse model was reported. This group used a construct with a loxP flanked STOP-
cassette in front of the EWS/FLI-1 type 1 fusion, knocked into the Rosa26 locus. 
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Upon Cre activity the STOP-cassette is excised and EWS/FLI-1 is expressed in the 
target cells (Figure 3B). Since ESFT is believed to arise in MPCs, which are located 
in the bone marrow compartment, a Cre recombinase under control of an 
interferon regulated promoter is employed. (Torchia et al. 2007) Upon stimulation 
of the interferon pathway, Mx1Cre is expressed in haematopoietic cells or the liver 
and to a lesser extent also in other tissues. (Kuhn et al. 2005) The conditional 
expression of EWS/FLI-1 induces rapid development of a myeloproliferative disease 
with expansion of immature erythroid progenitor cells, densely infiltrating the 
liver, spleen or bone marrow. This confirms the oncogenic potential of EWS/FLI-1 
in vivo, but no sarcoma formation could be observed with this model. (Torchia et 
al. 2007) 
Both publications mentioned above report mouse models with tumours in the 
haematopoietic system but do not mimic the human situation where ESFT arise in 
bone and soft tissue. (Codrington et al. 2005; Torchia et al. 2007) As discussed in 
1.1.3., it is currently hypothesised that ESFT originates from a primitive 
mesenchymal cell, in which EWS/FLI-1 has to be expressed in a proper mouse 
model. The selection of the right cellular background to express EWS/FLI-1 is the 
most tricky and essential part in designing a mouse model that develops sarcomas 
resembling ESFT. And this could also answer in part the question of the cellular 
origin.  
During the work for this PhD thesis the generation of a transgenic mouse which 
expresses EWS/FLI-1 in the primitive mesenchymal cells of the developing limb bud 
was published. (Lin et al. 2008) They used a similar strategy as Torchia et al. 2007 
but instead of the STOP-cassette, a loxP flanked GFP-cassette was introduced in 
front of the EWS/FLI-1 type 1 fusion (Figure 3B). Upon Cre activity, the GFP-
cassette is excised and EWS/FLI-1 is expressed in the target cells. This group uses 
the Prx1Cre, which is expressed early in the limb bud mesenchyme. (Logan et al. 
2002) Double transgenic mice show developmental defects like limb shortening and 
immature bone but do not display tumours. However, conditional deletion of p53 
with Prx1Cre results in the formation of predominantly osteosarcomas with a 
median tumour latency of 50 weeks. In this setting EWS/FLI-1 accelerates tumour 
formation and shifts the tumour spectrum to a more poorly differentiated sarcoma 
phenotype. (Lin et al. 2008) 
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1.1.5. Limb development 
To better understand the biology of ESFT origin, it is necessary to know how bone 
development occurs under normal circumstances. Skeletal elements are already 
formed in the embryo by either intramembranous ossification, where mesenchymal 
cells differentiate directly into osteoblasts, or endochondral ossification. Most 
parts of the skeleton are formed by the latter process, where a cartilage template 
is replaced by bone. Endochondral ossification starts with mesenchymal 
condensations at the place of the future bone. Mesenchymal progenitors, which 
originate from the neural crest, somites and lateral plates, differentiate first into 
chondrocytes and form the cartilage template. Later, differentiated osteoblasts 
invade from the perichondrium, the area surrounding the cartilage element, into 
the chondrocyte zones and form bone.  
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Figure 4: Endochondral bone formation. A cartilage template, divided into distinct zones of 
chondrocyte maturation stages, is replaced by the bone forming osteoblasts that invade from the 
perichondrium, the area surrounding the chondrocyte cells. Differentiation of chondrocytes is 
tightly coupled to osteoblast maturation. Secretion of Indian Hedgehog (Ihh) from pre-hypertrophic 
chondrocytes induces differentiation of osteoblasts. Moreover, Wnt/β-catenin signalling is required 
for the final maturation step of osteoblasts. Ihh = Indian Hedgehog, Osx = Osterix, Opn = 
Osteopontin. adapted from Day and Yang 2008 
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Endochondral bone formation is tightly linked to chondrocyte differentiation. The 
cartilage element consists of distinct zones of chondrocytes stages along the 
longitudinal axis (Figure 4). In the resting zone, chondrocytes divide slowly and are 
small and round. In the process of maturation, chondrocytes leave this zone, 
increase their proliferation rate and have an elongated shape. Then, the cells stop 
dividing, start to differentiate in pre-hypertrophic, later hypertrophic chondrocytes 
and finally die by apoptosis. Signalling molecules secreted by these differentiated 
chondrocytes are required for subsequent osteoblast differentiation. (Day and Yang 
2008; Hartmann 2007) 
 
Two key signalling pathways are indispensable for proper skeletal development, 
namely Hedgehog and Wnt signalling. Hedgehog and Wnt proteins are secreted 
ligands that bind to their respective receptors and transduce the signal to the 
nucleus (Figure 5). Hedgehog molecules bind to Patched1 (Ptch1) thus releasing 
Smoothened (Smo) from its inhibition. Smo can then transmit the signal into the 
nucleus where target genes like Ptch1 and Gli1 are transcribed. In the process of 
endochondral bone formation, Indian Hedgehog (Ihh) is released by pre-
hypertrophic chondrocytes and regulates the differentiation of osteoblasts (Figure 
4). (Day and Yang 2008) Moreover, Ihh blocks chondrocyte hypertrophy by up-
regulating parathyroid hormone related peptide (PTHRrP), generating a feedback 
loop that controls chondrocyte maturation. (Lai and Mitchell 2005) 
In absence of a Wnt signal, glycogen synthase kinase-3 (Gsk-3) phosphorylates β-
catenin and marks it for proteasomal degradation. GSK-3 acts in the “destruction 
complex” including adenomatous polyposis coli (APC) and Axin. Upon binding of 
Wnts to their co-receptors Frizzled (Fz) and lipoprotein receptor-related protein 
(LRP) 5/6, Dishevelled (Dsh) is activated causing disassembly of the “destruction 
complex”. β-catenin is stabilised, accumulates and translocates to the nuclear 
compartment. Together with T-cell factor (Tcf) / lymphoid enhancer factor (Lef) 
transcription factors β-catenin activates gene expression. Wnt/β-catenin signalling 
controls the differentiation of progenitor cells into either osteoblasts or 
chondrocytes and also plays a role downstream of Ihh in promoting maturation of 
osteoblasts (Figure 4 and 6). (Day and Yang 2008) 
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Figure 5: Hedgehog and Wnt signalling pathways. A In the absence of Hh molecules binding to its 
receptor Ptch1, Smo is repressed. Upon ligand binding, Ptch1 relieves its repression and Smo can 
transmit the signal to the nucleus, where target genes like Gli1 and Ptch1 are transcribed. B In the 
absence of Wnt molecules binding to its receptors Fz and LRP5/6, β–catenin is phosphorylated by 
Gsk-3, in a complex with Axin and APC, and degraded. Wnt binding to the receptors activates Dsh 
which inhibits the “distruction complex”. β–catenin is stabilised and together with Tcf/Lef induces 
gene transcription. Ptch1 = Patched1, Smo = Smoothened, Hh = Hedgehog, Fz = Frizzled, LRP5/6 = 
lipoprotein receptor-related protein 5/6, Gsk-3 = glycogen synthase kinase-3, APC = adenomatous 
B 
A 
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polyposis coli, Dsh = Dishevelled Tcf = T-cell factor, Lef = lymphoid enhancer factor. adapted from 
Day and Yang 2008 
 
During the process of chondrocyte and osteoblast differentiation, specific genes are 
up-regulated that can be used as markers to distinguish distinct stages (Figure 6). 
Mesenchymal condensations up-regulate Sox9 which is necessary for differentiation 
into chondrocytes. (Hartmann 2007) On the other hand Runx2 accounts for 
osteoblast differentiation. β-catenin is required for osteoblast lineage 
differentiation and inhibits chondrogenesis, which is associated with the repression 
of Sox9. (Hill et al. 2005) Along the osteoblast lineage Osterix (Osx) is expressed in 
immature osteoblast whereas Osteocalcin (Osc) and Collagen1 (Col1) are markers 
for mature osteoblasts. Collagen2 (Col2) is expressed in proliferating and pre-
hypertrophic chondrocytes, Ihh only in pre-hypertrophic chondrocytes and 
Collagen10 (Col10) is exclusively present in hypertrophic chondrocytes. (Day and 
Yang 2008; Hill et al. 2005; Lai and Mitchell 2005) 
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Figure 6: Markers for different stages of osteoblast and chondrocytes. Mesenchymal cell fate is 
dependent on Runx2, β-catenin and Sox9 levels. High Runx2 and β-catenin levels initiate the 
osteoblast differentiation programme whereas high Sox9 levels are responsible for commitment to 
the chondrocyte lineage. Markers depicted in pink are used for in situ hybridisation to distinguish 
distinct maturation stages of osteoblasts and chondrocytes. Osx = Osterix, Osc = Osteocalcin, Col1 = 
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Collagen1, Col2 = Collagen2, Ihh = Indian Hedgehog, Col10 = Collagen10; adapted and modified from 
http://www.imp.ac.at/research/christine-hartmann/research 
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1.2. The JAK/STAT pathway 
 
 
Cytokines are signalling molecules that play a critical role in the normal 
development and function of the immune system. They are responsible for the 
intercellular communication and transmit signals via the Janus kinase (JAK) / Signal 
transducer and activator of transcription (STAT) pathway. Cytokine receptors lack 
intrinsic kinase activity and instead depend on JAK to pass on the signal to the 
nucleus. (Ortmann et al. 1999) 
The JAK family is a rather small family of tyrosine kinases with four mammalian 
members - JAK1, JAK2, JAK3 and TYK2. In contrast to the other family members 
that are quite ubiquitously expressed, JAK3 has a more restricted expression. JAKs 
are quite large proteins with more than 1100 amino acids. The amino-terminal part 
facilitates binding to the appropriate cytokine receptor whereas the carboxyl-
terminus contains the kinase domain. (Ortmann et al. 1999) 
STATs are latent cytosolic transcription factors that upon phosphorylation 
translocate to the nucleus and activate target gene transcription. In mammalians 
seven members are identified: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and 
STAT6. (Yu and Jove 2004) The amino-terminal part of the protein is necessary for 
receptor docking, co-factor binding and oligomerisation (Figure 7). The coiled coil 
domain mediates binding to regulatory proteins and other transcription factors. 
The DNA binding domain confers direct contact to STAT consensus sequences. Two 
types of DNA motifs are essential: IFN stimulated response element (ISRE) 
AGTT(N3)TTTCC to which STAT1, STAT2 and interferon regulated factor (IRF) 9 
bind; γ-activated sequence (GAS) TT(N4-6)AA that is recognised by STAT1, STAT3, 
STAT4, STAT5A, STAT5B and STAT6. (Ortmann et al. 1999) The src homology 2 
(SH2) domain enables reciprocal binding to the phosphorylated tyrosine of the STAT 
dimerisation partner. Dimerisation and subsequent nuclear translocation are 
required for binding to DNA. At the most carboxy-terminal part resides the 
transactivation domain responsible for regulating gene transcription and the 
tyrosine phosphorylation site. Tyrosine phosphorylation is a prerequisite for 
dimerisation and nuclear translocation. (Yu and Jove 2004) Moreover, STAT1, 
STAT3, STAT4 (except the splice isoforms), STAT5A, STAT5B and STAT6 contain 
additional phosphorylation sites at serine and threonine residues that were 
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reported to enhance transcriptional activity in some STATs. (Friedbichler et al. 
2011) Unlike tyrosine phosphorylation, the functional significance of the 
phosphorylated serine residue is controversial but recent evidence points to a so 
far underrated role for cancer cell transformation or proper immune cell function. 
(Friedbichler et al. 2010; Pilz et al. 2009) 
 
 
Figure 7: Schematic representation of the general STAT structure. All STAT members have a 
quite similar domain organisation with a length of the whole protein varying from approximately 750 
amino acids (most of the STATs, except the β isoform of STAT1 and STAT3) to 850 amino acids 
(STAT2 and STAT6). The most amino-terminal part confers receptor docking, co-factor binding and 
oligomerisation. Binding to regulatory proteins and other transcription factors is enabled by the 
coiled coil domain. With the DBD STAT proteins specifically bind to the respective consensus 
sequences. The SH2 domain is necessary for dimerisation by facilitating binding to the 
phosphorylated tyrosine of the STAT dimerisation partner. Gene regulation is mediated by the 
carboxy-terminal part that contains the TAD and the tyrosine phosphorylation site. This domain is 
lacking in the β isoforms of STAT1 and STAT3. NTD = N-terminal domain, DBD = DNA binding domain, 
SH2 = src homology 2, TAD = transactivation domain, pY = tyrosine phosphorylation site 
 
In general, the process of signal transduction via the JAK/STAT pathway starts with 
ligand binding to the corresponding receptor (Figure 8). The individual receptor 
chains dimerise and bring the associated JAKs in close proximity which reciprocally 
phosphorylate each other. Subsequently, the cytoplasmic tails of the receptors are 
phosphorylated which serve as docking platforms for STAT proteins. (Aaronson and 
Horvath 2002) Not so long ago, it was believed that un-phosphorylated STAT 
proteins are present in the cytosol as monomers but researchers discovered that 
they exist as a STAT dimer which binds to the phosphorylated receptor. (Sehgal et 
al. 2008) The critical tyrosine residues are phosphorylated and the STAT dimer 
translocates to the nucleus and activates target gene transcription. (Aaronson and 
Horvath 2002) 
This “old-fashioned” linear view on JAK/STAT signal transmission is complemented 
with more and more new data leading to following conclusions: Not all of the 
phosphorylated STATs are located in the nucleus and possible cytoplasmic functions 
1 750-
850 
pY 
NH2- -COOH NTD  coiled-coil DBD SH2 TAD 
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could be modulation of the duration of signal transmission or cross-talk with other 
pathways. Un-phosphorylated STATs constantly shuttle between the nuclear and 
cytoplasmic compartment, so nuclear import is not dependent on tyrosine 
phosphorylation. (Sehgal et al. 2008) Moreover, un-phosphorylated STATs are 
transcriptionally active but with a set of target genes different from those 
activated during cytokine signalling. (Cheon et al. 2011) 
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Figure 8: Simplified schematic representation of signalling via the JAK/STAT pathway. Cytokine 
receptors are transmembrane proteins that lack an intrinsic kinase domain but have instead JAK 
kinases attached. Upon ligand binding, individual receptor chains are brought together so that the 
associated JAK kinases phosphorylate each other and the receptors. STAT proteins then bind to the 
phosphorylated region of the receptors and are phosphorylated by the JAK kinases. Subsequently, 
STAT dimers travel to the nucleus, bind to DNA consensus sequences and regulate gene 
transcription. 
 
In terms of regulation of this signal transduction pathway there are different means 
of shutting down signal transmission.  
Protein tyrosine phosphatases like SHP1, SHP2 and PTP1B act at the level of the 
receptor kinase complex or directly on STAT dimers. (Klampfer 2006) 
In contrast to regulating phosphorylation, there are also proteins that directly bind 
to JAKs and inhibit their activity. Suppressor of cytokine signalling (SOCS) members 
are SH2 domain proteins that are induced rapidly upon cytokine stimulation and 
serve as classical negative feedback inhibitors. (Klampfer 2006) 
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Moreover, protein inhibitors of activated STAT (PIAS) bind directly to activated 
STAT dimers and inhibit gene activation. (Aaronson and Horvath 2002; Klampfer 
2006) 
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Figure 9: Simplified overview of STAT1 and STAT3 activating cytokine signalling pathways. On 
the left side the receptors and cytokines that mainly activate STAT1 are depicted and the right side 
shows mainly STAT3 activating ligand/receptor combinations. IFN-γ employs to IFNGR1 and IFNGR2 
and only STAT1 homo-dimers, which bind GAS sequences, are formed. Via IFNAR1 and IFNAR2, type I 
IFNs (IFN-α and IFN-β) lead to activation of STAT1 homo-dimers as well as a complex consisting of 
STAT1, STAT2 and IRF9 that specifically binds to ISRE elements. STAT1 proteins are known to have 
following properties: anti-proliferative, pro-apoptotic, anti-viral, immunomodulatory and hence 
anti-cancer. Gp130 is a component of all IL-6 type cytokine receptor complexes together with an 
individual receptor chain. IL-6 binds two gp130 molecules and the specific IL-6R. LIFR is present in 
receptor complexes that bind CNTF, LIF and OSM. CNTF engages, together with gp130 and LIFR, the 
CNTFR chain. OSMR is exclusively present in the complex binding OSM. All these combinations 
activate mainly STAT3 and act therefore anti-apoptotic, pro-proliferative and hence cancer 
accelerating. IFN = interferon, IFNGR = interferon-γ receptor, IFNAR = interferon-α receptor, gp130 
= glycoprotein 130, IL-6 = interleukin-6, CNTF = ciliary neurotrophic factor, LIF = leukaemia 
inhibitory factor, OSM = oncostatin M, IL-6R = IL-6 receptor α, CNTFR = CNTF receptor α chain, LIFR 
= LIF receptor, OSMR = OSM receptor, ISRE = IFN stimulated response element, GAS =  γ-activated 
sequence 
 
Interferons (IFN) are cytokines that have the property to act in an anti-viral, anti-
proliferative and immunomodulatory manner. There are two main classes of IFNs, 
namely type I, which comprise IFN-α and IFN-β, and type II IFN including only IFN-γ. 
1. Introduction 
38 
Type I IFNs are distinct from the majority of STAT activating cytokines. Activation 
of JAK1 and TYK2 associated with type I IFN receptors leads to phosphorylation of 
STAT1 and STAT2 (Figure 9). These two STAT proteins constitute a trimeric 
complex together with IRF9, called interferon-stimulated gene factor 3 (ISGF3), 
which binds to ISRE elements and activates anti-viral target genes. (Platanias 2005) 
Activation of STAT3 is also induced by IFN-α but its function is not so well studied. 
A possible role for IFN-α activated STAT3 might be negative regulation of the 
inflammatory response which is obtained by STAT1 sequestration. (Ho and Ivashkiv 
2006) IFN-γ signalling requires JAK1 and JAK2, activating only STAT1 proteins. 
STAT1 homo-dimers recognise GAS elements and activate an anti-tumour immune 
response. (Platanias 2005) 
Moreover, other signalling pathways, like the mitogen-activated protein kinase 
(MAPK) or PI3K/AKT pathway, are also activated by IFNs. They interact with the 
JAK/STAT mediated signalling either on the level of gene transcription or by 
regulating serine phosphorylation of STAT1. (Platanias 2005) 
 
The interleukin (IL)-6 type cytokines activate mainly STAT3 (STAT1 phosphorylation 
is more transiently) and regulate differentiation, survival, proliferation and are 
also major players in immune responses. One receptor chain, glycoprotein (gp) 130, 
is included in all receptor complexes employed by the different family members 
(Figure 9). IL-6 type cytokines include ciliary neurotrophic factor (CNTF), 
leukaemia inhibitory factor (LIF) and oncostatin M (OSM). IL-6 and CNTF bind to a 
complex of gp130 molecules or gp130 and LIF receptor (LIFR) and the non-signalling 
IL-6 receptor α (IL-6R) or CNTF receptor α chain (CNTFR), respectively. In contrast, 
LIF and OSM bind to complexes consisting of one gp130 molecule and one LIFR or 
OSMR chain. (Heinrich et al. 2003) Gp130 can bind to JAK1, JAK2 and TYK2 and 
thereby activates STAT3. (Ortmann et al. 1999) 
 
 
1.2.1. JAK/STAT in cancer 
STATs regulate several processes that control proliferation, cell survival, 
angiogenesis and immune responses. Since de-regulation of these processes can 
lead to neoplastic transformation, perturbation of JAK/STAT signalling is 
predestined to be involved in tumourigenesis. (Klampfer 2006; Yu and Jove 2004) 
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There are no mutations in STAT genes found in tumours but many mutations affect 
tyrosine kinases. In fact, all four JAK kinases have been discovered to be mutated 
in human cancer. (Ghoreschi et al. 2009) Additionally, over-production of cytokines 
or their receptors, hyperactive tyrosine kinases or silencing of negative regulators 
(SOCS or PIAS) renders STAT proteins constitutively active. (Bromberg 2002; 
Klampfer 2006) 
Hyperactivation of STAT1 is only rarely found in some tumour types. Which is not 
surprising with STAT1 being a potent inhibitor of growth (induction of p21, p27; 
repression of c-myc, cyclins) and promoter of apoptosis (up-regulation of caspase-8 
expression). (Fulda et al. 2002; Regis et al. 2008) With these tumour suppressor 
properties, constitutive active STAT1 is rather an indicator of good prognosis for 
e.g. breast cancer patients than driving tumourigenesis. (Klampfer 2006) 
Constitutive active STAT3 is sufficient to transform fibroblasts in vitro, 
demonstrating the oncogenic properties of STAT3. (Bromberg 2002) STAT3 drives 
cell proliferation (up-regulation of cyclin D1, c-Myc), inhibits apoptosis (induction 
of Bcl family members), promotes angiogenesis (VEGF up-regulation) and 
suppresses anti-tumour immune responses, processes that are involved in 
tumourigenesis. (Regis et al. 2008) Indeed, constitutive activation of STAT3 is often 
discovered in lymphomas or solid tumours. (Yu and Jove 2004) 
STAT5 activation is frequently found in various leukaemias promoting proliferation 
and inhibiting apoptosis. One way to constitutively activate STAT5 is the presence 
of the well-known Bcr-Abl tyrosine kinase, resulting from a chromosomal 
translocation (Philadelphia chromosome) in chronic myelogenous leukaemia (CML). 
(Klampfer 2006) There are many other mechanisms how tumour cells render STAT5 
active and they are well described in the literature but only discussed shortly here 
since STAT5 was not relevant for the PhD thesis.  
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1.3. Aim of the thesis 
 
 
Chromosomal translocations are a hallmark of ESFT and present the driving force in 
ESFT pathogenesis. The most prominent one rearranges chromosome 11 with 
chromosome 22, resulting in the EWS/FLI-1 fusion gene. Depending on the cellular 
context, EWS/FLI-1 is able to transform cells or leads to apoptosis or growth arrest. 
The question for the cell of origin is still under debate but more and more evidence 
points to a mesenchymal origin. 
ESFT is usually treated by chemotherapy in combination with surgery and/or 
radiotherapy. But since there is only little progress in the field of chemotherapy, 
the need for a mouse model is evident. Several attempts were already undertaken 
to generate a mouse model for ESFT but at the beginning of this study no mouse 
expressing EWS/FLI-1 was available that recapitulates the human phenotype. 
Thus, our gaol was to establish a mouse model that expresses EWS/FLI-1 in the 
relevant cellular background and that later on develops a sarcoma similar to ESFT. 
We used a conditional EWS/FLI-1 mouse model, which upon Cre activity (controlled 
by a tissue specific promoter) expressed EWS/FLI-1 in the targeted cells. Since 
ESFT arises in bone and surrounding soft tissue we decided to direct expression of 
EWS/FLI-1 to the mesenchymal lineage. 
 
Cytokines, either produced in the tumour microenvironment or released by tumour 
cells, are important regulators of signalling networks controlling many functions 
necessary for a tumour cell such as proliferation, differentiation, survival or 
tumour surveillance. Among others, the JAK/STAT signalling pathway regulates 
these functions. Although components of this pathway are often de-regulated in 
human cancers, not much is known about its function in ESFT. Only a few 
publications demonstrate that JAK1 is up-regulated and STAT3 was reported to be 
activated to variable degrees in ESFT patient samples.  
The aim of the second study of this thesis was to better understand the role of the 
JAK/STAT pathway in ESFT. Therefore, we carefully analysed different ESFT cell 
lines for activation of the JAK/STAT pathway. 
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2. Materials and Methods 
 
 
 
 
2.1. Working with mice 
 
 
2.1.1. Colony management 
Mice were kept under standard conditions at the Decentralised Biomedical Facility 
from the Medical University of Vienna on a 12 hours light-dark cycle. All animal 
experiments were approved by the Austrian ministry for science and research 
(license number: BMWF-66009/0139-C/GT/2007).  
Between 18-21 days after birth pups were weaned, marked with ear tags and a 
small piece of tail was collected for genotyping.  
 
2.1.1.1. Transgenic mouse strains 
Mice harbouring a Cre-inducible EWS/FLI-1 knocked into the ubiquitous Rosa26 
locus (Rosa26loxP-STOPloxP-HA-EWS/FLI-1 allele, homozygous mice were hereafter 
referred to as EF) were kindly provided by Dr. Suzanne Baker (St. Jude Children’s 
Research Hospital, Memphis, Tennessee, USA) via Material Transfer Agreement 
(MTA). (Torchia et al. 2007)  
To express EWS/FLI-1 in a restricted manner in the osteoblast lineage, mice 
harbouring the EF allele were crossed to Runx2Cre mice (courtesy of Dr. Jan 
Tuckermann, Fritz Lipmann Institute, Jena, Germany). (Rauch et al. 2010) Two 
Runx2 isoforms exist that are expressed from promotors P1 and P2. (Stock and Otto 
2005) P1 is assumed to be highly regulated and expresses the bone specific variant 
of Runx2. (Stock and Otto 2005) Therefore, the P1 promotor is employed in the 
construct for generation of Runx2Cre transgenic mice. This strain was generated 
with a BAC (bacterial artificial chromosome) approach, thus there were different 
transgenic lines available (777, 784, 1634). (Rauch et al. 2010) Runx2Cre EF mice 
were also bred to mice deficient in p16INK4A and p19ARF, thereafter referred to as 
INK4A/ARF (kindly provided by Dr. Manuel Serrano, Spanish National Caner 
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Research Centre, Madrid, Spain) (Serrano et al.1996), since deletion of INK4A/ARF 
is present in 20% of ESFT. (Lopez-Guerrero et al. 2001) Moreover, expression of 
EWS/FLI-1 in the limb bud mesenchyme was achieved by crossing EF to Prx1Cre 
mice (kindly provided by Dr. Malcolm Logan, National Institute for Medical 
Research, Mill Hill, United Kingdom via MTA). (Logan et al. 2002)  
Additionally, Mx1Cre was crossed into EF mice to proof proper expression of 
EWS/FLI-1 from the EF allele as published originally by Dr. Suzanne Bakers group. 
(Torchia et al. 2007) 
 
2.1.1.2. Genotyping mice  
Tail biopsies were digested with 0,5 mg/ml Proteinase K (Sigma), diluted in tail 
digestion buffer at 56°C overnight. Thereafter, 1 µl was used for genotyping PCR 
and the products were visualised on an agarose gel. 
 
Tail digestion buffer 
50 mM KCl 
10 mM Tris pH 8,3 
2 mM MgCl2 
0,1 mg/ml gelatine 
0,45% NP-40 
0,45% Tween-20 
 
PCR reaction mix 
0,2 µl Taq polymerase (5 U/µl, 5Prime) 
3 µl PCR buffer (10 x, 5Prime) 
0,5 µl dNTP mix (10 mM, Fermentas) 
1 µl primer mix 
3 µl 10% DMSO (only required for EF PCR) 
ad 30µl ddH2O 
 
 
Sequences of Primers, the expected products and the corresponding genotype are 
given in the tables below. 
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Runx2Cre 
name sequence concentration 
product 
[Bp] 
genotype 
cbfa_30 5’ GGAGCTGCCGAGTCAATAAC 3’ 2,5 pmol   
cbfa_24 5’ CCAGGAAGACTGCAAGAAGG 3’ 10 pmol 
780 wt 
cbfa_25 5’ TGGCTTGCAGGTACAGGAG 3’ 10 pmol  
600 
 
Cre+ 
 
EF 
name sequence concentration 
product 
[Bp] 
genotype 
RosaWT-R 5’ACACACCAGGTTAGCCTTTAAG 3’ 15 pmol   
RosaWT-F 5’GAGTTGTTATCAGTAAGGGAGC 3’ 15 pmol 
240 wt 
RosaKI-R 5’GATCCACTAGTTCTAGAGCGGC 3’ 15 pmol  
366 
 
EF 
 
Prx1Cre and Mx1Cre 
name sequence concentration 
product 
[Bp] 
genotype 
Cre1 5’CGGTCGATGCAACGAGTGATGAGG 3’ 10 pmol 
Cre2 5’CCAGAGACGGAAATCCATCGCTCG 3’ 10 pmol 
700 Cre+ 
 
INK4A/ARF 
name sequence concentration 
product 
[Bp] 
genotype 
P16F 5’CCCAGGTGAGCATAGTTGGT 3’ 10 pmol 
P16R 5’GGACTGAGAGGCTGCAAAAC 3’ 10 pmol 
300 wt 
Neo_F 5’CTATCAGGACATAGCGTTGG 3’ 10 pmol 
UTR_R 5’AGTGAGAGTTTGGGGACAGAG 3’ 10 pmol 
700 knock-out 
 
 
PCR conditions: 
94°C   2 minutes    initial denaturation 
94°C    20 seconds    denaturation 
55°C    20 seconds        40x annealing 
72°C    90 seconds   elongation 
72°C    2 minutes   final elongation 
22°C      storage ∞ 
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The INK4A/ARF PCR required an annealing temperature of 60°C. 
 
2.1.1.3. Plug check  
For embryo experiments vaginal plugs of females in breeding cages were checked 
daily. If a plug was found the female was separated and noon at that day was 
counted as E (embryonic day) 0,5. Embryos were then harvested at indicated time 
points. 
 
 
2.1.2. Xenotransplantation 
Severe combined immunodeficiency (SCID) mice (Charles River, c.b.17/icrHanHsd) 
have a reduced immune system (B- and T-cell deficiency) and are therefore 
suitable for transplantation of human cells. Since they are highly susceptible to 
infections they were kept in filter top cages with a separate air supply to prevent 
entry of pathogens.  
Tumourigenicity was determined after subcutaneous injection of 4 x 106 cells. 
Tumour growth was assessed 3 times a week by measuring tumour size. For ethical 
reasons, mice were sacrificed when the mean tumour volume ((a2 x b) x 2) 
exceeded 1,5 mm3. Tumours were either fixed in 4% formaldehyde in PBS for at 
least 48 hours at room temperature and processed as described in 2.1.3. or snap 
frozen in liquid nitrogen for RNA and protein extraction.  
 
PBS (Phosphate buffered saline) 
2,7 mM KCl 
1,4 mM KH2PO4 
137 mM NaCl 
4,3 mM Na2HPO4 
pH 7,4 
 
 
2.1.3. Tissue preparation, paraffin embedding, sectioning 
Mice were sacrificed by cervical dislocation or by euthanising with diethyl ether, 
organs were excised with sterile scissors and cut into 5 mm x 5 mm pieces to 
ensure proper fixation. Bones were cut out and freed from surrounding muscle 
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tissue. Organs were then snap frozen in liquid nitrogen or fixed in 4% 
formaldehyde/PBS for at least 48 hours at room temperature, washed twice with 
PBS and stored at 4°C. Bones were additionally decalcified in 0,5 M EDTA for 2 - 4 
weeks before further usage. Embryos were fixed in 4% paraformaldehyde (PFA)/PBS 
overnight at 4°C, washed twice with PBS, dehydrated manually with an ascending 
ethanol series (25%, 50%, 75%, 100%) and stored in 100% ethanol at -20°C.  
Dehydration, if not done manually, and paraffinisation were done automatically as 
followed: Organs were dehydrated with an ascending ethanol series (50%, 2 x 70%, 
2 x 80%, 3 x 96%), washed twice with xylene at 40°C and incubated in paraffin at 
60°C with 3 changes. Then, organs were embedded in paraffin filled metal moulds 
and allowed to solidify. Blocks were stored at room temperature until needed. 
Blocks were sectioned with a microtome into 2 µm or 5 µm thick slices. The 
sections were transferred carefully to a 55°C water bath to get rid of wrinkles and 
were picked up with Superfrost microscopic slides. Sections were dried overnight 
and stored at room temperature or 4°C for several weeks. 
 
 
2.1.4. Histology 
 
2.1.4.1. Haematoxylin and eosin staining (H&E) 
Sections were deparaffinised by incubation in xylene substitute (Shandon) for 15 
minutes (twice) and re-hydrated with a descending ethanol series (2 x 100%, 75%, 
50%, 25%) for 5 minutes each. Slides were incubated 5 minutes in dH2O and stained 
with Mayer’s haematoxylin solution (1:1 dilution in dH2O, Merck) for 10 minutes. 
Subsequently, sections were incubated in tap water for 5 - 10 minutes followed by 
dipping twice in 3% HCl/70% ethanol. Slides were rinsed with tap water for 7 
minutes and de-hydrated using an ascending ethanol series (25%, 50%, 75%). The 
tissue was counterstained with eosin staining solution for 2,5 minutes and 
incubated twice in 100% ethanol for 2 minutes. After a final 2 minutes incubation in 
xylene substitute, tissue sections were mounted with Eukitt mounting medium 
(Lactan) and analysed with a Zeiss Axio Imager.Z1 microscope. 
 
Eosin staining solution 
0,1% Eosin Y  
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70% ethanol 
0,25% acetic acid  
 
 
2.1.4.2. Immunohistochemistry 
Sections were deparaffinised by incubation in xylene substitute (Shandon) for 15 
minutes (twice) and re-hydrated with a descending ethanol series (2 x 100%, 75%, 
50%, 25%) for 5 minutes each. Slides were incubated 5 minutes in dH2O. 
Antigen retrieval was achieved by heating in a microwave oven. Slides were 
brought to boil (800 W, 2 minutes) in 10 mM citrate buffer pH 6,0 (Dako) and then 
maintained at a sub-boiling temperature (210 W) for 10 minutes. Afterwards, the 
slides were allowed to cool down and washed three times with PBS. After every 
following step, slides were washed three times with PBS. 
Endogenous peroxidase can cause non-specific background staining when a horse 
radish peroxidase (HRP) coupled secondary antibody is used. Therefore, slides were 
incubated for 15 minutes in H2O2 block (3% H2O2 in PBS) to quench endogenous 
peroxidase activity and the tissue was encircled with Dako Pen (Dako). To 
eliminate background caused by endogenous avidin or biotin, an additional blocking 
step was employed. Slides were incubated for 10 minutes with Avidin Block 
(Avidin/Biotin Blocking Kit, Vector-Labs) and subsequently 10 minutes with Biotin 
Block, followed by incubation with Superblock (ID-Labs) for not more than 7 
minutes. Since the secondary antibody used later is polyvalent and therefore also 
recognises endogenous mouse immunoglobulins, another blocking step was utilised. 
Mouse Block (2 drops in 2,5 ml PBS, M.O.M. Vector Labs) was left on slides for one 
hour and then slides were incubated with the primary antibody diluted in 1% 
BSA/PBS at 4°C. 
The next day, slides were incubated with Anti Polyvalent Biotinylated Antibody (ID-
Labs) for 10 minutes and with Streptavidin-HRP (ID-Labs) for 10 minutes. 
Subsequently, signals were detected with the AEC Staining Kit (4 ml dH2O + 2 drops 
Acetate buffer, 1 drop AEC Chromogen, 1 drop H2O2; Sigma). Staining intensity was 
controlled under the microscope and when assessed as appropriate, the reaction 
was stopped with dH2O. To differentiate the nucleus from the cytoplasm, staining 
with haematoxylin for 2 - 5 minutes was applied. Slides were rinsed in tap water, 
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mounted with Aquatex (Lactan) and analysed with a Zeiss Axio Imager.Z1 
microscope. 
 
antibody recognises dilution features 
pSTAT1 STAT1 p-Tyr701 1:100 rabbit polyclonal (9171, Cell Signaling) 
pSTAT3 STAT3 p-Tyr705 1:50 rabbit polyclonal (9131, Cell Signaling) 
 
 
2.1.4.3. In situ hybridisation  
All solutions were prepared or diluted with DEPC treated water. 
Slides were de-waxed twice 15 minutes in xylene substitute (Shandon) and re-
hydrated to PBS with a descending ethanol series (2 x 100%, 75%, 50%, 25%) for 5 
minutes each. 
After fixation with 4% PFA/PBS for 10 minutes the slides were washed three times 
with PBS-T. Antigen retrieval was achieved with incubation in 1 µg/ml Proteinase 
K/PBS for 10 minutes. Subsequent washing with PBS-T was followed by fixation 
with 4% PFA/PBS for 10 minutes and another three washing steps. After acetylation 
for 15 minutes with 0,25% acetic anhydride in 0,1 M triethanolamine and three 
washing steps with PBS-T slides were air-dried for 30 minutes.  
For one slide 100 µl hybridisation solution was incubated for 3 minutes at 85°C, 
mixed with 1 µl labelled probe (see 2.5.5) and applied to the slide. To protect the 
solution from evaporation, slides were covered with coverslips avoiding air bubbles. 
Hybridisation was done in a 65°C water bath for at least 16 hours.  
All washes were carried out in a water bath and solutions were pre–warmed. 
Coverslips were removed by rinsing in 5 x SSC and slides were incubated for 30 
minutes at 65°C in 1 x SSC/50% formamide. Following a 10 minute wash in TNE at 
37°C for 10 minutes, RNA was digested with 20 µg/ml RNase A in TNE at 37°C for 
30 minutes. After another TNE wash at 37°C for 10 minutes, slides were incubated 
once in 2 x SSC and twice in 0,2 x SSC for 20 minutes each at 65°C. 
Two washes in MAB-T for 5 minutes at room temperature were followed by blocking 
in 20% HISS/MAB-T for one hour at room temperature. Anti-digoxigenin-alkaline 
phosphatase antibody (1:2000, Roche) was diluted in 2% HISS/MAB-T and slides 
were incubated overnight at 4°C in a humidified box.  
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The next day slides were washed 4 times in MAB-T, once in NTMT for 10 minutes 
and BM purple AP substrate (Roche) was added. Incubation was done for up to 3 
days until a colour reaction could be seen.  
To stop the reaction, slides were rinsed in NTMT and washed twice in PBS for 5 
minutes. Then the tissue was post-fixed in 4% PFA/PBS for 10 to 20 minutes. Slides 
were rinsed twice in PBS and then in dH2O. Finally, pre-warmed (65°C) glycergel 
mounting medium (Dako) was applied and slides were analysed with a Zeiss Axio 
Imager.Z1 microscope. 
 
ddH2O-DEPC 
DEPC (1 ml/l) was added to ddH2O, mixed well, incubated overnight at room 
temperature and autoclaved. 
 
PBS  
10 x PBS was diluted to 1 x concentration with ddH2O-DEPC. 
 
PBS-T 
1 x PBS + 0,1% Tween–20 
 
Hybridisation Solution 
10 mM Tris pH 7,5 
500 mM NaCl 
1 mM EDTA 
0,25% SDS 
10% Dextran sulphate 
1 x Denhardts’s 
200 µg/ml yeast tRNA (Gibco) 
50% formamide 
filtered and stored at -20°C 
 
      50 x Denhardt’s  
1% Ficoll 400 
1% Polyvinylpyrolidone 
1% BSA 
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filtered and stored at -20°C 
 
20 x SSC 
3 M NaCl 
0,3 M sodium citrate  
 
5 x TNE 
50 mM Tris pH 7,5 
2,5 M NaCl 
5 mM EDTA 
 
2 x MAB 
200 mM Maleic Acid  
300 mM NaCl 
adjusted to pH 7,5 with 10 M NaOH 
 
MAB-T 
1 x MAB + 0,1% Tween-20 
 
HISS 
Sheep serum (Sigma) was heat inactivated at 56°C for 30 minutes and stored at 
-20°C.  
 
NTMT  
100 mM NaCl 
100 mM Tris pH 9,5 
50 mM MgCl2 
0,1% Tween–20 
 
 
2.1.5. Skeletal staining  
Embryos were skinned, eviscerated and incubated in 96% ethanol for at least 24 
hours at room temperature (embryos could be stored for several weeks at this 
stage). E 16.5 or younger embryos were additionally fixed in 4% PFA/PBS at 4°C 
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overnight and then incubated in 96% ethanol. All further steps were carried out at 
room temperature. Fat was removed by incubating in acetone and the following 
day embryos were stained with Alcian Blue/Alizarin Red. After 24 hours skeletons 
were dehydrated in a descending alcohol series (96%, 70%, 50%, 25%) for 30 minutes 
each and then digested with 1% potassium hydroxide (KOH) until surrounding tissue 
was cleared and the bones could be nicely seen. To store the skeletons a 
KOH:glycerol series was applied (3:1, 1:1, 1:3) and finally transferred into pure 
glycerol. 
 
Alcian Blue/Alizarin Red 
60% ethanol 
5% acetic acid 
5% Alcian Blue stock 
5% Alizarin Red stock 
 
Alcian Blue stock 
0,3% Alcian Blue in 70% ethanol 
 
Alizarin Red stock 
0,1% Alizarin Red in 96% ethanol 
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2.2. Tissue culture 
 
 
2.2.1. Cell lines 
SK-N-MC 
ESFT cell line established by Dr. June Biedler (Memorial Sloan-Kettering Cancer 
Centre, New York, USA) from a metastatic site of a neuroepithelioma from a 14-
year-old Caucasian female. (Biedler et al. 1973) 
karyotype: pseudo-diploid (http://www.dsmz.de) 
INK4A/ARF locus: no genetic alteration but Rb absent (Kovar et al. 1997) 
p53: truncated (Kovar et al. 1997) 
EWS/FLI-1 fusion: type1 (Kovar et al. 2001) 
EWS expression: present (Kovar et al. 2001) 
 
STA-ET-7.2  
ESFT cell line established at the Children’s Cancer Research Institute, Vienna, 
Austria from a pleural effusion of a 4-year-old female patient (the primary tumour 
was located in the chest wall). (Kovar et al. 1997) 
karyotype: near-triploid (Kovar et al. 2001) 
INK4A/ARF locus: no mutation but lack of protein expression (Kovar et al. 1997) 
p53: mutated (Kovar et al. 1997) 
EWS/FLI-1 fusion: type2 (Kovar et al. 2001) 
EWS expression: absent (Kovar et al. 2001) 
 
TC-71 
Cell line established by Dr. Timothy Triche (Department of Pathology, University of 
Southern California, Los Angeles, USA) from a local Ewing’s sarcoma relapse of the 
humerus. (Whang-Peng et al. 1984) 
karyotype: hyper-triploid (http://www.dsmz.de) 
INK4A/ARF locus: lack of expression (Zhang et al. 2004) 
p53: mutated (Zhang et al. 2004) 
EWS/FLI-1 fusion: type1 (http://www.dsmz.de)  
EWS expression: present 
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All cell lines were provided by Dr. Heinrich Kovars group (Children’s Cancer 
Research Institute, Vienna, Austria) and were cultivated in RPMI (PAA) 
supplemented with 10% fetal calf serum (FCS, PAA) and 1% Penicillin-Streptomycin 
(PAA).  
 
 
2.2.2. Propagation of cell lines 
Cells were cultivated in an incubator at 37°C in an atmosphere with 5% CO2. 
It was important to split the cells every two to three days according to their 
doubling time so that the cells never became over-confluent. 
Medium was removed and cells were washed with PBS. Then Trypsin (PAA) or 
Accutase (PAA) was added. After 10 minutes of incubation the cells were detached 
from the petri dish. Next, new medium was added, cells were resuspended and the 
cell number was determined (see 2.2.3.). Then the cells were diluted as required 
and were plated on new dishes. 
Additionally, dishes for STA-ET-7.2 and TC-71 were coated with fibronectin. One 
milligram fibronectin (Chemicon) was diluted in 30 ml PBS and dishes were 
incubated for 45 minutes at room temperature. Fibronectin solution was collected 
and could be re-used several times. Either the dishes were used directly or stored 
at 4°C. When cells were harvested with Accutase, fibronectin coated dishes could 
be re-used several times. 
 
 
2.2.3. Quantitation of cell number 
For the determination of cell number, 20 µl of the cell suspension was counted in a 
Neubauer-chamber. The number of counts in a square multiplied with 104 indicated 
the number of cells/ml. 
 
 
2.2.4. Freezing/ Thawing of cells  
Cells were trypsinised and pelleted by centrifugation for 5 minutes at 1200 rpm. 
The pellet was resuspended in pre-cooled 90% FCS/10% DMSO and incubated on ice 
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for 20 minutes. Afterwards the cells were stored overnight in a freezing container 
(VWR) at -80°C and were then transferred to liquid nitrogen. 
To thaw cells, the frozen tube was incubated in a 37°C warm water bath until the 
cell suspension was liquid. Immediately afterwards, the cell suspension was diluted 
in 5 ml pre-warmed medium and centrifuged. Finally, the cell pellet was 
resuspended in the desired volume of the appropriate medium. 
 
 
2.2.5. Cytokine stimulation 
For protein extracts, cells were stimulated 30 minutes at 37°C with the required 
cytokine before they were harvested. 
Alternatively, for target gene expression analysis cells were stimulated for 4 hours 
with the appropriate cytokine at 37°C and RNA was isolated. 
To measure proliferation in response to a cytokine, cells were stimulated with this 
cytokine one day after seeding and then medium containing the cytokine was 
changed every second day. 
Following cytokines were usually used at indicated concentrations, if not stated 
otherwise: 10 ng/ml ciliary neutrophic factor (CNTF, Peprotech), 10 ng/ml 
interferon alpha (IFN-α, Roche), 1 ng/ml interferon gamma (IFN-γ, Boehringer 
Ingelheim), 100 ng/ml interleukin 6 (IL-6, Immunotools), 1 ng/ml leukaemia 
inhibitory factor (LIF, Chemicon), 10 ng/ml oncostatin M (OSM, Immunotools).  
 
 
2.2.6. Proliferation assay  
To follow proliferation of cell lines over a defined time span, a proliferation assay 
employing the ability of crystal violet to stain viable cells was applied. 
Cells were fixed in the culture dish for 30 minutes with 10% formalin at room 
temperature and washed with PBS. Either they were used directly or stored at 4°C 
in PBS until further needed.  
Then, cells were stained 30 minutes with 0,1% Crystal Violet (Sigma) and 
subsequently washed with dH2O until the washing water was clear. The dye was 
extracted with 10% acetic acid, diluted 1:4 with dH2O and measured in a 96well-
plate at 570 nm. The values for the optical density were then compared to control 
and experimental groups.  
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2.2.7. Flow cytometric analysis 
Cells were harvested with Accutase and cell number was determined. For one 
antibody staining 0,5 – 1x106 cells were resuspended in 100 µl 5% FCS/PBS. The first 
antibody (see list below) was added in the indicated concentration and cells were 
incubated for 30 minutes at 4°C in the dark. After washing with PBS, anti-mouse 
IgG FITC conjugate (Sigma) was diluted 1:100 in 100 µl 5% FCS/PBS and cells were 
incubated with the secondary antibody for 30 minutes at 4°C in the dark. After a 
final wash with PBS, cells were resuspended in 500 µl 5% FCS/PBS and analysed on a 
FACScan. 
 
antibody 
amount needed for 
1 x 106 cells 
features 
CNTFRα 5 µl mouse monoclonal, 0,2 µg/µl (AN-B2, Santa Cruz sc-9993) 
gp130 10 µl mouse monoclonal (BR-3, Diaclone) 
IL-6R 10 µl mouse monoclonal (BR-6, Diaclone) 
LIFR 10 µl mouse monoclonal (10B12, 1 µg/µl) 
OSMRβ 5 µl mouse monoclonal, 0,2 µg/µl (AN-A2, Santa Cruz sc-9992) 
 
The LIFR antibody was a courtesy of Dr. Gerhard Müller-Newen, University Hospital 
Aachen, Germany. 
 
For flow cytometric analysis of mouse tissue, cells were dissociated by passing the 
tissue through a 70 µm cell strainer (BD Biosciences). Red blood cells were lysed by 
incubating the homogenised tissue for 5 minutes at room temperature in ACK lysis 
buffer. Cells were resuspended in PBS and 50 µl were used for each antibody 
staining. Antibodies (directly linked to a chromogen) were diluted 1:100 in PBS and 
50 µl were added to the cell suspension. After incubation for 30 minutes at 4°C in 
the dark, cells were washed with PBS and analysed on a FACSCanto. 
 
ACK lysis buffer 
155 mM NH4Cl 
10 mM KHCO3 
0,1 mM EDTA pH 8,0 
adjusted to pH 7,3 with HCl  
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antibody conjugate features 
cKit PE-Cy5 conjugate mouse monoclonal, 0,2 µg/µl (BD Bioscience) 
CD43 Phycoerythrin (PE) rat monoclonal, 0,2 µg/µl (BD Bioscience) 
CD71 Fluorescein-5-isothiocyanat (FITC) mouse monoclonal (BD Bioscience) 
 
 
2.2.8. Isolation of fibroblasts from mouse ear skin 
Mice were sacrificed, ears were sterilised with ethanol and only the part without 
hairs was excised. Each ear was washed in PBS and then minced with a scalpel in 
600 µl DMEM with 4 µg/µl Collagenase D (Roche) and 4 µg/µl Dispase II (Sigma) in a 
well of a 12 well-plate. Ear pieces were incubated in a 37°C incubator. The next 
day 1,5 ml DMEM + 10% FCS was added and the cells were singularised with a 70 µm 
cell strainer. Cells from one ear were plated into one well of a 6 well-plate. The 
following day medium was changed and cells were grown until subconfluency. Then 
they were re-plated and used for experiments.  
 
 
2.2.9. Infection of cells with lentivirus 
Fibroblasts isolated from mouse ear skin were infected with lentiviral vectors 
(pRRL-GFP and pRRL-CreIRESGFP; courtesy of Dr. Christopher Baum, Hannover 
Medical School, Germany). 
Old medium was removed from cells in a 12 well-plate and 10 µl virus (pRRL-GFP 
and pRRL-CreIRESGFP; transduction efficiency: 6,3 x 107/ml) was added together 
with 400 µl DMEM and 4 µg/µl protamine sulphate. The cells were centrifuged in 
the plate at 2000 rpm for 1 hour at room temperature. After 6 hours at 37°C in the 
incubator 600 µl fresh medium was added. The next day medium was changed and 
cells were analysed for GFP expression 48 hours after infection. 
 
 
2.2.10. Isolation of osteoblasts  
Newborn mice (up to 6 days old) were sacrificed by cervical dislocation in a sterile 
hood and dipped into ethanol. Then the skin on top of the head was removed. 
Calvariae were cut out with a transsection from the back of the skull over the eyes 
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on both sides up to the nose and were lifted, avoiding taking the brain along. 
Residual skin was removed and calvariae from one pup were put into one tube with 
1 ml PBS + 1% Penicillin-Streptomycin (PAA) and kept on ice.  
PBS was replaced by 1 ml digestion solution (MEMalpha (PAA) + 1% Penicillin-
Streptomycin + 0,2% Collagenase A (Roche) and 0,2% Dispase II (Sigma)) and 
incubated at 37°C on a heating block shaking with 600 rpm for 10 minutes. The 
liquid phase (fraction 1) was discarded and digestion was repeated with 1 ml 
digestion solution. Fractions 2 - 5 were collected in a big tube and stored on ice in-
between. Cells were then collected by centrifugation at 1500 rpm for 5 minutes 
and cells from one pup were plated in a well of a 6 well-plate with 2 ml growth 
medium (MEMalpha +10% FCS + 1% Penicillin-Streptomycin).  
Cells were grown until subconfluency and re-plated at a density of 10 000 
cells/cm2. At confluency the cells were induced with 100 µg/ml ascorbic acid 
(Sigma) and 5 mM ß-glycerophosphate (Sigma) in growth medium. Medium was 
changed twice a week for a total of 14 days and then analysed. Mineralisation of 
cells was controlled with Alizarin Red staining. 
 
2.2.10.1. Alizarin Red staining 
Cells were fixed for 10 minutes in 4% formalin/PBS and then stained with Alizarin 
Red S (Sigma, 2% in dH2O, pH 4,1) for 5 minutes. After rinsing with dH2O, nuclei 
were stained with haematoxylin for 5 minutes. Dehydration with an ascending 
ethanol series (50%, 70%, 96%) and subsequent rinsing in xylene was followed by 
mounting with Eukitt (Sigma).  
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2.3. Working with Bacteria 
 
 
2.3.1. Bacterial strains and culture 
E.coli strains XL1-blue or DH5α were used for propagation of plasmids.  
 
XL1-blue (Stratagene): 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB lacIqZ∆M15 Tn10 
(Tetr)]. 
 
DH5α (Invitrogen):  
F- φ80lacZ∆M15 ∆(lacZYA-argF)U169 recA1 endA1 hsdR17(rk-, mk+) phoAsupE44 
thi-1 gyrA96 relA1 λ- 
 
Bacteria were grown in liquid culture or an agar plates at 37°C. 
 
LB-medium 
1% Bacto-tryptone 
0,5% Bacto-yeast extract 
85 mM NaCl 
 
LB-agar plates 
1% Bacto-tryptone 
0,5% Bacto-yeast extract 
85 mM NaCl 
1,5% Bacto agar 
100 µg/ml ampicillin or 30 µg/ml kanamycin (antibiotics were only added when 
agar cooled down) 
 
 
2.3.2. Freezing of bacteria 
To store transformed bacteria, 100 µl glycerol and 900 µl liquid culture were mixed 
and frozen at –80°C. 
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2.3.3. Generation of heat shock competent bacteria 
A single colony from a LB plate with non-competent bacteria was inoculated in 2,5 
ml LB medium and grown overnight at 37°C. The culture was then diluted 1:100 in 
250 ml LB + 20 mM MgSO4 and grown until OD595 = 0,4 - 0,6. Cells were pelleted by 
centrifugation at 5000 rpm for 5 minutes at 4°C. The pellet was resuspended in 10 
ml TFBI and incubated for 5 minutes on ice. After centrifugation at 5000 rpm for 5 
minutes at 4°C cells were resuspended in 10 ml TFBII and incubated on ice for 15 - 
60 minutes. 100 µl aliquots were then frozen on dry-ice with ethanol and stored at 
-80°C. 
 
TFBI 
30 mM potassium acetate 
100 mM RbCl 
10 mM CaCl2 
50 mM MnCl2 
15% glycerol 
adjusted to pH 5,8 with acetic acid and filtered  
 
TFBII 
10 mM MOPS (3-Morpholinopropanesulfonic acid) 
75 mM CaCl2 
10 mM RbCl 
15% glycerol 
adjusted to pH 6,5 with KOH and filtered 
 
 
2.3.4. Transformation of heat shock competent bacteria 
To transform the competent bacteria, an aliquot was thawed on ice and then 
incubated with up to 1 µg plasmid DNA (5 – 10 ng for retransformation or 10 µl of 
ligation reaction) on ice for 15 minutes. The transformation mixture was then 
transferred to a heating block at 42°C for 1 minute and after this it was put back 
on ice for another minute. One ml of LB broth was added and the suspension was 
left on a shaker at 37°C for 1 hour. After the incubation, an aliquot (200 µl) of the 
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transformed bacteria was spread onto LB agar plates, containing the appropriate 
antibiotics. Then the plate was incubated overnight at 37°C and stored at 4°C. 
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2.4. Working with DNA 
 
 
2.4.1. Plasmid isolation from bacteria 
 
2.4.1.1. Minipreparation 
Bacterial cells from an overnight culture were harvested by centrifugation at 5000 
rpm for 7 minutes. The pellet was resuspended in 250 µl Suspension Buffer (Roche), 
250 µl Lysis Buffer (Roche) was added and the tube was mixed by inverting. After 
incubation for 4 minutes at room temperature, 450 µl Neutralisation Buffer (Roche) 
was added. The suspension was gently mixed by inverting and centrifuged at 14000 
rpm for 15 minutes at 4°C. The supernatant was mixed with 600 µl isopropanol and 
centrifuged again at 14000 rpm for 30 minutes at 4°C. The pellet was washed with 
500 µl 70% ethanol. After centrifugation at 14000 rpm for 15 minutes at 4°C, the 
pellet was air-dried and resuspended in ddH2O. 
 
2.4.1.2. Midipreparation (Genopure Plasmid Midi Kit, Roche) 
One millilitre of an overnight culture was diluted in 30 ml LB-Amp and incubated at 
37°C with vigorous shaking over night. The cells were harvested by centrifugation 
at 5000 rpm for 15 minutes at 4°C. The pellet was resuspended in 4 ml Suspension 
Buffer + RNase, 4 ml Lysis Buffer were added and the tube was inverted 6 - 8 
times. After incubation for 2 - 3 minutes at room temperature, 4 ml chilled 
Neutralisation Buffer was added. The suspension was gently mixed by inverting 6 - 
8 times and incubated on ice for 5 minutes. After clearing the lysate by filtration it 
was applied to a column, which was previously equilibrated with 2,5 ml 
Equilibration Buffer. When the solution passed the column, the column was washed 
twice with 5 ml Wash Buffer. The DNA was then eluted with 5 ml pre-warmed 
(50°C) Elution Buffer. Next, 3,6 ml isopropanol was added and the tube was 
centrifuged at 12000 rpm for 30 minutes at 4°C. The pellet was washed with 3 ml 
chilled 70% ethanol and centrifuged at 12000 rpm for 10 minutes at 4°C. The pellet 
was air-dried and resuspended in 100 µl ddH2O. 
 
The DNA concentration was calculated by measuring the absorption at 260 nm. 
When OD260 =1 the solution contained 50 µg/ml double stranded DNA. 
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OD260 x dilution x 50 µg/ml = concentration in µg/ml 
 
 
2.4.2. Analytical digest 
All restriction endonucleases used were obtained from Fermentas.  
DNA (up to 1 µg) was mixed with 10 U enzyme and 1 x buffer in a total volume of 
20 µl and incubated at 37°C. After 2 hours digestion the fragments were separated 
on an agarose gel. 
 
 
2.4.3. Agarose gel electrophoresis 
Agarose (0,5 -  1,5 g) was dissolved in 100 ml 1 x TAE (0,5 – 1,5% w/v) and heated 
in a microwave oven. After cooling down to about 60°C, 5 µl ethidium bromide (10 
mg/ml, Sigma) was added to an end concentration of 0,5 µg/ml and the gel was 
poured in the appropriate apparatus with combs. After the gel was solidified, it 
was transferred into the electrophoresis-apparatus filled with 1 x TAE. When the 
probes, mixed with loading buffer, and 5 µl 100 Bp or 1 kB marker (Gene Ruler DNA 
ladders, Fermentas) were loaded, the gel was run at 100 V until separation was 
satisfying.  
 
50 x TAE 
2 M Tris 
50 mM EDTA pH 8 
5,7% acetic acid 
 
6 x loading buffer 
0,25% bromphenolblue 
0,25% xylene cyanol 
30% glycerol 
 
 
2.4.4. Gel extraction (GenElute Gel Extraction Kit, Sigma)  
To purify PCR products or DNA fragments after restriction digest, the samples were 
loaded on an agarose gel and excised with a clean scalpel. The piece was put in a 
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1,5 ml tube together with 3 gel volumes of Gel Solubilisation Solution and 
incubated at 50°C for 10 minutes under continuous shaking. The gel slice should be 
completely dissolved and the colour of the solution should be yellow. In the 
meantime the GenElute Binding Column G was prepared by loading 500 µl of the 
Column Preparation Solution, centrifugation for 1 minute at maximum speed and 
discarding the flow-through. One gel volume of isopropanol was added and 700 µl 
of the solution were applied to the column. If the total volume exceeded 700 µl, 
aliquots were successively loaded onto the column. After centrifugation for 1 
minute at full speed, the flow-through was discarded. When all the liquid was 
loaded, the column was washed with 750 µl Wash Solution and centrifuged 1 
minute at maximum speed. The flow-through was discarded and the column was 
centrifuged for another minute at maximum speed to remove excess ethanol. The 
column was then transferred to a new tube and DNA was eluted with 50 µl ddH2O 
by incubating 1 minute at room temperature and subsequent centrifugation for 1 
minute at maximum speed. 
 
 
2.4.5. DNA Ligation 
The ratio between insert and vector should be 5:1 and they must have the same or 
compatible end sites. 
Insert and plasmid were mixed with 1 x Ligation Buffer and 1 U T4 DNA Ligase 
(Fermentas) in a total volume of 20 µl. The ligation reaction was incubated in a 
16°C water bath overnight and subsequently used for transformation of bacteria 
(see 2.3.4.) or stored at 4°C. 
 
 
2.4.6. Isolation of genomic DNA from cells, tissues or bone 
Organs were cut into small pieces and bones were crushed with mortar and pestle 
while constantly cooled with liquid nitrogen. Samples were then transferred to a 
microcentrifuge tube with 800 µl DNA extraction buffer. 
For cells, the DNA extraction buffer was added to the culture dish. The plate was 
then incubated for at least one hour at 37°C and the viscous solution was 
transferred to a microcentrifuge tube with a cut-off blue pipette tip.  
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Elimination of proteins was achieved by digestion with 0,5 mg/ml Proteinase K 
overnight at 56°C with vigorous shaking. Proteins were precipitated by adding 0,3 
volumes 6 M NaCl, vortexing for 5 minutes and centrifugation at 13000 rpm for 5 
minutes at 4°C. The supernatant was transferred to a new tube and mixed with 1 
volume of Phenol:Chloroform:Isoamylalcohol (25:24:1, Invitrogen).The sample was 
centrifuged for 5 minutes at 13000 rpm and the aqueous upper phase was 
transferred to a new tube. DNA was precipitated with 0,7 volumes isopropanol 
followed by mixing and centrifugation at 13000 rpm for 15 minutes at 4°C. The 
pellet was washed once with 500 µl 70% ethanol to remove excess salt, air-dried for 
10 minutes and resuspended in ddH2O.  
 
DNA extraction buffer 
50 mM Tris pH 8,0 
100 mM EDTA pH 8,0 
100 mM NaCl 
1% SDS 
 
 
2.4.7. PCR to detect deletion of the STOP-cassette of the EF allele 
To detect deletion of the STOP-cassette of the Rosa26loxP-STOPloxP-HA-EWS/FLI-1 
(EF) allele a PCR strategy was established. The forward primer was located in the 
endogenous Rosa26 locus (RosaWT_F) and the reverse primers were located shortly 
after the first loxP site (RosaKI_R) and within EWS/FLI-1 (EF_R1). A product of the 
forward (RosaWT_F) and the EF_R1 primer could only be observed when the STOP-
cassette was cut out by the Cre-recombinase. Otherwise, the distance between the 
two primers would be too long for the DNA polymerase to amplify this sequence. 
Genomic DNA was used as a template and PCR reaction mix and PCR conditions 
(50°C annealing temperature) were already described above (see 2.1.1.2.) 
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name sequence concentration 
product 
[Bp] 
genotype 
RosaKI_R  5’GATCCACTAGTTCTAGAGCGGC 3’ 10 pmol   
RosaWT_F 5’GAGTTGTTATCAGTAAGGGAGC 3’ 10 pmol 
366 KI 
EF_R1 5’GGTATCATAAGCACCAGTG 3’ 10 pmol  
800 
 
∆STOP 
 
 
2.4.8. PCR to detect expression of EWS/FLI-1 and Cre 
Expression of EWS/FLI-1 or Cre on the mRNA level was analysed with conventional 
block PCR. mHPRT was used as a control for the reverse transcription reaction. 
cDNA (see 2.5.3.) was mixed with PCR reaction mix and amplified with standard 
PCR conditions (see 2.1.1.2.). The presence or absence of products was analysed on 
an agarose gel. 
 
name sequence concentration 
product 
[Bp] 
EF_F2 5’CAGAGTAGCTATGGTCAAC 3’ 10 pmol 
EF_R3 5’GTGATACAGCTGGCGTTG 3’ 10 pmol 
370 
    
Cre1 5’CGGTCGATGCAACGAGTGATGAGG 3’ 10 pmol 
Cre2 5’CCAGAGACGGAAATCCATCGCTCG 3’ 10 pmol 
700 
    
mHPRTa 5’CAAATCAAAAGTCTGGGGACGC 3’ 10 pmol 
mHPRTas 5’GCTTGCTGGTGAAAAGGACCTC 3’ 10 pmol 
350 
 
 
2.4.9. Template preparation for generation of in situ hybridisation probes 
Ten micrograms of the plasmid containing the sequence for the gene to be 
analysed were cut with the corresponding restriction enzyme in a volume of 100 µl 
for 2 hours at 37°C (2.4.2.). Completeness of digestion was checked by loading 2 µl 
of the samples on a 1% agarose gel. The linearised plasmid was then extracted by 
adding 1/10 volume of 3 M sodiumacetate and 1 volume of 
Phenol:Chloroform:Isoamylalcohol (25:24:1). After short vortexing, the sample was 
centrifuged for 5 minutes at 13000 rpm. The aqueous upper phase was transferred 
to a new tube and DNA was precipitated with 2,5 volumes absolute ethanol 
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followed by mixing and centrifugation at 13000 rpm for 15 minutes at 4°C. The 
pellet was washed once with 500 µl 70% ethanol to remove excess salt, air-dried for 
10 minutes and resuspended in 10 µl nuclease-free H2O (final concentration: 1 
µg/µl).  
 
List of plasmids used for in situ hybridisation (all kindly provided by Dr. Christine 
Hartmann, IMP, Vienna, Austria): 
gene vector 
restriction enzyme for 
antisense probe 
polymerase for 
antisense probe 
size 
[Bp] 
Col1a1 pBSKS BamHI T3 500 
Col2a1 Litmus28 EcoRI T7 405 
Col10a1 pBSKS ClaI T3 650 
IHH pBSKS XbaI T7 1800 
Osc pBSKS BamHI T3 320 
Osx 
pGEM     
T-easy 
SpeI T7 670 
Runx2 
pGEM     
T-easy 
NcoI SP6 550 
 
 
2.4.10. Dominant-negative STAT mutants 
STAT1 Y701F was kindly provided by Dr. Thomas Decker, Max F. Perutz 
Laboratories, Vienna, Austria and STAT3 Y705F and STAT3 ∆683 were provided by 
Dr. Richard Moriggl, Ludwig Boltzmann Institute for Cancer Research, Vienna, 
Austria. The mutated constructs were located in pMSCV, a vector based on the 
murine stem cell virus. The gene of interest is followed by an internal ribosomal 
entry site (IRES) and the green fluorescent protein (GFP), facilitating sorting of 
infected cells.  
STAT1 ∆677 was established based on STAT3 ∆683, the dominant-negative form of 
STAT3 lacking the last 90 amino acids harbouring the transactivation domain. S1_F 
and S1∆_R were designed in a way that STAT1 was truncated at amino acid 677, the 
end of the SH2 domain. Both primers haboured a unique restriction site (BamHI and 
SacII) with which the PCR product was ligated into pMSCV. 
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PCR reaction mix 
1 µl pMSCV STAT1 Y701F (diluted 1:100 from Midi-prep) 
0,4 µl High Fidelity PCR Enzyme Mix (5 U/µl, Fermentas) 
5 µl High Fidelity PCR buffer (10 x, Fermentas) 
0,5µl dNTP mix (10 mM, Fermentas) 
0,5 µl primer S1_F  
0,5 µl primer S1∆_R 
ad 50 µl ddH2O 
 
PCR conditions: 
95°C   4 minutes    initial denaturation 
95°C    40 seconds    denaturation 
50°C    1 minute     40x  annealing 
68°C    90 seconds   elongation 
68°C    7 minutes   final elongation 
22°C      storage 
 
name sequence concentration 
product 
[kB] 
S1_F 
5’GACGTAGTCATGCATGCATCATAGG
ATCCACCATGTCTCAGTGGTACG 3’ 
10 pmol 
S1∆_R 5’TACGATCCCGCGGTCAGGCATGGTC
TTTGTCAATATTTG3’ 
10 pmol 
2,1 
∞ 
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2.5. Working with RNA 
 
 
2.5.1. RNA isolation 
For cultured cells, 1 ml Trizol (Gibco) was added per 10 cm2, incubated for 5 
minutes at room temperature and then transferred to an RNase-free tube. Tissue 
samples (approximately 5 x 5 x 5 mm) were directly homogenised in 5 ml Trizol 
with a tissue homogeniser and incubated for 5 minutes at room temperature. 
Skeletal elements were crushed with mortar and pestle while constantly cooled 
with liquid nitrogen. The “bone powder” was then mixed with 5 ml Trizol and 
incubated for 5 minutes at room temperature. 
All following measurements correspond to the volumes needed per 1 ml initial 
Trizol. Chloroform (200 µl) was added to the homogenate, vortexed for 15 seconds 
and the mixture was incubated for 2 minutes at room temperature. After 
centrifugation at 10000 rpm for 15 minutes at 4°C, the upper aqueous phase was 
transferred to a new tube. Addition of 500 µl isopropanol and vortexing was 
followed by 10 minutes incubation at room temperature. The RNA was pelleted by 
centrifugation at 10000 rpm for 10 minutes at 4°C and washed with 1 ml 70% 
ethanol. After centrifugation at 7500 rpm for 5 minutes at 4°C, the pellet was air 
dried for 15 minutes and resuspended in 50 µl ddH2O-DEPC. RNA was stored at         
-20°C for short times and at -80°C for long-term storage. 
 
 
2.5.2. RNA agarose gel 
Agarose (0,8 g) was dissolved in 100 ml 1 x MOPS and heated in a microwave oven. 
After cooling down to about 60°C, 5 µl ethidium bromide (10 mg/ml) was added 
and the gel was poured in the appropriate tray containing combs. After the gel was 
solidified it was put in the electrophoresis-apparatus filled with running buffer. The 
probes were mixed with 2 x RNA loading buffer and boiled for 5 minutes at 95°C. 
The gel was run at 90 V until the blue front containing bromphenolblue reached the 
end of the gel. 
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2 x RNA loading buffer 
1 x MOPS 
6,8% formaldehyde 
50% formamide 
15% glycerol 
66 mM EDTA 
0,2% bromphenolblue in H2O 
 
50 x MOPS 
1 M MOPS 
250 mM sodiumacetate 
50 mM EDTA 
 
Running buffer 
1 x MOPS 
 
 
2.5.3. Reverse transcription 
To ensure amplification of RNA only, DNA was digested with RNase-free DNase. RNA 
(0,5 – 1 µg) was incubated with 10 U DNaseI (Roche) in a total volume of 10 µl for 
30 minutes at 37°C. The reaction was then stopped by incubating at 75°C for 10 
minutes and RNA was ready to use for cDNA synthesis or was stored at -80°C. 
Reverse transcription was carried out using the RevertAid H Minus First Strand cDNA 
Synthesis Kit (Fermentas) according to the manufacturer’s protocol. Briefly, 
template RNA was incubated with 1 µl random hexamer primer in a total volume of 
12 µl for 5 minutes at 70°C and chilled on ice. After addition of 4 µl 5 x reaction 
buffer, 0,5 µl RiboLock RNase Inhibitor and 2 µl 10 mM dNTP Mix, the mixture was 
incubated for 10 minutes at room temperature. RevertAid H Minus M-MuLV Reverse 
Transcriptase (1 µl) was added and the tube was incubated for 10 minutes at room 
temperature, followed by 60 minutes at 42°C. The reaction was terminated by 
heating at 70°C for 10 minutes. Resulting cDNA was directly used for PCR or stored 
at -20°C. 
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2.5.4. JAK/STAT specific target gene analysis with OligoGEArray (SuperArray) 
High quality RNA was isolated with the RNeasy Mini kit (Quiagen) according to 
manufacturer’s protocol. Cells were trypsinised and pelleted by centrifugation at 
1200 rpm for 5 minutes. The cell pellet was then disrupted by addition of Buffer 
600 µl RLT (for 5 x 106 – 1 x 107 cells). The lysate was applied to a QIAshredder and 
centrifuged for 2 minutes at 13000 rpm to homogenise the sample. The flow-
through was mixed with 600 µl 70% ethanol, applied to the column and centrifuged 
for 15 seconds at 10000 rpm. If the volume exceeded 700 µl, aliquots were 
successively loaded onto the column. The flow-through was discarded and 700 µl 
Buffer RW1 were applied to the column. After centrifugation for 15 seconds at 
10000 rpm, the column was transferred to a new collection tube and 500 µl Buffer 
RPE were added. Centrifugation for 15 seconds at 10000 rpm was followed by 
another wash with 500 µl Buffer RPE. The column was transferred to a new 
collection tube and centrifuged again for 1 minute at 13000 rpm to get rid of 
residual ethanol. Finally, the column was transferred in a new microcentrifuge 
tube and RNA was eluted by addition of 30 µl ddH2O-DEPC and centrifugation for 1 
minute at 10000 rpm. 
 
cDNA synthesis 
Total RNA (3 µg) was mixed with component G1 in a final volume of 10 µl and 
incubated for 10 minutes at 70°C. RNase-free H2O (4 µl), 4µl 5x cDNA Synthesis 
Buffer (G3), 1 µl RNase inhibitor (RI) and 1 µl cDNA Synthesis Enzyme Mix (G2) were 
added and incubated at 42°C for 50 minutes. Following incubation at 75°C for 5 
minutes, the sample was allowed to cool down to 37°C.  
 
cRNA synthesis and purification 
Amplification Master Mix (16 µl 2,5 x RNA Polymerase Buffer (G24), 2 µl 10mM 
Biotinylated-UTP, 2 µl RNA Polymerase Enzyme (G25) in a total volume of 20 µl) 
was added to the cDNA synthesis reaction and incubated for 1 hour at 37°C. 
RNase-free H2O (50 µl) was added to the cRNA synthesis reaction and the sample 
was mixed with 315 µl Lysis & Binding Buffer (G6). Absolute ethanol (315 µl) was 
added, mixed and the sample was loaded onto the column provided. After 
centrifugation at 8700 rpm for 30 seconds, the column was washed with 600 µl 
Washing Buffer (G17). The flow-through was discarded and the column was washed 
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with 200 µl Washing Buffer (G17). Centrifugation at 10000 rpm for 1 minute was 
followed by another centrifugation step for 2 minutes at 10000 rpm. cRNA was 
eluted by addition of 50 µl RNase-Free 10 mM Tris Buffer pH 8,0 (G26), incubation 
for 2 minutes and centrifugation at 8700 rpm for 1 minute. cRNA was measured by 
UV spectrometry and 4 µg were used for hybridisation. 
 
Hybridisation 
The array membrane was put into hybridisation tube, pre-wet with 5 ml dH2O for 5 
minutes and incubated with 2 ml pre-warmed (60°C) GEAhyb Hybridisation Solution 
for 1 hour at 60°C with slow agitation. cRNA (4 µg) was mixed with 0,75 ml GEAhyb 
Hybridisation Solution and added to the pre-hybridised membrane. Hybridisation 
was done overnight at 60°C. Then, the membrane was washed with 5 ml Wash 
Solution 1 (2 x SSC, 1% SDS) at 60°C for 15 minutes. Another washing step with 5  
ml Wash Solution 2 (0,1 x SSC, 0,5% SDS) at 60°C for exactly 15 minutes was 
applied. Wash Solution was discarded and the membrane was allowed to cool to 
room temperature inside the hybridisation tube.  
 
Chemiluminescent detection 
GEAblocking Solution Q (2 ml) was added to the membrane and the tube was 
incubated with continuous agitation for 40 minutes at room temperature. Next, AP-
SA Buffer (alkaline phosphatase-conjugated streptavidin diluted 1:8000 in 1 x 
BufferF) was added and the tube was incubated for exactly 10 minutes with gentle 
agitation. The membrane was washed four times with 4 ml 1 x BufferF for 5 
minutes and rinsed twice with 3 ml Buffer G. CDP-Star chemiluminescent substrate 
(1 ml) was added to the membrane and the tube was incubated for 5 minutes. The 
membrane was then wrapped in saran foil and exposed to ECL films (Pierce) for 
various time periods. 
 
 
2.5.5. Generation of digoxogenin labelled cRNA probes for in situ hybridisation 
One microgram of the linearised plasmid (2.4.10.) was transcribed in vitro with the 
RNA DIG labelling kit (Roche) according to the manufacturer’s protocol. All 
solutions were prepared or diluted with DEPC treated water. DNA was mixed with 1 
x Transcription Buffer, 1 x DIG RNA Labeling Mix, 0,5 µl RNase Inhibitor, 1,5 µl RNA 
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polymerase in a total volume of 20 µl. After transcription at 37°C for 2 hours, 1 µl 
of the reaction was checked on a 1% agarose gel and residual DNA was digested 
with 1 µl DNase (Roche). The labelled RNA probe was purified by adding 1 µl 
glycogen (Roche), 10 µl 4 M LiCl 100 µl TE pH 8, 300 µl absolute ethanol (-20°C) 
and incubating at -20°C for 1 hour or overnight. Following 15 minutes 
centrifugation at 13500 rpm at 4°C, the pellet was washed once with 500 µl 70% 
ethanol. The labelled RNA probe was air-dried for 5 to 10 minutes, resuspended in 
100 µl ddH2O-DEPC and stored at -20°C.  
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2.6. Working with Protein 
 
 
2.6.1. Protein extraction 
 
2.6.1.1. Preparation of protein lysates of mammalian cells and tissues 
Small pieces of tissue samples were directly homogenised in a minimal amount of 
IP-buffer with a tissue homogeniser. Skeletal elements were crushed with mortar 
and pestle while constantly cooled with liquid nitrogen. The “bone powder” was 
then mixed with a minimal amount of IP-buffer and incubated at 4°C on a rotating 
shaker for at least 1 hour. 
Growth medium was removed from adherent cells and they were washed twice 
with PBS. The cells were scraped off and the liquid including the cell debris was 
transferred to a 1,5 ml tube. Cells were centrifuged at 1200 rpm for 5 minutes and 
the appropriate amount of IP-buffer was added (approximately 100 µl IP-buffer for 
106 cells). To enhance cell disruption, the tube was incubated at 4°C on a rotating 
shaker for at least 1 hour. 
Subsequently, cellular debris was removed by centrifugation at 13000 rpm for 30 
minutes at 4°C. The supernatant was transferred to a new tube and protein 
concentration was determined. Protein samples were stored at -20°C or for longer 
periods at -80°C. 
 
IP-buffer base 
25 mM Hepes pH 7,5 
150 mM NaCl 
10 mM EDTA 
0,1% Tween-20 
0,5% NP-40 
10 mM β-glycerophosphate 
 
IP buffer (IP buffer base + freshly added inhibitors) 
1 mM Na3VO4 
1 mM NaF 
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10 µg/ml Leupeptin 
10 µg/ml Aprotinin 
1 mM PMSF 
1 x complete (25 x stock: 1 Protease Inhibitor Cocktail Tablet in 2 ml H2O;  
Roche) 
 
2.6.1.2. Preparation of protein lysates of mammalian cells for EMSA 
Culture dishes of adherent cells were rinsed twice with ice-cold PBS, cells were 
scraped off and pelleted by centrifugation for 5 minutes at 1200 rpm. Pellets were 
mixed with two times the volume of the pellet with whole cell extract buffer, 
vortexed, frozen in liquid nitrogen and thawed on ice. Freeze-thaw cycles were 
repeated 4 times. Extracts were centrifuged at 13000 rpm for 20 minutes at 4°C 
and the supernatant was transferred to a new tube. Protein concentration was 
determined and samples were directly subjected to EMSA or stored at –80°C. 
 
whole cell extract buffer 
20 mM Hepes pH 7,9 
20% Glycerol 
50 mM KCl 
1 mM EDTA 
1 mM DTT 
400 mM NaCl 
5 µg/ml Leupeptin 
0,2 U/ml Aprotinin 
1 mM PMSF 
5 mM Na3VO4 
10 mM NaF 
5 mM β-glycerophosphate 
stored at –20°C 
 
 
2.6.2. Determination of protein concentration (Bradford)  
Protein concentration was quantified with Bradford reagent (Bio-Rad Protein 
Assay). Different concentrations of BSA (1 µg, 5 µg, 10 µg and 15 µg) were used as a 
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standard. One microlitre of the lysate or the standard were mixed with 1 ml 
Bradford reagent (diluted 1:5 with dH2O) in a cuvette and incubated for 7 minutes 
at room temperature. The absorption at 595 nm was measured in a 
spectrophotometer and the protein concentration of the lysates was calculated 
using the values of the standard as a reference.  
 
 
2.6.3. Western blot analysis  
 
2.6.3.1. Polyacrylamid (PAA) gel electrophoresis  
For Western blotting the Mini-PROTEAN 3 system from Bio-Rad was used. The glass 
plates were cleaned with water and ethanol and the gel unit was assembled. First, 
the components for the separating gel were mixed and poured between the glass 
plates, leaving 2,5 cm space for the stacking gel to be added later. After pouring, 
the gel was overlaid with isopropanol and left to solidify. When the separating gel 
was polymerised, isopropanol was removed, the remaining space was filled with 
the stacking gel and the comb was inserted, avoiding to generate air bubbles. The 
polymerised gel was then inserted into the running unit and submerged with 1 x 
running buffer. Now the comb was removed carefully and the slots were rinsed 
with running buffer to remove unpolymerised acrylamide. 
 
 
separating gel: 8% 10% 12% 
Acrylamide/Bis (30%) 2,7 ml 3,3 ml 4,3 ml 
1,5 M Tris pH 8,8 2,5 ml 2,5 ml 2,5 ml 
ddH2O 4,6 ml 4 ml 3 ml 
10% SDS 100 µl 100 µl 100 µl 
10% APS 100 µl 100 µl 100 µl 
TEMED 6 µl 6 µl 6 µl 
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stacking gel:  
Acrylamide/Bis (30%) 0,5 ml 
1 M Tris pH 6,8 0,38 ml 
10% SDS 30 µl 
ddH2O 2,1 ml 
10% APS 30 µl 
TEMED 3 µl 
 
 
2.6.3.2. Sample preparation 
Before the proteins were loaded onto the gel, the samples were boiled for 5 
minutes mixed with 4 x sample buffer. PageRuler Prestained Protein Ladder 
(Fermentas) was also loaded on the gel (5 µl). 
Gels were run at 30 mA per gel. When the proteins reached the separating gel the 
current was elevated to 50 mA per gel. 
 
2.6.3.3. Protein transfer 
After separation of the proteins on a SDS-PAA gel, they were transferred onto a 
nitrocellulose membrane for immunodetection. Therefore the stacking gel was 
removed, the filterpaper (Whatman Chromatography Paper) and the nitrocellulose 
membrane (GE Healthcare) were cut to the size of the gel and the sandwich was 
assembled in the following order: support pad soaked in transfer buffer, one sheet 
of filterpaper (soaked in transfer buffer), gel, nitrocellulose membrane (wetted in 
transfer buffer), one sheet of filterpaper (again soaked in transfer buffer) and a 
support pad (also soaked in transfer buffer). 
 
 
 
 
 
 
 
support pad 
filter paper 
gel 
membrane 
filter paper 
support pad 
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It was necessary to pay attention avoiding air bubbles in all steps of the assembly. 
The sandwich was put into the transfer buffer filled transfer unit with the gel on 
the side of the minus pole. After blotting at 4°C with a constant voltage of 100 V 
for 1,5 hours the sandwich was dissembled and the membrane was washed with 
dH2O. Transfer efficiency was controlled with a PonceauS staining whereby the 
membrane was stained for 5 minutes with PonceauS staining solution. To remove 
excess dye, the membrane was de-stained with dH2O until bands were visible.  
 
2.6.3.4. Immunodetection  
The Western blot membrane was blocked with blocking solution at room 
temperature for one hour under gentle shaking in a plastic tray. After blocking, the 
membrane was incubated at 4°C with the primary antibody (diluted as listed 
below). The next day the primary antibody was removed and the membrane was 
washed three times for 5 minutes with washing buffer. Then the membrane was 
incubated with the secondary mouse or rabbit antibody (horse raddish peroxidase 
linked, GE Healthcare) diluted 1:5000 in antibody-solution for 1 hour at room 
temperature. Next it was washed three times for 10 minutes in washing buffer. 
Finally, the proteins were detected with SuperSignal West Pico Chemiluminescent 
Substrate (Pierce). Equal amounts of Luminol/Enhancer and Stable Peroxide Buffer 
were mixed, poured on the membrane and incubated for 1 minute, ensuring an 
even distribution of the reagents. After the ECL solution was removed, the 
membrane was wrapped in saran foil and exposed to ECL films (Pierce) for various 
time periods. 
 
After a protein was detected, the membrane could be blocked again half an hour 
and incubated with other primary and secondary antibodies to detect a different 
protein or the membrane was stripped for 30 minutes at 50°C with stripping 
solution. Afterwards the membrane was extensively washed with washing buffer, 
blocked for one hour and incubated with the required antibody.  
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4 x sample buffer 
240 mM Tris pH 6,8 
40 mM DTT 
8% SDS 
0,01% bromphenol blue 
40% glycerol 
2,5 mM Na3VO4 
stored at -20 °C 
 
10 x Running buffer 
250 mM Tris  
2 M glycine  
1% SDS 
 
Transfer buffer 
25 mM Tris  
192 mM glycine  
20% methanol 
 
PonceauS staining solution 
0,1% PonceauS (Sigma) 
5% acetic acid 
 
10 x Washing buffer (TBS-T) 
250 mM Tris pH 8  
1,5 M NaCl 
0,5% Tween-20  
 
Blocking buffer 
5% BSA in washing buffer 
 
Antibody solution  
1% BSA in washing buffer 
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Stripping solution 
2% SDS 
62,5 mM Tris pH 6,8 
1,4% β-mercaptoethanol 
 
antibody recognises dilution features kD 
β-Actin N-terminus of β-Actin 1:10000 mouse monoclonal, (A 5316, Sigma) 42 
STAT1 N-terminus of STAT1 1:1000 mouse monoclonal (610115, BD) 84/91 
pSTAT1 STAT1 p-Tyr701 1:1000 rabbit polyclonal (9171, Cell Signaling) 84/91 
STAT3 N-terminus of STAT3 1:1000 mouse monoclonal (610190, BD) 92 
pSTAT3 STAT3 p-Tyr705 1:1000 rabbit polyclonal (9131, Cell Signaling) 92 
HA HA-tag 1:1000 mouse monoclonal 16B12 (Covance)  
Cre Cre 1:5000 rabbit polyclonal 38 
FLI-1 C-terminus of hFLI-1 1:3 mouse monoclonal (Hybridoma Fli 7.3) 70 
HSC-70 C-terminus of hHSC-70 1:10000 mouse monoclonal (sc-7298, Santa Cruz) 70 
 
Fli 7.3 hybridoma supernatant was a kind gift of Dr. Heinrich Kovars group 
(Children’s Research Institute, Vienna, Austria). The Cre antibody was kindly 
provided by Dr. Gitta Erdmann (German Cancer Research Centre, Heidelberg, 
Germany). 
 
 
2.6.4. Electrophoretic mobility shift assay (EMSA) 
EMSA (or band shift assay) is a widely used technique to analyse the binding ability 
of proteins (mostly transcription factors) to defined DNA elements. Binding of the 
native protein to the labelled oligonucleotide results in a shift of the 
electrophoretic mobility of the designated DNA element. This can be seen as a 
band on a non-reducing PAA-gel. Moreover, to proof that the identified band really 
contains the protein of interest, a supershift can be performed. An antibody 
specific to the favoured protein is added to the DNA-protein mixture. When the 
identified band changes its migratory ability (either migrates slower or is absent at 
all) the antibody recognised the DNA-protein complex and the protein is therefore 
proven as the right one, binding to the DNA element of interest. 
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2.6.4.1. Oligo Annealing 
Oligos were purchased from VBC-biotech and resuspended in the indicated volume 
needed for 250 pmol/µl. Exact DNA concentration was measured with a photometer 
and oligos were diluted to a final concentration of 100 pmol/µl. 
Both oligos were mixed in an equimolar ratio together with 1 x annealing buffer (10 
x = 0.625 x PCR BufferII (Roche); 9,4 mM MgCl2) in a total volume of 100 µl. The 
mixture was then incubated in a 95°C heating block for 10 minutes and slowly 
cooled down to room temperature. The annealed oligo was then incubated on ice 
for 10 minutes, diluted to 2,5 µM and stored at -80°C. 
 
2.6.4.2. Oligo Labelling 
Five picomol double stranded annealed oligo were radioactively labelled in a 
reaction with 5 µl γ-32P-ATP (Amersham; 370 MBq/ml) and 10 U polynucleotide 
kinase (Roche) in a total volume of 20 µl at 37°C for 1 hour.  
The radiolabelled oligo was then separated from free ATP through purification on 
size exclusion columns (Micro Bio-Spin Chromatography Columns; Bio-Rad). The 
lower cap from the column was removed and several drops were drained on paper. 
The column was then put into an empty collection tube and centrifuged at 2500 
rpm for 1 minute to get rid of excess liquid.  
The labelling mix was stretched with 30 µl ddH2O and applied onto middle of the 
column matrix. After centrifugation at 2500 rpm for 1 minute the flow-through was 
collected and stored at -80°C. 
 
2.6.4.3. Binding Reaction 
In a 20 µl reaction, 10 - 20 µg protein sample, 2 µl BSA solution, 2 µl Poly dI-dC (1 
µg/µl; Roche), 4 µl 5 x binding buffer and 0,5 to 1 µl hot probe were mixed and 
incubated for 5 to 30 minutes at room temperature before loading. For supershifts, 
protein samples were pre-incubated for at least 5 minutes on ice with antibody.  
 
2.6.4.4. Electrophoresis 
Complexes were separated on a non-denaturating 4% PAA-gel containing 0,25 x TBE 
and run in 0,25 x TBE at 200 V for about 3 hours. Orange G was used as a mobility 
dye. As soon as the Orange G reached the lower part of the gel it was transferred 
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onto filter paper, dried on a vacuum gel dryer at 80°C for two hours and exposed 
to x-ray films (Kodak Biomax MR) at –80°C for at least one day. 
 
BSA solution 
10 mg/ml BSA  
20 mM KPO4 
50 mM NaCl 
0,1 mM EDTA 
5% glycerol 
 
5 x Binding buffer 
50 mM Tris 
5 mM DTT 
1 mM PMSF 
0,5 mM EDTA 
25% glycerol 
250 mM NaCl 
0,5% NP-40 
 
Orange G 
0,5% Orange G (Sigma) 
25% Ficoll T400 
100 mM EDTA 
 
10 x TBE 
0,89 M Tris  
0,89 M boric acid  
20 mM EDTA  
 
Oligos 
M67 
 
β-casein  
 
CATTTCCCGTAAATC 
GATTTACGGGAAATG 
AGATTTCTAGGAATTCAAATC  
GATTTGAATTCCTAGAAATCT 
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antibody recognises dilution features 
M-22X STAT1, C-terminus 1:20 rabbit polyclonal (sc-592, Santa Cruz) 
C-20X STAT3, C-terminus 1:20 rabbit polyclonal (sc-482, Santa Cruz) 
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3. Results 
 
 
 
 
3.1. Establishment of a conditional EWS/FLI-1 knock-in 
mouse model 
 
 
3.1.1. The search for the appropriate Cre recombinase 
A lot of effort was already made to generate a mouse model for ESFT but no report 
about a mouse recapitulating the human phenotype existed when we started this 
project. As mentioned in the introduction, the cellular context for EWS/FLI-1 
expression is important but lack of knowledge about the tissue of origin makes it 
difficult to target expression of the fusion protein to the right cellular environment 
in a mouse model. 
Since ESFT arises in bone and surrounding soft tissue we first decided to direct 
expression of EWS/FLI-1 to a skeletal precursor that can differentiate into 
osteoblasts, the bone forming cells (Figure 6). For this purpose we made use of the 
Cre-inducible EWS/FLI-1 knock-in mouse (hereafter referred to as EF) (Torchia et 
al. 2007) and crossed it to mice harbouring the Cre recombinase under the control 
of the Runx2 promoter, a transcription factor necessary for differentiation of 
mesenchymal cells into the osteoblastic lineage. (Komori 2000) There are three 
different lines of the Runx2Cre transgenic mice available (Rauch et al. 2010) but 
we concentrated our analysis on two Runx2Cre transgenic lines in the beginning: 
1634 Runx2Cre, with Cre activity in bone, cartilage and heart, and 784 Runx2Cre, 
where Cre is active in bone and cartilage (Dr. Jan Tuckermann, personal 
communication and Rauch et al. 2010). Resulting Runx2Cre EF mice were viable 
and fertile but showed no overt phenotype at young age. Mice were carefully 
controlled over a period of 18 month but no tumour formation or any other 
phenotype could be observed (n = 10 for each Runx2Cre line). Analysis of these 
mice for the deletion activity of the Cre recombinase revealed that there was 
excision of the STOP-cassette in bone, bone marrow, testis and isolated osteoblasts 
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(n = 8 for each Runx2Cre line) (Figure 10A). However, the efficiency was probably 
not very strong since deletion of the STOP-cassette could not be detected by 
Southern blotting (data not shown). Only a PCR strategy, which is a more sensitive 
method, revealed that excision of the STOP-cassette took place. Surprisingly, we 
were not able to detect EWS/FLI-1 RNA in tissues of Runx2Cre EF mice (n = 8 for 
each Runx2Cre line) (Figure 10B). Both lines, 784 and 1634, had the same results in 
respect to phenotype, deletion of the STOP-cassette and EWS/FLI-1 expression, so 
only one representative example is shown in the following figures.  
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Figure 10: Molecular analysis of Runx2Cre EF mice. A Genomic DNA (gDNA), isolated from several 
different tissues and isolated osteoblasts of 784 Runx2Cre EF mice, was analysed for deletion of 
STOP-cassette (∆STOP) with a PCR strategy (see 2.4.7.). Existence of the knocked in EF allele (KI) 
was used as a control to ensure presence of gDNA in the sample. STOP-cassette deletion was 
detected in bone, bone marrow, isolated osteoblasts and testis. B EWS/FLI-1 RNA was detected with 
specific primers from reverse transcribed cDNA, but could not be observed in tissues of 784 
Runx2Cre EF mice. mHPRT was used to ensure proper cDNA transcription. The human TC71 cell line 
had no mHPRT band since the primers were specific for the mouse homologue and did not recognise 
the human counterpart. NIH3T3: mouse cell line used as a negative control for EWS/FLI-1 
expression; TC71: ESFT cell line used as a positive control for EWS/FLI-1 expression. 
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In the course of this study, we analysed a third transgenic line of the Runx2Cre 
mice (777). Apart from bone, Cre activity in the 777 Runx2Cre line could also be 
detected in the haematopoietic system (Dr. Jan Tuckermann, personal 
communication). Crossing this 777 Runx2Cre line to EF mice did not result in viable 
double positive offspring (12 litters), rather 777 Runx2Cre EF embryos died before 
E 13.5 (n = 13, from two litters).  
 
 
3.1.1.1. A two-hit mouse model for ESFT? 
It is already known from in vitro studies that EWS/FLI-1 can lead to apoptosis and 
growth arrest in mouse as well as in human primary fibroblasts but can be rescued 
by deletion of the INK4A/ARF locus or disruption of the p53 pathway. (Deneen and 
Denny 2001; Lessnick et al. 2002) Moreover, alterations of the INK4A/ARF locus are 
the most common second hit in ESFT, occurring in approximately one quarter of 
patients. (Huang et al. 2005; Kovar et al. 1997; Lopez-Guerrero et al. 2001) 
Therefore, we decided to cross Runx2Cre EF mice onto the p16INK4A/p19ARF 
(hereafter named INK4A/ARF-/-) knock-out background. Careful analysis of these 
Runx2Cre EF INK4A/ARF-/- mice did not result in enhanced EWS/FLI-1 expression, 
similar as seen in Runx2Cre EF mice (n = 7 for each Runx2Cre line). Deletion of the 
STOP-cassette was detected in bone and testis (Figure 11A), but no significant 
EWS/FLI-1 RNA could be observed in these tissues (Figure 11B). Moreover, 
INK4A/ARF-/- mice are prone to tumour formation (e.g. fibrosarcoma, liposarcoma, 
lymphomas) (Serrano et al. 1996) and expression of an oncogene like EWS/FLI-1 
should aggravate tumour phenotypes and shift the tumour spectrum towards ESFT. 
Of 14 Runx2Cre EF INK4A/ARF-/- mice analysed, the median latency of tumour 
development was 23 weeks (compared to 29 weeks in the original publication), 
with primarily malignancies arising from haematopoietic cells but also tumours in 
muscle and fat were observed. However, we failed to reproducibly detect the 
fusion protein in the tumours (Figure 11B), so the slight discrepancy might have 
been due to mouse housing conditions or different monitoring status. Certainly, the 
earlier tumour onset was not linked to EWS/FLI-1 expression. 
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Figure 11: Molecular analysis of Runx2Cre EF INK4A/ARF-/- mice. The representative example (784 
Runx2Cre EF INK4A/ARF-/-) shown in this figure had a tumour in the leg near the bone at 15 weeks of 
age. A Genomic DNA (gDNA), isolated from several different tissues of 784 Runx2Cre EF INK4A/ARF-/- 
mice, was analysed for deletion of STOP-cassette (∆STOP) with a PCR strategy (see 2.4.7.). 
Existence of the knocked in EF allele (KI) was used as a control to ensure presence of gDNA in the 
sample. STOP-cassette deletion was only detected in bone and testis but not in the tumour sample. 
B EWS/FLI-1 RNA was detected with specific primers from reverse transcribed cDNA but could not 
be observed in tissues of 784 Runx2Cre EF INK4A/ARF-/- mice. mHPRT was used to ensure proper 
cDNA transcription. The human TC71 cell line had no HPRT band since the primers were specific for 
the mouse homologue and did not recognise the human counterpart. NIH3T3: mouse cell line used 
as a negative control for EWS/FLI-1 expression; TC71: ESFT cell line used as a positive control for 
EWS/FLI-1 expression. 
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3.1.1.2. Runx2Cre expression  
Since only low levels of STOP-cassette deletion could be detected and no 
EWS/FLI-1 RNA was seen, we asked whether the Cre recombinase is expressed 
correctly in Runx2Cre EF mice. Thus, we analysed cDNA from wild type, Runx2Cre, 
Runx2Cre EF and Runx2Cre EF INK4A/ARF-/- mice for the presence of a Cre 
transcript (n = 3 for each Runx2Cre line). Cre expression could only be verified in 
Runx2Cre mice, lacking the EF allele (Figure 12). But mice harbouring Runx2Cre 
and the EF allele, whether deficient in the INK4A/ARF locus or not, did not express 
the Cre recombinase.  
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Figure 12: Analysis of Cre expression in Runx2Cre mice. Cre RNA was detected from reverse 
transcribed cDNA with primers specific for the Cre recombinase. gDNA from wild type (wt) and 784 
Runx2Cre EF mice were used as negative and positive controls for presence of Cre DNA. Presence of 
Cre transcript could only be verified in 784 Runx2Cre mice but not in 784 Runx2Cre EF and 784 
Runx2Cre EF INK4A/ARF-/- mice. mHPRT was used to ensure proper cDNA transcription. The primers 
specific for mHPRT were designed in two different exons so that only mRNA but not the genomic 
allele was recognised. Therefore, there was no HPRT band visible in gDNA samples. NIH3T3: mouse 
cell line used as a negative control for Cre expression.  
 
 
3.1.2. Verification of EF knock-in mice 
EWS/FLI-1 could not be expressed in Runx2Cre EF mice due to absent Cre 
expression. To ensure that the EF knock-in locus generally allows expression of the 
transgene in our mouse background, we analysed in more detail this locus in vitro 
as well as in vivo. 
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3.1.2.1. Analysis of EWS/FLI-1 expression from the EF knock-in allele in vitro 
To analyse the accessibility of the EF knock-in locus in vitro, we first isolated 
fibroblasts from an EF mouse and transduced them with a lentivirus containing GFP 
or the Cre recombinase. The STOP-cassette was efficiently excised in fibroblasts 
expressing the Cre recombinase and no deletion was observed in fibroblasts 
transduced with a GFP construct (Figure 13A). Moreover, EWS/FLI-1 RNA and 
protein were present in Cre transduced fibroblasts (Figure 13B-C). 
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Figure 13: Analysis of EWS/FLI-1 expression from the EF knock-in allele. A Deletion of STOP-
cassette (∆STOP) was detected with a PCR strategy in fibroblasts isolated from EF mice (lentivirally 
transduced with a construct containing GFP or the Cre recombinase) and tissues of wild type or 
Mx1Cre EF mice, 4 days after polyinosinic and polycytydilic acid (PolyIC) injection (=Mx1Cre EF*). 
STOP-cassette deletion was demonstrated in isolated fibroblasts expressing the Cre recombinase 
and in tissues of Mx1Cre EF* mice. Existence of the knocked in EF allele (KI) was used as a control to 
ensure presence of gDNA in the sample. B EWS/FLI-1 RNA was detected from reverse transcribed 
cDNA with primers specific for EWS/FLI-1 and was present in fibroblasts isolated from EF mice 
expressing Cre and in liver and spleen of Mx1Cre EF* mice. mHPRT was used to ensure proper cDNA 
transcription. The human TC71 cell line had no HPRT band since the primers were specific for the 
mouse homologue and did not recognise the human counterpart. TC71: ESFT cell line used as a 
positive control for EWS/FLI-1 expression; NIH3T3: mouse cell line used as a negative control for 
EWS/FLI-1 expression. C Presence of EWS/FLI-1 protein in fibroblasts isolated from EF mice 
expressing Cre and in liver of Mx1Cre EF* mice was verified with Western blot analysis using an 
antibody specific for the HA-tag. β-Actin was used as a loading control.  
 
 
3.1.2.1. Analysis of EWS/FLI-1 expression from the EF knock-in allele in vivo 
We also assessed functionality of the EF knock-in locus in vivo. Thus, we crossed EF 
mice to the polyinosinic and polycytydilic acid (PolyIC) inducible Mx1Cre mice. 
Resulting Mx1Cre EF mice were peritoneally injected with PolyIC (= Mx1Cre EF*) 
and analysed at indicated time points. Deletion of the STOP-cassette, EWS/FLI-1 
RNA and protein could be detected already 4 days after Cre induction, most 
prominent in liver and spleen (n = 4) (Figure 13). To further test the biological 
functionality of EWS/FLI-1 expression in these mice, we wanted to recapitulate the 
phenotype of Mx1Cre EF* mice published by Torchia et al. 2007. We carefully 
analysed Mx1Cre EF* mice until 17 days after PolyIC injection, the approximate 
time when signs of disease emerged (scrubby fur, hunchback, swelled belly). 
Histological analysis revealed that Mx1Cre EF* mice (n = 6) had massive infiltrations 
in spleen and liver (Figure 14A) and therefore a strong increase in 
spleen/bodyweight and liver/bodyweight ratio (Figure 14B).  
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Figure 14: Histological analysis of Mx1Cre EF* mice. A Haematoxylin and eosin staining on 
sectioned livers or spleens of wild type (wt) or Mx1Cre EF mice, 17 days after PolyIC injection 
(=Mx1Cre EF*) revealed disorganisation of spleen structure and massive infiltration in the liver of 
Mx1Cre EF* mice. B Ratios of spleen or liver to bodyweight were massively increased in Mx1Cre EF 
mice* compared to wild type mice (n = 6).  
 
 
The original finding reported a myeloproliferative neoplasm with expansion of a 
CD43/CD71/CD117 positive population, representing a severe increase in 
erythroblasts. (Torchia et al. 2007) We detected the same population in Mx1Cre EF* 
mice (n = 2) with antibodies specific for these surface molecules by flow 
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cytometric analysis (Figure 15). Thus, we could prove that the EF knock-in locus is 
functional in vitro as well as in vivo in our transgenic animals and in our housing 
conditions, very similar as published. (Torchia et al. 2007) 
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Figure 15: Flow cytometric analysis of Mx1Cre EF* mice. Splenocytes from wild type (wt) or 
Mx1Cre EF mice, 17 days after PolyIC injection (=Mx1Cre EF*), were stained with antibodies specific 
for CD71 (transferrine receptor essential for iron transport, expressed on immature erythroid cells), 
CD43 (highly expressed in myeloid and lymphoid precursors) and CD117 (expressed on 
haematopoietic stem cells and other haematopoietic progenitors). A CD43, CD71 and CD117 positive 
population could be identified only in Mx1Cre EF* but not in wild type mice.  
 
 
3.1.3. Severe limb defects in Prx1Cre EF mice 
It is currently hypothesised that ESFT originates from a cell with mesenchymal 
origin in which EWS/FLI-1 triggers development of ESFT (see 1.1.3.). Therefore, we 
conditionally expressed EWS/FLI-1 in the mesenchymal lineage using the Prx1Cre 
line. Prx1, a paired-related homeobox gene, is expressed early in the limb bud 
mesenchyme from which skeletal cells arise. (Logan et al. 2002) We crossed the 
former mentioned EF mice to the Prx1Cre line. Double transgenic mice (hereafter 
called Prx1Cre EF) were not viable; they died a few hours after birth probably 
caused by an inability to consume milk (open facial cleft and abnormal limbs) and 
due to suffocation. Since Prx1Cre was also active in the sternum anlage, 
malformation of the sternum resulted in an open rib cage (Figure 17B). Thus, we 
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relied on analysis of embryos at different developmental stages. Prx1Cre EF mice 
had severe shortening of the limbs which could be seen from stage E 15.5 on and 
the phenotype got more pronounced the older the embryos were (Figure 16).  
Skeletal analysis with Alcian Blue/Alizarin Red staining revealed an absence of 
calcification in the mutant limbs (Figure 17C). We could detect only cartilaginous 
elements in the place where the long bones should develop. Moreover, the head 
skeleton was also affected. Parietal, occipital and temporal bones were missing 
(Figure 17A). The facial bones and the axial skeleton were normally developed 
which is consistent with the expression pattern of Prx1Cre. (Logan et al. 2002) In 
addition, Prx1Cre EF mice displayed polydactyly being more severe in the forelimb 
than the hindlimb, which correlates with Cre activity (Figure 17C). (Logan et al. 
2002) 
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Figure 16: Skeletal defects in Prx1Cre EF mice. Developmental abnormalities in Prx1Cre EF mice 
were clearly visible from E 15.5 stage embryos on. Limbs from mutant mice were shorter when 
compared to wild type (wt) extremities. Representative examples are shown (n = 4 litters per 
embryonic day). 
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Figure 17: Skeletal analysis of Prx1Cre EF mice. Representative example of skeletal preparations 
of E 17.5 wild type (wt) and Prx1Cre EF embryos (n = 13). Blue staining marks cartilage elements 
whereas pink colour indicates calcified bone. Prx1Cre EF embryos had defects in development of 
parietal, occipital and temporal bones (A), the sternum (B) and most prominent in limb 
development (C). sc = scapula, hu = humerus, ra = radius, ul = ulna, fe = femur, ti = tibia, fi = fibula 
 
 
Analysis of genomic DNA demonstrated efficient deletion of the STOP-cassette in 
limbs of Prx1Cre EF mice but no significant recombination could be observed in 
control tissue of Prx1Cre EF or wild type mice (Figure 18A). EWS/FLI-1 RNA and 
protein could only be detected in limbs of Prx1Cre EF mice (Figure 18B-C). 
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Figure 18: Expression of EWS/FLI-1 in the developing limb of Prx1Cre EF mice. A Genomic DNA 
(gDNA) of wild type (wt) and Prx1Cre mice (E 17.5) was analysed for deletion of STOP-cassette 
(∆STOP) with a PCR strategy. STOP-cassette deletion was demonstrated in fibroblasts isolated from 
EF mice expressing the Cre recombinase and in limbs of Prx1Cre mice. B EWS/FLI-1 RNA was 
detected from reverse transcribed cDNA with specific primers in controls (TC71 and fibroblasts 
isolated from EF mice expressing Cre recombinase) and in limbs of Prx1Cre mice. mHPRT was used 
to ensure proper cDNA transcription. The human TC71 cell line had no HPRT band since the primers 
were specific for the mouse homologue and did not recognise the human counterpart. TC71: ESFT 
cell line used as a positive control for EWS/FLI-1 expression C Presence of EWS/FLI-1 protein in 
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Prx1Cre limbs was verified with Western blot analysis using an antibody specific for the HA-tag. 
HSC-70 was used as a loading control. fibro GFP or Cre: fibroblasts isolated from EF mice lentivirally 
transduced with a construct containing GFP or the Cre recombinase. 
 
 
Histological analysis of E 18.5 limbs revealed that there was no hypertrophic region 
or mature chondrocytes present in Prx1Cre EF extremities (Figure 19A). The limbs 
of wild type mice were structured normally with the epiphysis at the end, diaphysis 
in the middle of the bone and an intact medullary cavity. All these structures were 
lacking in Prx1Cre EF limbs and only a condensed cartilaginous element was left. In 
addition, the periosteum displayed abnormal zones. 
 
To determine the identity of these densely packed cells, we performed in situ 
hybridisation analysis with markers specific for distinct differentiation stages of 
chondrocytes and osteoblasts (see 1.1.5.). Col2a1, a marker for all chondrocyte 
stages was expressed in the epiphysis of wild type bone and also in the residual 
elements in Prx1Cre EF limbs (Figure 19B). But when it comes to markers for more 
differentiated chondrocytes like Ihh and Col10a1, they were completely lacking in 
limbs of Prx1Cre EF mice (Figure 19C-D). Ihh is secreted by prehypertrophic 
chondrocytes and Col10a1 is expressed in hypertrophic chondrocytes. Both zones 
were nicely stained with the respective marker in wild type bones (Figure 19C-D). 
Concerning the differentiation of osteoblasts, Runx2 is essential for precursor cells 
to enter the osteoblastic lineage and is itself induced by Ihh. Due to the lack of Ihh 
we also could not detect Runx2 in Prx1Cre EF limbs (Figure 19E). Thus, markers for 
more mature osteoblasts were also absent (Figure 19F-H). Osx is expressed in 
committed osteo-progenitors whereas Col1a1 and Osc are markers for mature 
osteoblast (see 1.1.5.). In bones of wild type mice all of these osteoblast markers 
were nicely expressed (Figure 19E-H).  
 
 
In summary, expression of EWS/FLI-1 in developing limb buds resulted in a block of 
chondrocyte maturation and absence of mature osteoblasts, resulting in a severe 
malformation of the limbs. 
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Figure 19: Lack of mature chondrocyte and osteoblast markers in Prx1Cre EF mice. 
Haematoxylin and eosin staining (H&E, A) on sectioned limbs of wild type and Prx1Cre EF mice 
(18.5) and non-radioactive in situ hybridisation using markers specific for different maturation 
stages of chondrocytes and osteoblasts. Col2a1 (B), Ihh (C) and Col10a1 (D) were expressed from 
chondrocytes at different maturation stages and Runx2 (E), Osx (F), Col1a1 (G) and Osc (H) were 
present in different osteoblast stages of wild type (wt) bone. In Prx1Cre limbs only Col2a1 was 
present. 
 
 
 
 
 offspring 
EWS/FLI-1 
expression 
phenotype 
784 Runx2Cre EF viable no none 
1634 Runx2Cre EF viable no none 
777 Runx2Cre EF 
embryonic 
lethal  
n.d. n.d. 
784 Runx2Cre EF INK4A/ARF-/- viable no 
no shift in tumour spectrum 
compared to INK4A/ARF-/-
control mice 
1634 Runx2Cre EF INK4A/ARF-/- viable no 
no shift in tumour spectrum 
compared to INK4A/ARF-/-
control mice 
Mx1Cre EF viable yes myeloid/erythroid leukemia 
Prx1Cre EF 
die shortly 
after birth 
yes (limb 
specific) 
limb shortening (no mature 
chondrocytes and osteoblasts) 
 
Table 2: Overview of mouse colonies generated during this study. n.d.= not determined 
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3.2. JAK/STAT signalling in ESFT 
Although the JAK/STAT signalling cascade is often de-regulated in cancer, not 
much is known about this pathway in ESFT. Several publications demonstrated that 
JAK1 is up-regulated and STAT3 is activated to variable degrees in ESFT patient 
samples but the cytokine signalling pathway involvement remains enigmatic. (Lai et 
al. 2006; Baird et al. 2005) Thus, the role of the JAK/STAT pathway in ESFT was 
investigated, in particular with respect to upstream cytokine receptors which can 
lead to STAT1 or STAT3 activation. 
 
3.2.1. JAK/STAT activity in ESFT cells 
Three ESFT cell lines (SK-N-MC; STA-ET-7.2; TC71) with a differential profile of p53 
mutation, EWS/FLI-1 fusion type and endogenous EWS expression (see 2.2.1.) were 
analysed for activation of the JAK/STAT signalling pathway. Cells were grown in 
monolayer culture in standard cell culture dishes. Alternatively, cells were also 
grown as spheroids in bacterial plates since formation of these multicellular 
structures resembled the situation in primary tumours more closely than monolayer 
culture. DNA binding and hence activity of STAT proteins was examined with 
electrophoretic mobility shift assays (EMSA). Neither in plain monolayer culture nor 
in spheroid cultures, activation of STAT1, STAT3 or STAT5 could be observed 
(Figure 20). 
 
It was previously shown that STAT3 is constitutively activated in colon cancer but is 
lost in cell culture and can be restored in xenografts. (Corvinus et al. 2005) 
Therefore ESFT cell lines were subcutaneously injected into immunocompromised 
mice (SCID) where they formed tumours within two to three weeks on average. 
When xenograft samples (n=18) were analysed for DNA binding ability of STAT 
proteins, activation of STAT1 and STAT3 could be detected with antibodies specific 
for the corresponding protein in EMSA (Figure 21A). In contrast, specific STAT5 
activation could not be observed in xenograft samples (Figure 21B).  
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Figure 20: Analysis of JAK/STAT activity in ESFT cell lines. A Phase contrast micrograph of three 
different ESFT cell lines, grown in monolayer culture in standard cell culture dishes or as spheroids 
in bacterial plates. B Electrophoretic mobility shift assay (EMSA) with radioactively labelled 
oligonucleotides specific for either STAT1 and STAT3 (SIE-M67) or STAT5 (β-casein) demonstrated 
absence of specific activity in the three analysed cell lines whether grown as monolayer or 
spheroids. Positive control for STAT1: NIH3T3 cells stimulated with 10 ng/ml IFN-γ for 30 minutes; 
positive control for STAT3: 293T cells, transfected with STAT3 and stimulated with 20 ng/ml IL-6 for 
30 minutes; positive control for STAT5: 293T cells, transfected with STAT5A and erythropoietin 
receptor, stimulated with 50 U/ml erythropoietin for 30 minutes. (STAT3 and STAT5 controls were a 
kind gift of Dr. Richard Moriggl and Dr. Jan-Wilhelm Kornfeld) 
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Figure 21: Analysis of JAK/STAT activity in ESFT cell line xenografts. Subcutaneous injection of 
ESFT cell lines into immunocompromised mice (SCID) resulted in tumour formation and xenografts 
were analysed for activity of STAT proteins. A EMSA was performed with radioactively labelled 
oligonucleotides specific for STAT1 and STAT3 (SIE-M67) and supershift with antibodies recognising 
either STAT1 or STAT3. The three analysed cell lines did not show STAT1 or STAT3 activation 
whereas upon xenograft injection, both STAT proteins were activated in tumour cell extracts. B 
Absence of specific STAT5 activation in extracts of cell lines and xenografts was demonstrated by 
EMSA using radioactively labelled oligonucleotides specific for STAT5 (β-casein). Positive control for 
STAT5: 293T cells, transfected with STAT5A and erythropoietin receptor, stimulated with 50 U/ml 
erythropoietin for 30 minutes (gift of Dr. Richard Moriggl and Dr. Jan-Wilhelm Kornfeld) 
 
 
In consideration of these results, we concentrated on analysis of STAT1 and STAT3 
and excluded STAT5 for further experiments. 
Since the three cell lines used in this study were similar in their behaviour in regard 
to the analysed aspects, only one representative example is shown in up-coming 
figures. 
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Figure 22: Histological analysis of ESFT cell line xenografts and ESFT tumour samples. A Sections 
of ESFT cell line xenografts were immunohistochemically stained with haematoxylin and eosin (H&E; 
I and I’), for CD99 (II and II’) and for activated STAT3 (P-Y-STAT3; III and III’). H&E staining revealed 
that the tumours had a homogenous structure (I and I’). CD99, a cell surface marker used to identify 
ESFT, was expressed on the plasma membrane of tumour cells but not in adjacent cell types (II’). 
Most of the tyrosine phosphorylated STAT3 could be detected in the cytoplasm of ESFT xenografts 
and only weak staining was present in surrounding cells (III’). SK-N-MC xenograft samples are shown 
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as a representative example. B Immunohistochemical staining for activated STAT3 on sections of 
Ewing’s tumour samples. A tissue microarray with 45 patients was stained with an antibody specific 
for P-Y-STAT3. Four examples representing the heterogenousity of staining pattern are shown: I -
intermediate staining in nucleus and cytoplasm (normal bone structures were P-Y-STAT3 negative); 
II - strong staining only in the nucleus; III - weak staining only in the cytoplasm; IV - intermediate 
staining in nucleus and cytoplasm. 
 
 
Five xenograft tumours were analysed for immunohistological features and one 
representative example is depicted in Figure 22A. H&E staining showed a 
homogenous structure in the xenograft tumours. CD99, a surface molecule used in 
diagnosis of ESFT, was only expressed in the tumour area but not in the surrounding 
tissue (Figure 22A-II’). Moreover, profound phosphorylation of STAT3 was present in 
the xenograft (Figure 22A-III and –III’) and also in samples from ESFT patients 
(Figure 22B). Overall, 73% of the 45 patient samples analysed on a tissue micro 
array (in collaboration with Dr. Christopher Poremba, Research Park Trier, Center 
of Histopathology, Cytology, and Molecular Diagnostics, Trier, Germany) stained 
positively for phosphorylated STAT3. The staining pattern was very heterogeneous 
and varied from weakly positive to an intense staining (Figure 22B-III and –II, 
respectively). The cellular localisation was also not uniform, with most of the 
samples having a P-Y-STAT3 staining in both nucleus and cytoplasm (Figure 22B-I 
and -IV), but also only nuclear (Figure 22B-II) or only cytoplasmic localisation 
(Figure 22B-III) of P-Y-STAT3 staining was present. The status of STAT1 would also 
have been interesting but the immunohistology for P-Y-STAT1 unfortunately never 
worked properly.  
 
 
3.2.2. Cytokines activating STAT1/STAT3 
Absence of basal levels of JAK/STAT activation in cell culture and strong activation 
in xenograft tumours and patient samples suggested that signalling molecules 
present in the microenvironment of tumours, but not in cell culture, led to 
activation of this pathway. Thus, we tested a selection of cytokines, known to 
activate STAT1 and/or STAT3, on ESFT cell lines. 
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Figure 23: Response of ESFT cell lines to STAT1/STAT3 activating cytokines. ESFT cells were 
stimulated for 30 minutes with indicated concentrations of various cytokines or left untreated. The 
results from SK-N-MC are shown as a representative since the same picture was seen in TC71 and 
STA-ET-7.2. A EMSA was performed with radioactively labelled oligonucleotides specific for STAT1 
and STAT3 (SIE-M67) and supershift with antibodies recognising either STAT1 or STAT3 was used to 
distinguish the STAT proteins present. DNA binding ability of STAT1 and STAT3 could be 
demonstrated upon IFN-α, CNTF, LIF and OSM stimulation whereas IFN-γ administration activated 
only STAT1. IL-6 stimulation led only to a weak STAT1 and STAT3 DNA binding. B Tyrosine 
phosphorylation and total levels of STAT1 and STAT3 were analysed with Western blot analysis. IFN-
α, CNTF, LIF and OSM stimulation led to phosphorylation of STAT1 and STAT3, IFN-γ administration 
resulted in STAT1 phosphorylation and no phosphorylation of STAT1 or STAT3 was detected after IL-
6 stimulation.HSC-70 was used as a loading control. IFN = interferon, IL-6 = interleukin-6, CNTF = 
ciliary neurotrophic factor, LIF = leukaemia inhibitory factor, OSM = oncostatin M 
 
 
ESFT cells were incubated with indicated cytokines for 30 minutes at different 
concentrations. The potency of activating STAT1 and STAT3 varied greatly (data 
not shown) and only one concentration of each cytokine was chosen for the 
following experiments so that activation levels were quite equal. Interferon (IFN)-
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α, ciliary neurotrophic factor (CNTF), leukaemia inhibitory factor (LIF) and 
oncostatin M (OSM) led to a profound activation of STAT1 and STAT3 as shown by 
the DNA binding ability to a STAT1 and STAT3 responsive element, whereas IFN-γ 
activated only STAT1 (Figure 23A). Surprisingly, ESFT cells were weakly responsive 
to the wide-range cytokine interleukin-6 (IL-6), only high levels of IL-6 (at least 100 
ng/ml) could activate STAT3 as well as STAT1 to some extent. 
Moreover, the data from the DNA binding assay could be verified with Western blot 
analysis using antibodies specific for the tyrosine phosphorylated forms of STAT1 or 
STAT3 (Figure 23B). Phosphorylation of STAT1 could be detected in IFN-α, IFN-γ, 
CNTF, LIF and OSM stimulated cells and STAT3 was phosphorylated upon 
stimulation with IFN-α, CNTF, LIF and OSM. Although a weak DNA binding ability of 
STAT1 and STAT3 could be detected in IL-6 stimulated cells (Figure 23A), 
significant tyrosine phosphorylation of the STAT proteins could not be observed in 
Western blot analysis (Figure 23B). 
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Figure 24: Duration of STAT activity in stimulated ESFT cell lines. ESFT cells were stimulated for 
indicated time periods with 10 ng/ml or 100 ng/ml of various cytokines or left untreated. EMSA was 
performed with radioactively labelled oligonucleotides specific for STAT1 and STAT3 (SIE-M67). Only 
IFN-γ caused prolonged STAT1 activity over time whereas gp130 cytokines led to a shotgun 
activation of STAT1/STAT3. Data from SK-N-MC are shown as a representative example; the same 
results were obtained for TC71 and STA-ET-7.2. 
 
 
Furthermore, we investigated the duration of the JAK/STAT signal in cytokine 
stimulated cells. Therefore, we stimulated ESFT cells for different time periods 
with the cytokines most potently activating STAT1 and STAT3. We used an 
approximately ten fold higher concentration as needed to see DNA binding to 
circumvent limitation of the cytokine during the experiment. EMSA revealed that 
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gp130 cytokines (CNTF, LIF and OSM) activated STAT1 and STAT3 transiently 
whereas IFN-γ led to a sustained activation (Figure 24). 
 
To better understand the mechanisms of JAK/STAT signalling we also investigated 
the corresponding receptors on the surface of ESFT cells. Gp130 is part of every 
gp130 cytokine receptor complex and therefore indispensable for activation of 
STAT1and STAT3 in response to IL-6, CNTF, LIF or OSM. As expected, gp130 was 
nicely expressed in ESFT cells (Figure 25). Also LIF receptor (LIFR) and OSM 
receptor (OSMR) were highly expressed but no significant IL-6 receptor α (IL-6R) 
could be found on the ESFT cells analysed. Surprisingly, CNTF receptor α chain 
(CNTFR) could also not be detected, although the cells were clearly responsive to 
CNTF. This suggests signalling through an alternative complex, consisting of gp130, 
LIFR and the soluble IL-6R, which might be present but cannot be detected with 
flow cytometric analysis. (Schuster et al. 2003) 
 
 
Figure 25: Cytokine receptor surface expression in ESFT cells. Flow cytometric analysis of non-
permeabilised ESFT cell lines stained with antibodies specific for the receptors of the gp130 
cytokine receptor family demonstrated prominent surface expression of gp130, LIFR and OSMR 
whereas IL-6R and CNTFR could not be detected. Black filled histograms represent the negative 
control without first antibody and the coloured line shows the level of the indicated receptor 
present on the surface of ESFT cells. Functionality of antibodies was tested with control cells. 293T 
cells expressed IL-6R and SH cells, a neuroblastoma cell line, expressed CNTFR on the cell surface. 
The results from SK-N-MC are shown as a representative; the same receptors were present in TC71 
and STA-ET-7.2. Gp130 = glycoprotein 130, IL-6R = IL-6 receptor α, CNTFR = CNTF receptor α chain, 
LIFR = LIF receptor, OSMT = OSM receptor. 
 
 
In regard to the biological functions of the tested cytokines, known to enhance or 
reduce cellular expansion, we investigated the effect on ESFT cell proliferation. A 
profound reduction in cell number was observed when cells were stimulated with 
fluorescence intensity 
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IFN-γ (Figure 26). IFN-α stimulation demonstrated a mild inhibition of proliferation. 
However, proliferation in response to gp130-cytokines was not altered 
dramatically; LIF stimulation was able to enhance cell growth to some extent but 
only at high concentrations (Figure 26 and data not shown).  
 
Figure 26: Proliferation in response to cytokines. ESFT cell lines were stimulated with 10 ng/ml 
cytokine and proliferation was monitored over a period of 8 days. Cell numbers were determined by 
incorporation of crystal violet and measurement of the extracted dye at 560 nm. IFN-γ led to a 
massive reduction in cell number, IFN-α reduced proliferation only modestly and administration of 
gp130 cytokines did not much alter proliferation in comparison to the untreated control. Results 
from SK-N-MC are shown as a representative but analysis was also performed with TC71 and STA-ET-
7.2 having the same outcome.  
 
 
Since STAT proteins are transcription factors regulating transcription of target 
genes we wanted to know which target genes are changed in cytokine stimulated 
ESFT cells. Analysis of JAK/STAT specific target genes with an OligoGEArrayTM 
demonstrated that STAT1 targets were clearly up-regulated in INF-γ stimulated 
cells (Figure 27). Some STAT1 targets, like CDKN1A or IRF1 were also expressed at a 
higher level in response to CNTF, LIF or OSM. CXCL9 and SOCS1 were up-regulated 
after CNTF administration whereas LIF and OSM stimulation led in addition to an 
induction of INDO. Unexpectedly, STAT3 induced genes (BCL2L1, MMP3, MYC) did 
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not change their expression significantly. The level of the STAT3 target gene CRP 
was even lower after cytokine stimulation. 
 
Figure 27: Analysis of JAK/STAT specific target genes. ESFT cell lines were stimulated with 
indicated cytokines for 4 hours and analysed for JAK/STAT relevant genes with an OligoGEArrayTM. 
The left part of the graph shows selected STAT1 targets genes, the middle depicts a selection of 
STAT3 relevant targets and the right side presents genes that negatively regulate the JAK/STAT 
pathway. Stimulation with IFN-γ up-regulated almost all indicated STAT1 target genes while gp130 
cytokines led to expression of some STAT1 targets, but no STAT3 target was significantly up-
regulated. Data from SK-N-MC are shown as a representative though analysis was also performed 
with TC71, showing the same result. 
 
 
 
3.2.3. Dominant negative forms of STAT1/STAT3 in ESFT cell lines 
To answer the question if STAT1 and/or STAT3 were essential for ESFT tumour 
formation, we introduced mutant forms of STAT1 and STAT3 acting in a dominant 
negative way into ESFT cell lines. We used STAT mutants where the critical 
tyrosine residue was changed to phenylalanine so that it cannot be phosphorylated 
anymore (STAT1 Y701F and STAT3 Y705F later abbreviated as S1YF and S3YF, Figure 
28B). These mutant forms of STATs bind to the receptor and block recruitment of 
wild type STAT proteins, inhibiting phosphorylation of wild type STATs and hence 
signal transduction. (Kaptein et al. 1996) The second mutant form we used was a 
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truncation of the carboxy-terminal part (STAT1 ∆677 and STAT3 ∆683 later 
abbreviated as S1∆ and S3∆, Figure 28C). Since the transactivation domain is 
located in this region, the modified STAT proteins could not regulate gene 
expression anymore.  
 
STAT3 ∆683STAT1 ∆677
STAT1 STAT3
STAT1 Y701F STAT3 Y705F
A
B
C
pY701
1 750
NH2- -COOHSH2 TADNTD coiled-coil DBD
1 758
F701
NH2- -COOHSH2 TADNTD coiled-coil DBD
1 676
NH2- -COOHSH2NTD coiled-coil DBD
pY705
1 770
NH2- -COOHSH2 TADNTD coiled-coil DBD
1 778
F705
NH2- -COOHSH2 TADNTD coiled-coil DBD
1 682
NH2- -COOHSH2NTD coiled-coil DBD
FLAG FLAG
 
Figure 28. Dominant negative forms of STAT1 and STAT3. A Unmodified structure of STAT1 and 
STAT3. B Modified forms of STAT1 and STAT3 with a point mutation of the essential tyrosine 
necessary for STAT activity. A FLAG tag was introduced to distinguish the mutant from the 
endogenous STAT protein. C Mutant forms of STAT1 and STAT3 lacking the carboxy-terminal part, 
harbouring the transactivation domain. The mutated constructs were cloned into pMSCV, a vector 
based on the murine stem cell virus. The gene of interest was followed by an internal ribosomal 
entry site (IRES) and the green fluorescent protein (GFP), facilitating sorting of infected cells. NTD = 
N-terminal domain, DBD = DNA binding domain, SH2 = src homology 2, TAD = transactivation 
domain, pY = tyrosine phosphorylation site 
 
 
SK-N-MC and TC71 cell lines were retrovirally transduced with dominant negative 
constructs of STAT1 or STAT3 and sorted for GFP (in collaboration with Dr. Matthias 
Mayerhofer, General Hospital Vienna, Austria and Gabi Stengl, Institute of 
Molecular Pathology, Vienna, Austria). Since both cell lines used in these 
experiments were similar in their behaviour in regard to the analysed aspects, only 
one representative example is shown in up-coming figures. 
Expression of mutant STAT proteins was verified with Western blot analysis (Figure 
29A). Cells transduced with the empty vector (GFP) were used as a control. The 
S1∆ mutant could not be detected with a specific antibody recognising the amino-
terminal part of STAT1 (Figure 29A) even though GFP expression could be verified 
with flow cytometry (Figure 29B). Thus, this mutant was excluded for further 
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experiments. Expression of S1YF and S3YF proteins could be demonstrated with an 
antibody detecting the FLAG-tag of these mutants and S3∆ could be nicely 
visualised with an antibody specific for the STAT3 amino-terminus (Figure 29A). In 
extracts from S3YF transduced cells, the STAT3 antibody recognised a band that 
migrated similarly to the S3∆ protein, but the same band appeared when the 
membrane was incubated with a FLAG specific antibody. Since the FLAG-tag is only 
present in the S3YF mutant form but not in S3∆, a contamination could be excluded 
(Figure 29A). 
 
We wanted to analyse if there were differences in growth of xenografts expressing 
the STAT mutants, so we tested as a pre-experiment whether the established cell 
lines varied in their growth behaviour in vitro. A proliferation assay based on 
incorporation of crystal violet (see 2.2.6.) revealed that the cell lines expressing 
mutant forms of STAT1 or STAT3 did not differ much in their proliferation 
behaviour (Figure 29C). These data were in line with the observed absence of 
STAT1 and STAT3 activity in cell culture (Figure 23). 
Next, we subcutaneously injected the established cell lines into 
immunocompromised mice and examined the resulting tumours. The dominant 
negative STAT forms were still expressed in the xenografts, but to a slightly lower 
level (Figure 30A). Tumour growth was not much altered when looking at the 
different mutants but all the manipulated cell lines grew a little slower in 
xenografted tumours than control cells (Figure 30B). Moreover, histological analysis 
with H&E, TUNEL and Ki67 staining (in collaboration with DI Michaela Schlederer) 
did not reveal any striking differences (Figure 31). 
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Figure 29: Expression of dominant-negative STATs in ESFT cell lines. A Western blot analysis of 
cells transduced with different mutant forms of STAT1, STAT3 or empty vector (GFP) with 
antibodies specific for STAT1, STAT3 or the FLAG-tag. β–Actin was used as a loading control. S1YF, 
S3∆ and S3YF were nicely expressed whereas S1∆ could not be detected. B Flow cytometric analysis 
for expression of GFP in cell lines transduced with mutant STATs indicated presence of the 
construct in all cell lines. Untransduced ESFT cells were used as a control. C Analysis for 
proliferation of cell lines expressing different mutant forms of STAT1 and STAT3 revealed quite 
similar growth curves. Data from SK-N-MC cell lines are shown as a representative; analysis of TC71 
cell lines had the same results. 
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Figure 30: Analysis of ESFT cell line xenografts expressing dominant-negative forms of STAT 
proteins. A Western blot analysis of different mutant forms of STAT1 or STAT3 with antibodies 
specific for STAT1, STAT3 or the FLAG-tag in cell lines and xenograft samples. HSC-70 was used as a 
loading control. Mutant STAT proteins were expressed in the cell lines as well as in the xenograft 
tumours. B ESFT cell lines expressing dominant-negative forms of STAT1 or STAT3 were 
subcutaneously injected into SCID mice and tumour growth was monitored but was not much 
altered. Data from SK-N-MC are shown as a representative since analysis of TC71 demonstrated the 
same results. 
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Figure 31: Analysis of ESFT cell line xenografts expressing dominant-negative forms of STAT 
proteins for markers of apoptosis and proliferation. Haematoxylin and eosin (H&E) staining 
showed a comparable structure of tumours expressing different mutant STAT proteins. Terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) detects DNA fragmentation, one sign 
of cell death, and only few cells stained positive in control (GFP) cells as well as in cells expressing 
dominant-negative STATs. KI67, associated with cellular proliferation, was present in most cells of 
the control (GFP) and comparable in cells expressing different STAT mutants. DAPI staining was used 
to visualise nuclei. Representative regions of SK-N-MC xenografts are shown; TC71 xenografts were 
also analysed, with the same result. 
 
 
STAT activity should be diminished when cells expressing the dominant-negative 
forms are stimulated with STAT1 and/or STAT3 activating cytokines. Thus, we 
analysed the DNA binding of STAT1 and STAT3 in extracts of the established cell 
lines expressing the mutant STAT forms (Figure 32A). IFN-γ activated STAT1 to a 
lesser extent in the cell line expressing S1YF as in the control cell line (GFP). After 
stimulation with LIF, DNA binding ability of STAT3 and STAT1 was absent in cells 
containing the S3YF mutant. S3∆ expressing cells did not show a reduction in 
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complexes that specifically bind to the STAT1/STAT3 consensus sequence, which 
was not surprising as only the transactivation domain was lacking in this mutant 
form but the domains for oligomerisation and DNA binding were still present.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: Activation of STATs in ESFT cell lines expressing dominant-negative forms of STAT 
proteins. SK-N-MC cells were stimulated for 30 minutes with 10 ng/ml cytokine or left untreated. A 
Equal amounts of total protein were analysed by EMSA with radioactively labelled oligonucleotides 
specific for STAT1 and STAT3 (SIE-M67). STAT1 complexes were reduced in IFN-γ stimulated S1YF 
cells and STAT1/STAT3 complexes were absent in LIF stimulated S3YF expressing cells. B Western 
blot analysis for tyrosine phosphorylation and total levels of STAT1 and STAT3 proteins revealed 
diminished phosphorylation of STAT1 and STAT3 in LIF stimulated S3YF expressing cells and a lower 
ratio of phosphorylated STAT1 compared to total STAT1 in IFN-γ stimulated cells expressing the S1YF 
mutant. The S3∆ mutant led to a mildly reduced tyrosine phosphorylation of endogenous STAT3 
upon LIF stimulation. 
 
 
Additionally, we tested the mutants for tyrosine phosphorylation upon cytokine 
stimulation (Figure 32B). After stimulation with IFN-γ, cells expressing S1YF showed 
 
B 
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quite the same amount of phosphorylated STAT1 than control cells expressing only 
GFP. However, when comparing P-Y-STAT1 and total STAT1 levels, there was a 
reduction in activated STAT1 in relation to the whole amount of STAT1 protein in 
S1YF expressing cells. The S3∆ mutant did result in a mild reduction of endogenous 
STAT3 phosphorylation upon LIF administration. Notably, the mutant protein 
migrating faster than the full length STAT3 was not tyrosine phosphorylated in 
response to LIF. Upon LIF stimulation, cells expressing the S3YF mutant did only 
show low levels of STAT1 and STAT3 phosphorylation, confirming the results from 
EMSA. 
So, by two different methods at least the tyrosine mutated STATs were shown to 
diminish STAT activity but a biological relevance for ESFT cell growth in xenografts 
could not be observed. 
 
 
Follow-up studies on the role of JAK/STAT signalling in ESFT are currently 
performed by Mag. Marc Wiedner. He compared SK-N-MC, an ESFT cell line also 
used in this work, and human MPCs, most likely the cellular origin of ESFT. From 
the analysed gp130 cytokines, MPCs were only responsive to OSM. Moreover, a 
second wave of STAT activation was seen in both cell types at about four to eight 
hours after initial cytokine administration. Interestingly, MPCs re-activated both 
STAT1 and STAT3 whereas in ESFT cells only STAT3 was activated a second time.  
A closer look on STAT target genes revealed that c-fos was induced upon OSM 
stimulation in MPCs and SK-N-MC. However, up-regulation of the STAT3 target gene 
was more pronounced in the analysed ESFT cell line (Marc Wiedner, unpublished). 
C-fos is a component of the AP-1 complex which regulates many steps of 
tumourigenesis, for instance proliferation, apoptosis, angiogenesis and metastasis. 
(Jochum et al. 2001) Hence, c-fos induction by OSM via JAK/STAT might provide 
insight how STAT3 activation could contribute to ESFT development. 
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4. Discussion 
 
 
 
 
4.1. Establishment of a conditional EWS/FLI-1 knock-in 
mouse model 
 
Although progress in the field of surgery and chemotherapy could increase survival 
rates, still less than 60% of ESFT patients survive long-term. (Khoury 2005) Novel 
treatment regimens are therefore needed, going along with the requirement of 
animals models for pre-clinical drug testing. Several groups already tried to 
establish a suitable mouse model but so far no mouse recapitulating the human 
phenotype could be created. (Codrington et al. 2005; Torchia et al. 2007) 
Recent advances in the quest for the cellular origin of ESFT uncover a multi-potent 
mesenchymal progenitor as the starting point for this disease. (Kauer et al. 2009; 
Lin et al. 2008; Riggi et al. 2005; Tirode et al. 2007) It seems that only MPCs, 
which are able to differentiate along the osteogenic, chondrogenic and adipogenic 
lineage, have the adequate cellular background to allow expression of EWS/FLI-1. 
(Riggi et al. 2005) Moreover, differentiation of this cell type is blocked by EWS/FLI-
1 and tumour formation in xenograft models is facilitated. (Lin et al. 2008; Riggi et 
al. 2005; Torchia et al. 2003) In ESFT cells EWS/FLI-1 suppression permits the 
tumour cells to differentiate into mesenchymal lineages but also impairs tumour 
growth. (Ouchida et al. 1995; Takigami et al. 2011; Tirode et al. 2007) These 
studies indicate that EWS/FLI-1 contributes to the ESFT morphology by maintaining 
the tumour cells in an undifferentiated state resulting in uncontrolled proliferation 
and eventually tumour growth. 
 
Based on the assumption that ESFT arise in a mesenchymal progenitor, we 
established conditional EWS/FLI-1 knock-in mouse models where expression of the 
fusion protein is controlled by the presence/absence of the Cre recombinase in a 
particular target cell.  
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In the course of this study we used two different promoters for directing Cre 
expression into different stages of bone precursor cells, namely Runx2 and Prx1. 
Runx2 is expressed early in the mesenchymal lineage at the stage of skeletal 
precursor cells (Figure 6) and it is an essential transcription factor necessary for 
differentiation into the osteoblastic lineage. (Komori 2000) Expression in the 
embryo starts at around E 11.5. (Otto et al. 1997) Prx1 is a homeobox gene which is 
expressed in mesenchymal cells (Figure 6) of the early limb bud mesenchyme from 
E 9.5 on. (Logan et al. 2002) Not only that Runx2 has a later timing in embryonic 
development, expression is initiated in a cell type that is more mature compared to 
the primitive mesenchymal cell in which Prx1 is present. These differences had a 
drastic effect on the outcome of EWS/FLI-1 expression.  
 
Researchers already showed that dependent at which stage of mesenchymal cell 
maturation manipulation of the same gene can have different effects. Deletion of 
Dicer in committed osteo-progenitors has a deleterious effect whereas lack of the 
same gene in mature osteoblasts gives a viable mouse and only a mild effect. (Gaur 
et al. 2010) But already minor differences in the onset of gene deletion in the same 
cell type can have opposing outcomes. For example, inactivation of Ptch1 in 
Prx1Cre expressing cells results in a loss of digits in the forelimb but to a gain of 
digits in the hindlimb. (Butterfield et al. 2009) This discrepancy is due to a one day 
later activation of Cre. (Logan et al. 2002) Hence, perfect timing of gene 
manipulation in the process of bone development is essential since skeletal 
formation is a complex and sensitive system. 
 
In Runx2Cre (784 and 1634 transgenic line) EF mice no EWS/FLI-1 transcript was 
detectable whereas it was prominently expressed in the bones of Prx1Cre EF mice. 
Rearranged cells were only barely detectable and most of the cells in the adult 
bone of Runx2Cre EF mice had an unchanged EF allele with the STOP-cassette still 
present.  
It is possible that Cre and hence EWS/FLI-1 expression was toxic and rearranged 
cells had growth/survival defects. Several studies have reported that the Cre 
recombinase alone can lead to apoptosis in certain cell types. (Naiche and 
Papaioannou 2007; Jeannotte et al. 2011) However, analysis of Cre expression in 
bones of Runx2Cre and Runx2Cre EF mice revealed that the Cre recombinase 
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transcript was present when the EWS/FLI-1 construct was not. Thus, we could 
exclude that Runx2Cre on its own was toxic to the cells in our transgenic mice. 
Additionally, Runx2Cre mice were already used successfully in other studies. 
(Rauch et al. 2010) 
EWS/FLI-1 is known to have a growth inhibitory effect in primary cells and that loss 
of the INK4A/ARF locus or inhibition of p53 enables the cells to express EWS/FLI-1. 
(Deneen and Denny 2001; Lessnick et al. 2002) Moreover, human paediatric MPCs, 
whose gene expression profile resembles that of ESFT more closely than that of 
their adult counterparts, have lower p16INK4A/p14ARF levels than adult MPCs. (Riggi 
et al. 2010) Therefore, we assumed that the lethal effect EWS/FLI-1 might have 
had on Runx2Cre expressing cells could be relieved by deleting p16INK4A/p19ARF. We 
crossed Runx2Cre EF mice to an INK4A/ARF deficient background, thereby 
eliminating two important regulators of Rb and p53 checkpoint control. However, 
impairment of RB/p16INK4A and p53/p19ARF pathways in osteoblast precursors did not 
create an environment permissive for EWS/FLI-1, in contrast to in vitro studies. 
(Deneen and Denny 2001; Lessnick et al. 2002) EWS/FLI-1 was not detectable in 
these mice, suggesting that the toxic effect during embryonal development could 
not be abrogated. So, other mechanism apart from growth arrest could have been 
responsible for the absence of Cre and EWS/FLI-1 expression.  
 
Although we could detect at least some rearrangement of the EF allele, Cre 
expression was completely absent in bones of Runx2Cre EF and Runx2Cre EF 
INK4A/ARF-/- mice. At some point Runx2Cre must have been active otherwise we 
would not have been able to detect any deletion of the STOP-cassette. A possible 
explanation would be silencing of Runx2 by EWS/FLI-1, which we did not expect 
prior to the start of our experiments. Indeed, presence of the fusion protein in 
ESFT cells results in low levels of Runx2 and vice versa Runx2 is induced upon 
EWS/FLI-1 silencing. (Tirode et al. 2007) One could assume that EWS/FLI-1 down-
regulates Runx2 at the transcriptional level which would explain the lack of Cre 
expression from the Runx2 promoter seen in Runx2Cre EF mice. But caution is 
advised when interpreting that EWS/FLI-1 directly regulates Runx2 since there is no 
evidence that Runx2 is a target gene of EWS/FLI-1 and down-regulation of Runx2 
might be just the consequence of EWS/FLI-1 hindering the osteoblast 
differentiation programme. It was recently published that EWS/FLI-1 is able to bind 
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Runx2 thereby regulating its activity and inhibiting differentiation of mesenchymal 
cells along the osteoblastic lineage. (Li et al. 2010) The Runx2 promoter harbours 
runx consensus binging sites to which the protein can bind and auto-regulate itself. 
(Stock and Otto 2005) Therefore, it is conceivable that EWS/FLI-1 binds to Runx2 
and shuts down expression from the Runx2 promoter. This negative feedback loop 
would result in loss of Cre expression but would also lead to a block in osteoblast 
differentiation due to absent Runx2 protein. However, there are two Runx2 
promoters and the transgenic Runx2Cre lines we used contain the bone specific P1 
promoter. (Rauch et al. 2010; Stock and Otto 2005) Normal bone development 
could be accomplished by the other Runx2 isoform expressed from the P2 promoter 
since it was shown that the isoforms can substitute each other to some extent. 
(Stock and Otto 2005) Mice that are specifically deficient in the Runx2 isoform 
expressed from the P1 promoter show a certain degree of compensation. They 
display abnormal bone development, although the phenotype is not as severe as in 
the complete knock-out where calcified bones are almost completely lacking. 
(Zhang et al. 2009) Nonetheless, we did not observe overt differences in size or 
bone development in Runx2Cre EF compared to wild type mice. But this hypothesis 
might at least explain why we could observe rearrangement of the EF allele in 
some rare cells but no Cre expression at all. The selective pressure might have 
been so strong that most of these rearranged cells died and were replaced by non-
rearranged cells to ensure proper bone development. 
 
Runx2 is expressed from the skeletal precursor stage on (Figure 6) but cells earlier 
in this lineage, the mesenchymal cells, do not express it yet. During the maturation 
process these primitive mesenchymal cells that still have a non-rearranged EF 
allele must inevitably express Runx2 to initiate the osteoblast differentiation 
programme. Hence, Cre and EWS/FLI-1 would also be expressed and initiate the 
negative feedback loop discussed above, resulting in a blockage of differentiation 
along the osteoblastic lineage. Silencing of the exogenous Runx2 promoter by e.g. 
methylation in mesenchymal cells would circumvent this differentiation arrest 
since the endogenous Runx2 promoter would not have been affected. These cells 
would have a selective advantage and would replace the rearranged cells to 
guarantee normal bone development. In Prx1Cre EF mice expression of EWS/FLI-1 
was directed to the early mesenchymal cell (Figure 6), so there was no earlier cell 
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type in the limb bud that could have compensated for the arrested EWS/FLI-1 
expressing cells. Hence, we could detect the phenotype of a differentiation block 
that lead to disturbed limb development. 
 
Skeletal malformation in Prx1Cre EF mice was due to a lack of calcification in 
bones of the skull, the limbs and the rib cage. The absence of mature chondrocytes 
and osteoblasts would explain the lack of calcified bone. As already mentioned 
earlier, there is in vitro evidence that EWS/FLI-1 blocks differentiation of several 
cell types. (Eliazer et al. 2003; Li et al. 2010; Torchia et al. 2003) This ability of 
EWS/FLI-1 could account for the defective chondrocyte maturation seen in Prx1Cre 
EF mice.  
The phenotype of absent bone mineralisation in Prx1Cre EF mice partly resembled 
the β–catenin knock-out, where β-catenin deficiency impairs differentiation of 
osteoblasts. (Hill et al. 2005) However, the phenotype observed in Prx1Cre EF mice 
is more severe, since already pre-hypertrophic chondrocytes are missing while they 
are still present in the β–catenin knock-out. EWS/FLI1 was shown to reduce 
expression of the Wnt inhibitor DKK-1 and to impede β-catenin/TCF-dependent 
transcription by binding to the transcription factor Lef1. (Navarro et al. 2010) This 
inhibition of the Wnt pathway by EWS/FLI-1 might explain in part the 
differentiation block seen in Prx1Cre EF mice. 
Loss of IHH causes shortened limbs and disturbs chondrocyte differentiation, the 
same defects presented in Prx1Cre EF mice. (St-Jacques et al. 1999) The proposed 
involvement of Hedgehog signalling in ESFT as mentioned later might explain the 
similarity of phenotypes. 
Reduced TGF-βRII signalling could also account for the phenotype we detected in 
Prx1Cre EF mice. EWS/FLI-1 directly represses TGF-βRII and it is suggested that 
TGF-βRII acts to limit chondrogenesis thereby maintaining the interzone in 
endochondral bone formation. (Hahm et al. 1999; Seo and Serra 2007) It was 
further demonstrated that deletion of TGF-βRII in Prx1Cre expressing cells results 
in limb shortening and a failure of chondrocyte differentiation. (Seo and Serra 
2007) So, part of the Prx1Cre EF phenotype might be explained with repression of 
TGF-βRII by EWS/FLI-1 resulting in a disturbed chondrocyte development. 
Altogether, perturbed chondrocyte development can be observed in mouse models 
where components of the Wnt, Hedgehog and TGF-β pathway are deleted but none 
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of the phenotypes is as severe as the effects we examined in our mouse model. The 
differentiation block at the stage of chondroblasts in Prx1Cre EF mice was possibly 
due to a dysfunction of a combination of these pathways but this has still to be 
elucidated. Additionally, more work particularly on younger embryos needs to be 
performed, which is currently done at the Ludwig Boltzmann Institute for Cancer 
Research with a successor of this project. 
 
Additionally, Prx1Cre EF mice displayed polydactyly reminiscent of the GLI3 knock-
out mouse. (Hui and Joyner 1993) Polydactyly is also present in a hypermorphic 
GLI3 mutant mouse and in the hindlimbs of mice with conditional deletion of Ptch1 
in Prx1 expressing cells. (Butterfield et al. 2009; Wang et al. 2007) As determined 
by GLI1 expression, Hedgehog signalling is enhanced in limbs deficient in Ptch1, the 
negative regulator of this pathway. (Butterfield et al. 2009) EWS/FLI-1 was shown 
to directly regulate GLI1 and to increase its expression. (Beauchamp et al. 2009; 
Zwerner et al. 2008) This might explain at least in part the similarity of phenotypes 
in these mice although the Hedgehog pathway was so far not analysed in detail in 
our mice. We concentrated our analysis on the developmental defects causing the 
limb shortening. 
 
During the work for this thesis a new EWS/FLI-1 transgenic mouse which was 
crossed with the Prx1Cre line was published. (Lin et al. 2008) The design of the 
construct that is present in these mice has some similarity to the one employed in 
EF mice (Figure 3C and B). Both constructs harbour a loxP cassette that silences 
the rearranged EWS/FLI-1 gene and only upon Cre activity the fusion gene is 
expressed. (Lin et al. 2008; Torchia et al. 2007) The construct in EF mice contains 
several STOP signals between the two loxP sites whereas a GFP-cassette is located 
at this site in the other construct. In EF mice the EWS/FLI-1 construct is under 
control of the ubiquitous Rosa26 promoter while transgene expression in the other 
mouse model is driven by a β–actin promoter. Moreover, the EWS/FLI-1 construct in 
EF mice resides in the endogenous Rosa26 locus which is widely used for the 
generation of transgenic mice and does not encode for protein. (Torchia et al. 
2007) In contrast, there are several copy numbers of the EWS/FLI-1 construct 
present in the other mouse model and the genomic localisation of the constructs 
was not determined. (Lin et al. 2008) Loss or enhancement of gene expression of 
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unknown targets caused by the random introduction of the EWS/FLI-1 construct 
might have influenced the observed phenotype.  
Three transgenic lines were established by this group: the first one has shorter 
limbs, another one shows a mild polydactyly and a third line has severe limb 
defects but is not viable. The short limb phenotype in the first transgenic line is 
not as prominent as in our Prx1Cre EF mice and also the polydactyly of the second 
line is not as severe. None of the lines develops tumours per se but the first 
EWS/FLI-1 transgenic line in combination with conditional deleted p53 leads to 
formation of poorly differentiated sarcomas. p53 deficiency in mesenchymal 
progenitors alone results already in formation of predominantly osteosarcomas and 
additional presence of EWS/FLI-1 then shifts the tumour spectrum and reduces the 
median tumour latency. (Lin et al. 2008) The phenotype of our Prx1Cre EF mice 
was more severe compared to the two viable EWS/FLI-1 transgenic lines. (Lin et al. 
2008) Therefore we focused our analysis on the developmental aspects present in 
Prx1Cre EF mice which might contribute to the understanding of ESFT 
pathogenesis.  
 
 
In addition to the so far discussed 784 and 1634 transgenic Runx2Cre EF mice, we 
analysed another transgenic Runx2Cre line. However, we could not obtain double 
transgenic offspring from crosses with mice harbouring the EF allele and the 777 
line of Runx2Cre. Fetal survival in 777Runx2Cre EF mice was compromised at E 
13.5. Cre recombinase in the 777 line was expressed at higher levels compared to 
the 784 and 1634 line and Cre activity was shown in bone, cartilage and also in the 
haematopoietic system (Dr. Jan Tuckermann, personal communication). High levels 
of EWS/FLI-1 and expression in the haematopoietic system might have led to the 
early fatal effect. In line, EWS/FLI-1 was already demonstrated to have a drastic 
impact on haematopoiesis. (Torchia et al. 2007) 
 
 
 
We have shown that mesenchymal progenitors (expressing Prx1) but not sekeletal 
precursors (being more committed to the osteoblast lineage and expressing Runx2) 
offer a suitable background for EWS/FLI-1 expression in vivo. Furthermore, the 
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absence of mature chondrocytes in our transgenic mouse model would support the 
finding that the presence of EWS/FLI-1 results in a differentiation block. (Eliazer et 
al. 2003; Li et al. 2010; Torchia et al. 2003) The severe developmental defects we 
observed in Prx1Cre EF mice and the fact that they die shortly after birth due to an 
open rib cage causing suffocation could be circumvented by utilisation of an 
inducible Prx1Cre transgenic line (Dr. Malcolm Logan, unpublished). Cre activation 
and hence EWS/FLI-1 expression can then be temporally controlled and started 
only after birth at different time points. These mice could be prone to develop 
tumours since tumour formation was already shown to be facilitated by EWS/FLI-1 
expression in mesenchymal progenitor cells. (Lin et al. 2008; Riggi et al. 2005) 
Therefore, we imported inducible Prx1Cre-ERT2 mice and generated compound 
mice with EF and INK4A/ARF deletion. Analysis of these mice is currently ongoing 
at the Ludwig Boltzmann Institute for Cancer Research in close collaboration with 
the CCRI and Prof. Erben to obtain a sarcoma mouse model resembling the 
phenotype of ESFT. 
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4.2. JAK/STAT signalling in ESFT 
 
Among other signalling pathways, the JAK/STAT pathway is often de-regulated in 
human cancers but not much is known about its function in ESFT. Only JAK1 and 
STAT3 activation were shown to be elevated in ESFT patient samples. (Baird et al. 
2005; Lai et al. 2006) On this informative basis and the fact that this pathway was 
not well studied we were interested in the role of the JAK/STAT pathway in ESFT. 
 
We analysed three different ESFT cell lines and could demonstrate that JAK/STAT 
signalling is active in ESFT cell line xenografts but absent in monolayer and 
spheroid culture. Additionally, most of the tumours on a ESFT tissue micro array 
also displayed tyrosine phosphorylation of STAT3, pointing to the relevance for 
Ewing’s tumours. Hence, we could exclude the possibility that cells produce an 
autocrine factor activating STAT1 and STAT3 proteins. Rather cytokines released by 
the microenvironment were suggested to stimulate this pathway. Similar results 
were already obtained for colon cancer cells, where STAT3 is constitutively 
activated in colon cancer cells but is lost in cell culture. However, activation can 
be restored in xenografts by extracellular stimuli. (Corvinus et al. 2005) 
 
The question then was which cytokines were able to activate STAT proteins in the 
xenograft tumours. ESFT cell lines were responsive to INF-α, IFN-γ and gp130 
cytokines like CNTF, LIF and OSM. Surprisingly, these cells were unresponsive to the 
well-known inflammatory cytokine IL-6 which was due to a lack of IL-6 receptor 
alpha chain expression, as measured by flow cytometric analysis. High cytokine 
receptor surface expression could be demonstrated for gp130, LIFR and OSMR. 
CNTFR was not present on ESFT cell lines but cells were clearly responsive to the 
cytokine CNTF which would argue for an alternative usage of gp130 cytokine 
receptor combinations. In the absence of CNTFR, signalling through gp130 and LIFR 
upon CNTF administration can be sustained by engagement of soluble IL-6R (sIL-
6R). (Schuster et al. 2003) It is feasible that sIL-6R was present in our cell cultures 
but we did not analyse this in detail. sIL-6R is either produced by alternative mRNA 
splicing or proteolytic cleavage of the membrane bound IL-6R and can be measured 
by analysis of mRNA or by an enzyme-linked immunosorbent assay. (Chalaris et al. 
2011) 
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Proliferation in response to the analysed cytokines was not changed dramatically. 
Only interferons led to a reduction in cell number whereby IFN-γ, which only 
activated STAT1, was very potent and IFN-α was less effective, which could be due 
to dual activation of STAT1 and STAT3.  
Analysis of JAK/STAT specific target genes in gp130 stimulated cells revealed that 
some STAT1 induced genes (CDKN1A, IRF1) were up-regulated as also seen in IFN-γ 
treated cells. Expression of STAT3 target genes was not increased in CNTF, LIF or 
OSM stimulated ESFT cells although we demonstrated DNA binding of STAT3 
complexes. We used a commercially available OligoGEArrayTM with a defined but 
limited set of STAT target genes (classical targets of tyrosine phosphorylated STAT 
proteins) which could explain that we have missed target genes induced by gp130 
cytokines. Clearly, we could detect tyrosine phosphorylation and DNA binding 
ability of STAT1 and STAT3 upon gp130 cytokine stimulation. An alternative 
possibility would be that the absence of STAT3 target gene activation could be due 
to functions of phosphorylated STAT proteins in the cytoplasm. (Sehgal et al. 2008) 
Based on the DNA binding ability, STAT1 had a more profound activation than 
STAT3. It is conceivable that this overbalance of STAT1 could have resulted in 
sequestration of STAT3 and consequently suppression of STAT3 target gene 
activation but the opposite case was reported. In response to IFN-α, activated 
STAT3 is able to sequester activated STAT1 thereby hindering STAT1 homodimer 
formation and hence STAT1-dependent target gene activation. (Ho and Ivashkiv 
2006) However, the biological role of this STAT1/STAT3 heterodimers is not clear 
yet. (Regis et al. 2008) 
Examination of the duration of STAT protein activation in ESFT cells revealed that 
STAT1 and STAT3 complexes were active over a period of at least 16 hours in IFN-γ 
stimulated cells whereas stimulation with CNTF, LIF and OSM led to a transient 
activation. DNA binding ability of STAT1 and STAT3 was prominent at 30 minutes, 
but highly diminished at 60 minutes. PIAS proteins negatively regulate the 
JAK/STAT pathway by binding activated STAT dimers and inhibiting STAT-mediated 
gene transcription. (Klampfer 2006) It is possible that the PIAS expression per se 
was already high in ESFT cells compared to other cell lines that initiate target gene 
transcription in response to activated STATs. Indeed, we found significant PIAS1 
and PIAS3 expression on the array, which could account for inhibition of STAT1 and 
STAT3 DNA binding complexes in ESFT cells. The increased expression of PIAS was 
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even more pronounced in the gp130 stimulated cells which could account for the 
short STAT activation.  
 
Since STAT1 and STAT3 were activated in ESFT xenografts we asked whether these 
STAT proteins were essential for tumour formation. We established ESFT cell lines 
with dominant-negative forms of STAT1 and STAT3, analysed them in vitro and 
subjected these cells to xenotransplantation.  
The mutant forms S1YF, S3∆ and S3YF were nicely expressed, but S1∆ was not 
detected appropriately on the protein level, which could be a result of misfolding 
resulting in an unstable protein. This mutant form of STAT1 was cloned based on 
the reported and widely used S3∆ mutant, where the protein is truncated after the 
SH2 domain lacking the transactivation domain. (Oh and Eaves 2002) 
In vitro growth of the cell lines expressing mutant forms of STAT1 and STAT3 was 
not much altered. Since STATs were not activated in ESFT cells in cell culture we 
did not anticipate a change in their proliferation capacity.  
Unfortunately, we could also not observe a difference in tumour growth although 
strong activation of STAT1 and STAT3 was noticed in xenografts arguing for a too 
weak expression of the dominant negative acting STAT variants or counter selection 
of ESFT cells expressing low levels of STAT variants. However, we could detect 
significant expression in endpoint xenograft samples and hence excluded these 
theories. STAT3 in particular was reported to have immunomodulatory function in 
tumours and it could be possible that an immunocompromised mouse model will 
not show effects upon blocked STAT activity. Alternatively, the long term ESFT cell 
lines we have used for our studies of blocking STAT activity might have had too 
many other genetic alterations which could bypass any functional role of STAT 
protein activation.  
The critical tyrosine residue was missing in all of the mutants, impeding full 
activation of STAT proteins. Moreover, the S1YF and S3YF mutants block 
recruitment of wild type STAT proteins to the receptors. (Kaptein et al. 1996) 
Therefore, a reduced DNA binding was expected in the established cell lines. EMSA 
revealed that S1YF and S3YF expressing cells displayed a reduction in STAT DNA 
binding ability when stimulated with INF-γ and LIF, respectively. DNA binding of the 
other mutants retained pretty much the same. Moreover, Western blot analysis for 
tyrosine phosphorylated STAT proteins showed the same inhibition of STAT activity 
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in S1YF and S3YF expressing cells. Additionally, the S3∆ mutant was demonstrated 
to diminish endogenous STAT3 phosphorylation to some extent. Hence, the 
dominant negative forms of STAT1 and STAT3 were shown to impair STAT activity in 
ESFT cells. Although the mutant forms of STAT proteins were already reported to 
have biological relevance in many different cell lines their effect in ESFT cells 
remains illusive. (Corvinus et al. 2005; Kortylewski et al. 2004; Oh and Eaves 2002; 
Walter et al. 1997) 
In this study we used mutant forms of STAT proteins that block recruitment of wild 
type STAT proteins to the receptors thereby inhibiting phosphorylation of wild type 
STATs (Kaptein et al. 1996) or a mutant with a truncation of the transactivation 
domain that could not induce gene transcription and concentrated our analysis on 
the classical role of the JAK/STAT pathway. But what about the role of un-
phosphorylated STAT proteins or cytoplasmic functions of phosphorylated STATs? 
The latter process could at least explain why we detected pronounced STAT1 and 
STAT3 activity in response to gp130 cytokines but no induction of classical target 
genes. To answer the question if these “non-classical” functions were involved in 
ESFT tumourigenesis total STAT protein levels should have been reduced which can 
be achieved by employment of the RNAi technology. 
 
 
In summary, with our work we could give some insight to the JAK/STAT pathway, a 
signalling pathway that is often de-regulated in cancer, but further analysis is 
needed to understand the biological function and consequences of STAT activation 
in ESFT cancer cells which is an ongoing project at the Ludwig Boltzmann Institute 
for Cancer Research. 
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6. Abbreviations 
 
A     ampere 
AEC     3-amino-9-ethylcarbazole 
ALK    anaplastic lymphoma kinase 
APC     adenomatous polyposis coli  
APS     ammoniumpersulfate 
ATP     adenosintriphosphat 
BCL2L1    B-cell lymphoma 2 like 1 
Bp     base pairs 
BSA     bovine serum albumin 
CAV1     caveolin-1  
CD  cluster of differentiation, cell surface molecule to 
identify haematopoietic cell lineages  
cDNA     complementary desoxyribonucleic acid 
cKit     transmembrane tyrosine kinase receptor, CD117 
CNTF     ciliary neurotrophic factor  
CNTFR    ciliary neurotrophic factor receptor a chain 
Col1     collagen1 
Col10     collagen10  
Col2     collagen2  
CRP     c-reactive protein 
CSC     cancer stem cell 
CXCL9    chemokine (C-X-C motif) ligand 9  
DAX1     dosage-sensitive sex reversal 
DBD     DNA binding domain 
ddH2O    double distilled water 
DEPC     diethylpyrocarbonate 
dH2O    distilled water 
DKK-1    dickkopf-1 
DMEM    Dulbecco’s Modified Eagle Medium 
DMSO     dimethylsulfoxide 
DNA     desoxyribonucleic acid 
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DNase    deoxyribonuclease 
dNTP     deoxyribonucleotide triphosphate 
Dsh     dishevelled 
DTT     dithiothreitol 
E     embryonic day 
ECL     enhanced chemiluminescence 
EDTA     ethylenediaminetetraacetic acid 
EMSA     electrophoretic mobility shift assay 
ERG     ets related gene 
ESFT     Ewing's sarcoma family of tumours 
ETS     e-twenty six 
EWS     Ewing's sarcoma breakpoint region 1 
EZH2     enhancer of zeste homolog 2 
FACS     fluorescence activated cell sorting 
FCS     fetal calf serume 
FISH     fluorescence in situ hybridisation 
FITC     fluorescein-5-isothiocyanat  
FLI1     Friend leukaemia virus integration site 1 
Fz     frizzled  
GAS     γ-activated sequence 
gDNA    genomic desoxyribonucleic acid 
GFP     green fluorescent protein 
gp130    glycoprotein 130 
Gsk3     glycogen synthase kinase 3 
H&E     haematoxylin n and eosin staining  
HA     hemagglutinin  
HRP    horseradish peroxidase 
ID2     inhibitor of DNA binding 2 
IFN     interferon 
IGF     insulin-like growth factor 
IGF-1    insulin-like growth factor-1 
IGF-1R    insulin-like growth factor-1 receptor 
IGFBP3    insulin-like growth factor binding protein 3  
Ihh     Indian Hedgehog 
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IL     interleukin 
IL-6R    interleukin-6 receptor a 
INDO     indoleamine-pyrrole 2,3-dioxygenase 
IRES    internal ribosomal entry site 
IRF     interferon regulated factor  
ISGF3     interferon-stimulated gene factor 3  
ISRE     interferon stimulated response element  
JAK     Janus kinase  
kB     kilobases 
kD     kilodalton 
l     litre 
LB     lysogeny broth 
Lef     lymphoid enhancer factor 
LIF    leukaemia inhibitory factor  
LIFR     leukaemia inhibitory factor receptor 
loxP     Cre recombinase recognition site 
LRP    lipoprotein receptor-related protein  
m    meter 
m    milli (10-3) 
M     molar  (mol/l) 
MAPK     mitogen activated protein kinase 
MEF     mouse embryonic fibroblasts 
MEM     Minimum Essential Medium  
miRNA   micro ribonucleic acid 
MK-STYX  mitogen-activated protein kinase phospho-
serine/threonine/tyrosine-binding protein  
MMP     matrix metalloprotease 
MOPS     morpholino propane sulfonic acid 
MPC     mesenchymal progenitor cell 
mRNA    messenger RNA 
MSC     mesenchymal stem cell 
mTOR    mammalian target of rapamycin 
Mx1     myxovirus resistance 1 
n     nano (10-9) 
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n    number 
NKX2.2    homeobox protein NK2.2 
NP-40    nonidet P-40 
NTD      n-terminal domain 
NTRK1   neurotrophic tyrosine kinase 
OD     optical density 
Osc     osteocalcin  
OSM     oncostatin M  
OSMR     oncostatin M receptor 
Osx     osterix  
p     pico (10-12) 
p16INK4a  cyclin-dependent kinase inhibitor 2A, inhibitor of CDK4 
kinase  
p19ARF    alternate open reading frame  
p21     waf1, cyclin-dependent kinase inhibitor 1A 
p57     kip2, cyclin-dependent kinase inhibitor 1C  
PAA     polyacrylamid 
PBS     phosphate buffered saline 
PCR    polymerase chain reaction 
PE     phycoerythrin 
PIAS  protein inhibitor of activated signal transducer and 
activator of transcription 
PI3K phosphatidylinositol 3-kinase 
pMSCV    vector based on the murine stem cell virus 
PMSF     phenylmethylsulfonylfluorid 
PNET     primitive neuroectodermal tumour 
PolyIC    polyinosinic and polycytydilic acid  
Prx1     paired related homeobox gene-1 
Prx1Cre EF mice   mice expressing EWS/FLI-1 in Prx1 positive cells 
Ptch1     patched1  
PTHRrP    parathyroid hormone related peptide 
PTP1B    protein tyrosine phosphatase 1B 
RNA     ribonucleic acid 
rpm     rotations per minute 
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RPMI     Roswell Park Memorial Institute medium 
runx     runt-related transcription factor 
Runx     runt-related transcription factor 
Runx2Cre EF mice   mice expressing EWS/FLI-1 in Runx2 positive cells 
SCID     severe combined immunodeficiency 
SDS     sodiumdodecylsulfate 
SH2     src homology 2  
SHP  src homology domain containing protein tyrosine 
phosphatase  
SIE-M67 serum inducible element from the c-fos promotor 
mutated at position 67 
siRNA     small interfering ribonucleic acid 
Smo      smoothened 
SOCS     suppressor of cytokine signalling 
SOX     SRY-like HMG-box gene 
STAT     signal transducer and activator of transcription 
S1∆     mutant form of STAT1 lacking the transactivation domain 
S1YF mutant form of STAT1 where tyrosine 701 is changed to 
phenylalanine  
S3∆     mutant form of STAT3 lacking the transactivation domain 
S3YF  mutant form of STAT3 where tyrosine 705 is changed to 
phenylalanine  
TAD     transactivation domain 
Taq     Thermus aquaticus 
Tcf     T-cell factor 
TEMED    N,N,N’,N’-tetramethylethylendiamine 
TET     TLS/FUS, EWS, TAFII68 
TFIID     transcription factor IID 
TGF-β    tumour growth factor beta 
TGF-βRII    tumour growth factor beta receptor type II 
TLS/FUS    translocated in liposarcoma/fused in sarcoma   
Tris     tris(hydroxymethyl)-aminomethan 
U     enzymatic unit 
UTR     untranslated region 
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V     volt 
VEGF     vascular endothelial growth factor  
VEGFR-2    vascular endothelial growth factor receptor-2 
W     watt 
Wnt     wingless, int-1  
wt     wild type 
µ     micro (10-6) 
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